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Abstract 
The societal burden of thyroid cancer is increasing, with both incidence and mortality 
on the rise.  Thyroid cancer can take several forms, each which dictate a different 
clinical progression.  Mutations in the REarranged during Transfection (RET) gene 
are found in both the papillary and medullary subtype of thyroid cancer. In the past, 
patients with widespread metastatic disease had few treatment options.  Medullary 
thyroid cancer (MTC), in particular, is resistant to traditional chemotherapy agents. 
Patients with aggressive papillary carcinomas (PTC) previously struggled with 
radioiodine refractory disease, and were left with no effective systemic therapies. 
However, both diagnosis and treatment have improved over the last decade. 
The publication of several phase II and III trials in advanced thyroid cancer (both 
medullary and papillary) showed the potential of targeted therapy regimes.  The data 
demonstrates an increase in progression-free survival following the use of small 
molecule inhibitors, targeting the signalling cascades.  In 2011, as a result of a phase 
III trial, the multikinase inhibitor vandetanib was FDA approved.  However, these 
new therapies have limitations.  Firstly, the tyrosine kinase inhibitors are yet to 
achieve a consistent prolonged therapeutic response, potentially due to development 
of escape pathways and resistance mechanisms.  Other clinical challenges include 
toxicities requiring dose reductions or delays.  As a result, the action of the inhibitor is 
often compromised, allowing oncogenesis to continue. Hence, there is a pressing need 
to identify novel therapies for this disease.  
The goal of this project was to identify alternative strategies for the development of 
targeted treatment for thyroid cancer.   The shared lineage of neuroendocrine tumours 
(NET) and MTC, suggested that capitalising on the successes of targeted therapy for 
NETs may extend to MTCs.  mTOR inhibitors had been shown to increase 
progression-free survival in pancreatic NETs. There was a paucity of data on the role 
of mTOR in MTCs. Combination therapy, where multiple pathways were 
simultaneously inhibited, was only beginning to take shape in thyroid cancer models. 
The possible utility of HSP90 inhibitors had also been understudied in thyroid cancer. 
Lastly, protumourogenic actions of tumour associated macrophages (TAMs) had been 
shown to have an association with poor prognosis and differentiation in thyroid 
cancer. Their role in tumour progression and initiation had yet to be understood. 
 xxii 
The initial work in this thesis confirmed oncogenic addiction of RET in mutant 
tumours.  Constitutive activation of RET was associated with increased activation of 
mTOR, which was inhibited with the dual mTOR inhibitor INK128.  Tolerability and 
efficacy of combining a RET kinase inhibitor and the mTOR inhibitor was 
demonstrated in a murine model.    
Subsequent work in this thesis explored the effect of a novel HSP90 inhibitor 
AUY922 on RET mutant tumours. AUY922 treatment of MTC cell lines resulted in 
increased apoptosis, consistent with reduced expression of key pro-survival proteins.  
Furthermore, AUY922 increased radioactive iodine uptake in PTC cell lines, by a 
non-sodium iodide symporter (NIS) dependent mechanism.  
Lastly, TAMs in the microenvironment were shown to play a pivotal role in thyroid 
cancer development. Following genetic ablation of TAMs in mouse models, there was 
profound remodelling of the tumour stroma.  Less extrathyroidal invasion and tumour 
cell proliferation was observed as well as a change in the phenotype to a more 
follicular, well differentiated pattern. Additionally, there was an unexpected decrease 
in cancer associated fibroblasts following TAM depletion. Collectively, this shows 
the protumourogenic role of TAMs in PTC progression.  
Overall this thesis has identified novel therapeutic mechanisms for targeted treatment 
of thyroid cancer which may lead to clinical trials, and better patient outcomes. In 
particular, targeting multiple signalling proteins, either through low dose combination 
therapy and/or HSP90 inhibition, may improve clinical efficacy, tolerability and 
outcomes of patients with metastatic thyroid cancer.   
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Chapter 1. 
Review of the literature 
  
2 
1.1 Introduction 
Thyroid cancer is a rare but challenging malignancy whose incidence is on the rise.  
In Australia, the risk of developing thyroid cancer is 1 in 117 people under the age of 
85.  Despite new treatments for thyroid cancer, mortality remains stable in Australia 
and has even increased in the United States [1]. Patients with thyroid cancer that 
progress despite surgery and/or radioactive iodine respond poorly to standard 
chemotherapy regimens.  New treatments have appeared based upon understanding of 
molecular drivers in thyroid cancer.  Gain-of-function mutations of the RET proto-
oncogene have emerged as important initiators of two different thyroid cancer 
subtypes, namely papillary and medullary.  Use of novel therapies that inhibit this 
oncogenic kinase driver has commenced in clinical practice. Despite this progress, a 
number of clinical challenges persist in the management of thyroid cancer:  
1. Mutant RET is known to trigger multiple signalling cascades that cause 
aggressive malignant disease.  Key proteins involved in proliferation pathways 
need to be identified to provide alternative therapy targets. 
2. Duration of progression-free survival remains relatively short even with new 
targeted therapies, at least partly due to development of drug resistance by 
means of secondary mutations. 
3. Current novel therapies often have side effects that are dose limiting, thereby 
preventing maximum therapeutic efficacy. 
4. The tumour microenvironment may have a promoting role in thyroid cancer 
progression.  Identifying key mediators from stromal tissue may provide 
alternative treatment strategies. 
This chapter provides an overview of thyroid cancer, specifically the different 
histological subtypes and their corresponding genetic mutations. Since RET is a 
central focus of this thesis, a summary of RET evolution and signalling is included 
together with a review of the literature concerning targeted therapy for thyroid cancer.  
3 
1.2 Thyroid cancer incidence and prevalence 
In 2013, prevalence of thyroid cancer in the United States was 535,000. 60,220 new 
cases were estimated to be diagnosed this year (approximately 3.6% of all new 
cancers).  In 2008, 37,340 new cases were diagnosed which increased to 44,670 new 
diagnoses in 2010 [1].  In Australia, the percentages are similar with thyroid cancer 
accounting for 1.8% of new cancers [2].   
Thyroid cancer is more common in women, but incidence is increasing in both sexes.  
The age adjusted female incidence increased by 4.3% per year from 1992 through 
2001. Of all cancers in women, thyroid cancer has had the greatest increase in 
incidence over the past decade [1].  Experts agree that a significant component of this 
increase is due to increased detection of small carcinomas in the preclinical stage 
which were unlikely to have any adverse consequence [3]. However, in contrast to the 
downward mortality trend for many other cancers, mortality in thyroid cancer has 
been either stable or increased [3], reinforcing the need for further research. 
1.3 Clinical presentation 
The thyroid gland is a butterfly shaped, highly vascular gland situated anteriorly at the 
level of the fifth cervical to the first thoracic vertebrae.  Thyroid cancer may present 
with a rapidly expanding single nodule, or as an incidental imaging finding. 
Associated symptoms such as hoarseness and lymphadenopathy are infrequent. 
Diagnosis is usually suggested on fine needle biopsy, then confirmed histologically 
after total thyroidectomy.  
1.3.1 Histological subtypes 
The thyroid is composed of follicular cells, which selectively absorb iodine and 
secrete thyroid hormone; and the parafollicular cells (or C cells) which are 
interspersed between the follicular cells and secrete calcitonin. These cellular 
antecedents give rise to different cancer subtypes. Traditionally there are four types of 
thyroid cancer: medullary arising from parafollicular cells; and papillary, follicular 
and anaplastic that arise from follicular cells. Approximately 94% of thyroid cancer is 
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of papillary or follicular subtype, 5% is medullary and only 1% is anaplastic [4].  
There are other varieties beyond this classification, particularly in the follicular group, 
but they are not relevant to the scope of this thesis.  
 
 
 
 
 
 
 
Figure 1.1 Pathology of thyroid cancer: (A) Variants of thyroid cancer based on pathological state of 
differentiation and cell of origin. (B) Representative histological section of papillary thyroid cancer 
(PTC) (left) and medullary thyroid cancer (MTC) (right) at 20x magnification.  Nuclear features 
described in 1.3.2 are seen in PTC.  Pathological features consistent with neuroendocrine neoplasms 
are seen in the MTC section (see 1.3.3). Sourced from Anatomical Pathology Department, Royal North 
Shore Hospital, NSW, Australia. 
1.3.2 Cancers originating from follicular cells  
Papillary thyroid cancers (PTCs) are usually not encapsulated and have cystic 
structures.  Typically they have an absence of colloid or recognisable follicles. 
Papillae dominate the microscopic characterisation and psammoma bodies are found 
in 50% of papillary cancers which are the remnants of infarcted papillae (Figure 1.1). 
Nuclear features illustrated include: enlarged, elongated, overlapping nuclei with 
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irregular nuclear membranes; intranuclear inclusions; and nuclear grooves. Follicular 
thyroid cancer (FTC) is a well differentiated malignancy that is histologically 
distinguished from adenoma by presence of capsular and/or vascular invasion [5]. 
Both PTCs and FTCs are typically well differentiated enough to secrete 
thyroglobulin, which provides a reasonably sensitive circulating marker for disease 
recurrence.  By contrast, anaplastic thyroid carcinomas are very poorly differentiated 
and show pleomorphic giant tumour cell nuclei.  Many of these tumours have 
cavernous blood filled sinuses resembling aneurysmal bone cysts and deep necrotic 
areas interspaced with better differentiated cells [6].  Vascular invasion is common. 
1.3.3 Medullary thyroid cancer (MTC) 
The C (or parafollicular) cells give rise to MTCs and originate from the embryonic 
neural crest, which begets their shared lineage properties with other neuroendocrine 
tumours.  Histologically, MTCs appear as solid masses of cells with large vesicular 
nuclei and occasionally amyloid deposits.  Pathological features are common to 
neuroendocrine neoplasms and include stippled chromatin with nested and trabecular 
architecture (Figure 1.1).  Calcitonin secretion from MTCs provides a highly sensitive 
marker for recurrent disease. The parafollicular cells have also been reported to 
secrete neuroendocrine peptides [5].  
C cells make up only 0.1% of total thyroid mass and are largely found in the upper 
and middle third of the thyroid gland.  C cell hyperplasia (CCH) is a pathological 
term for pre-malignant lesions caused by an increase in C cell number [7]. 
Progression from macroscopic MTC to distant metastatic disease may take many 
years, but spread to regional lymph nodes can occur early [7, 8].  In 35-50% of index 
cases, lymph node involvement is present in central, lateral, cervical, and/or 
mediastinal compartments at diagnosis [9].  Distant metastases in lung, liver and bone 
are found in 10-15% of patients at the time of diagnosis [9].  Early diagnosis of MTC, 
prior to metastasis, is vital to the prospects of surgical cure and forms the basis for 
current recommendations.  Since surgery offers the only chance of curing MTC, 
current guidelines favour total thyroidectomy and aggressive lymph node dissection 
of central and lateral compartments (see 1.5.1.2).  In the presence of distant metastatic 
disease, less aggressive neck surgery may be appropriate to preserve speech, 
parathyroid function and swallowing [10].  In April 2011, the pankinase inhibitor 
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vandetanib was approved for use in MTC [11].  The role of tyrosine kinase inhibitors 
in thyroid cancer is further discussed in 1.6.3. 
1.3.3.4 Hereditary MTC 
There are several hereditary syndromes associated with MTC.  Multiple Endocrine 
Neoplasia type 2 (MEN2) is a rare inherited cancer syndrome.  MEN2A, MEN2B and 
Familial Medullary Thyroid Cancer (FMTC) are all components of this broader 
group.  MEN2A is characterised by a high penetrance of MTC, modest risk of 
pheochromocytoma and lower risk of primary hyperparathyroidism.  MEN2B 
presents similarly, but demonstrates a more aggressive clinical presentation with 
MTC, but without hyperparathyroidism.  FMTC is included in this group as it also 
incurs a strong likelihood of MTC but not the other manifestations of MEN2A, and 
may simply be a lower risk variant of MEN2A.  Mutations in the REarranged during 
Transfection (RET) gene have been established as the cause of this syndrome [12]. 
MTC is often the first manifestation of the MEN2A Syndrome [13].    
Management is altered once hereditary disease is established through germline RET 
mutation testing. MEN2A is the most common of the MEN2 syndromes and typically 
presents in the third or fourth decade of life although may occur much earlier. 
MEN2B is characterised by early presentation with MTC (sometimes in the first year 
of life), absence of primary hyperparathyroidism and the presence of distinguishing 
developmental and facial features [14].  There is a strong genotype to phenotype 
correlation (detailed in 1.4.1), indicating the best practice of treatment according to 
the aggression of disease. ATA guidelines include prophylactic thyroidectomy for 
certain variants at very early ages (Table 1.2) and this has reduced mortality in MEN2 
affected individuals [10].  Total thyroidectomy and cervicocentral lymph node 
dissection are at minimum required for hereditary MTC (see 1.5.1.2 for current 
treatments).  Furthermore, patients harbouring certain RET mutations are more likely 
to develop late stage lymph node metastases and may not require such initial 
extensive surgery [15]. Further study is required to determine long term outcomes in 
these patients.   
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A negative family history in patients with thyroid cancer does not exclude hereditary 
disease.  The prevalence of hereditary MTC in apparently sporadic disease has been 
reported as 14.6% [16].  
1.4  Genetics  
In the last twenty years, the field of thyroid cancer genetics has burgeoned with the 
identification of mutant genes.  Table 1.1 outlines those characterised.   RAS (Rat 
Sarcoma) is a protein subfamily of small GTPases which are involved in cellular 
signalling. Mutations in the RAS genes (H-RAS, K-RAS, N-RAS) occur in 
approximately 10-15% of human cancers, commonly from single base substitutions in 
codons 12, 13 or 61 and are well characterised in PTC [17].  More recently they have 
also been identified in MTCs [18].  The most common mutation in PTC is the serine 
kinase BRAF. The activating point mutation encodes for BRAFV600E, is found in 45% 
of papillary cancers, and is henceforth referred to in this thesis as BRAF [19]. The 
ensuing constitutive activation of the MAPK pathway is thought to be central to the 
establishment of this disease [20].   
The effect of radiation also generates mutations specific to thyroid cancer.  Incidence 
peaks in thyroid cancer after nuclear accidents and childhood neck radiation. The 
average time from radiation exposure to tumour recognition is 10 years but may be up 
to 30.  Following Hiroshima and Chernobyl, there was an increase of recombination 
events particularly leading to the fusion proteins RET/PTC. This fusion product 
allows activation and dimerization in the absence of the ligand, leading to constitutive 
activation of the MAPK pathway (reviewed in [21]). 
These somatic genetic mutations outlined in Table 1.1 correlate with specific 
histological subtypes.  RET/PTC rearrangements are found in early disease [22] and 
confer classical PTCs with good prognosis which rarely progress to poorly 
differentiated thyroid cancer. RAS mutations mostly correlate to follicular variant 
cancers with an increase in distant metastasis risk. BRAF mutations are found in 
classical or tall cell variant PTC. These tend to be more invasive and refractory to 
radioactive iodine and are associated with increased mortality [23].   Furthermore, in 
PTC none of the established somatic mutations have been found in the germline 
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setting. Linkage analysis has identified five chromosomal regions that may harbour 
punitive susceptibility to hereditary PTC [16].   
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Table 1.1 Thyroid tumour variant and genetic mutations:  
Legend:  Somatic mutations  
Germline mutations 
Both somatic and germline mutation  
RET mutations are discussed in detail below. 
Thyroid Tumour 
Variant 
Genetic Aberration Frequency if known 
Follicular RAS mutations (overall) 
Activating: H-RAS Codon 12, 13 
of exon 1, N-RAS Codon 61 of 
exon 2 
K-RAS exon 1  
~>40% 
2-3% 
~19%  
 
1.6% [24] 
PAX8-PPARƴ chromosomal 
rearrangement 
t(2;3)(q13;p25) [25] 
 
63% [25] 
PIK3CA 5-15% [26] 
 
Hypermethylation of RASSF1A, a 
known tumour suppressor gene 
75% [27] 
Papillary  NTRK1 rearrangement: 1q21-22 12% [28] 
PIK3CA 1-2% [26] 
RET/PTC1; RET/PTC3 (most 
frequent) chromosomal 
rearrangement (including up to 12 
known variants) 
10-30%* [29] 
60% in children, 80% in 
children post nuclear 
accident 
BRAF mutations- Activating: 
V600E 
Rarely rearrangement AKAP9-
BRAF 
~44%* of PTC[30] (30-
50% accepted) 
11% following ionising 
radiation [31] 
RAS: most commonly codon 61 
(N-RAS) then H-RAS 
Follicular variant of PTC: 
Sequence variants - G/C 
heterozygosity within the precursor 
of microRNA-146a,  
~10-15% [26] 
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SNP at 9q22.33 (close to FOXE1) 
and 14q13.3 close to TTF1 [26] 
Upregulation of microRNA (miR-
221, miR-222, miR-146) [32] 
Anaplastic p53 
Inactivating mutations in exon 5-8 
83% [33] 
beta-catenin (CTNNB1)- mutation 
in exon 3 
61% [34] 
PIK3CA; exon 9 and exon 20 23% [35] 
IDH-1 10-30% [26] 
Medullary RET gain-of-function mutation in 
codon 8,10,11, 13-16 
M918T point mutation 
>50% in sporadic 
tumours [36] 
Found in >95% 
hereditary (see 1.3.3.4) 
HRAS mutation M72I 
 
KRAS  
10.1% (17.6% in RET 
negative cases) [37] 
<1% [18] 
* In the last 15 years, data has shown an increase in BRAF mutations and a decrease 
in RET/PTC rearrangements in PTC [29]. Further research is required to determine 
the reason for this change.   
1.4.1 RET mutations 
RET is the dominant mutation in MTC. RET is known to play a crucial role in thyroid 
tumourogenesis (see 1.6.1). Almost all hereditary MTC syndromes are caused by 
constitutively activating germline RET point mutations, and can present as MEN2A 
and MEN2B, or FMTC [38-40]. Somatic RET mutations are found in up to 50% of 
the sporadic forms of the disease [36].   In sporadic tumours, point mutations are most 
common.  Germline testing of RET can be used to distinguish cases of sporadic or 
hereditary MTC as the specific mutations are associated with observed phenotypes 
(Table 1.2).  
There is well-established genotype-phenotype correlation in hereditary MTC.  Both 
age at first diagnosis of tumour, and risk of progression are related to underlying 
genotype [13].  Specific RET mutations predict the aggressiveness of the MTC and 
the phenotypic expression of disease.  Evidence based guidelines from the American 
Thyroid Association (ATA) for early intervention are employed [10].  Treatment is 
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outlined in 1.5.1.2. RET mutations have been stratified into 3 groups depending on 
biological aggressiveness (Table 1.2) where Level 1 is the mildest.  The mechanism 
of the RET proto-oncogene is outlined in 1.6.1. 
 
Table 1.2: Genotype-phenotype correlations in MEN2 
Codon 
(exon) 
Aggression MTC Pheochromocytoma Hyperparathyroidism 
609 (10) 
1 
X X X 
768 (13) X very rare - 
790 (13) X very rare - 
791 (13) X rare X 
804 (14)  X X X 
891 (15) X very rare very rare 
611 (10) 
2 
X X X 
618 (10) X X X 
620 (10) X X - 
634 (11) X X X 
883 (15) 3 X X - 918 (16) X X - 
Aggression Level 1: Less aggressive MTC leads to recommendation for 
thyroidectomy <10 years of age 
Aggression Level 2: Early development of MTC (age 2 reported) with metastasis 
leads to recommendation for thyroidectomy <5 years of age 
Aggression Level 3: Highest risk leads to recommendation for thyroidectomy at 6 
months of age 
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1.5 Evolution of targeted therapy 
1.5.1 Traditional treatment 
1.5.1.1 Differentiated papillary thyroid cancer 
Definitive treatment for differentiated thyroid cancer is surgery: total thyroidectomy 
and a degree of neck compartment dissection is performed depending on staging. 
DTC uses the AJCC TNM staging system (Appendix 1; Appendix 2). Briefly, 
following total thyroidectomy, ATA guidelines advise central compartment lymph 
node neck dissection in patients with clinically evident nodal disease.  In patients with 
advanced primary tumours (T3 or T4), prophylactic central compartment neck 
dissection is also recommended [4]. Ipsilateral or bilateral lateral neck dissection is 
indicated in the presence of cervical lymphadenopathy.  As a prophylactic surgery, 
this is more controversial and depends on the surgical protocols of the institution. In 
view of less aggressive RAI protocols, central LN status as determined following 
prophylactic nodal dissection is becoming more useful in the treatment algorithm.  
Subsequent adjuvant radioactive iodine (I131) ablation follows in patients with known 
distant metastases, extrathyroidal extension, or if >T3 [41].  In patients with less 
aggressive disease, stratifying these patients into low risk groups and avoiding 
adjuvant I131 treatment has been shown to be clinically appropriate.  However, the 
actual stratification can be challenging, as the determinants of recurrent disease can be 
varied [42].  Tuttle et al describes low risk as: patients of any age with a confined 
PTC; primary tumour size <1cm; and an absence of nodal disease.  They can be safely 
followed with 6 monthly Tg (on suppression) and 6-12 monthly neck ultrasounds for 
3-5 years [42].  
Patients who receive I131 ablate all residual thyroid tissue through cytotoxicity, by the 
emission of short path length beta radiation.  Those metastatic thyroid cancers that are 
refractory to radioiodine have a poorer prognosis [43].  Novel therapies aimed at 
enhancing radioiodine uptake are in development [44]. Surgical resection may be 
appropriate in some cases of isolated pulmonary, liver or brain metastases [45]. Other 
treatment options also include external beam radiotherapy for patients with T4 
disease. External beam radiotherapy is also used to treat brain metastases (with or 
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without surgical resection) and painful bone metastases. Occasionally, cytotoxic 
agents are utilised in these patients but long term responses are unusual.  The 
anthracycline derivative doxorubicin, has been established to have a partial response 
in (at best) 30% of patients.  Combination with a platinum based compound has 
produced inconsistent results [46].   
Long term follow up in all patients typically includes at least annual measurement of 
serum thyroglobulin and anti-thyroglobulin antibodies, and annual neck ultrasound. 
Patients with local or distant recurrence also require whole-body iodine scanning 
(WBS) (after thyroid hormone withdrawal or rhTSH) to determine need for further 
radioactive iodine treatment. In patients with positive thyroglobulin (and/or anti-
thyroglobulin antibodies) but negative WBS may benefit from FDG-PET imaging to 
diagnose more poorly differentiated metastatic disease [41].  
1.5.1.2 Medullary thyroid cancer 
Medullary thyroid cancers are treated with meticulous and extensive surgery if they 
are diagnosed before metastasis.  Following thyroidectomy, a bilateral level VI 
(central) lymph node compartmental dissection is performed in all patients 
irrespective of the presence or absence of palpable nodal disease [10].  The addition 
of a prophylactic lateral node dissection is dependent on the centre however 
involvement of lateral LN does correlate with the size of the primary lesion.  Most 
high volume units would perform an ipsilateral lateral neck dissection for a primary 
MTC >1cm. Patients with distant metastatic disease may still benefit from palliative 
surgery for symptom control.  Following surgery, patients receive thyroxine 
replacement and there is no benefit from I131 treatment.  External beam radiotherapy 
(ERBT) can be used for patients with a high risk of local recurrence.  One study 
showed a 10 year relapse free rate of 86% post EBRT as opposed to 52% for those 
who had not received the adjuvant treatment [47]. Traditional cytotoxic chemotherapy 
is generally ineffective [48, 49]. 
Follow up includes regular assessment of calcitonin (and sometimes CEA), initially 6-
12 monthly and then annually.  If the calcitonin rises, further imaging including neck 
ultrasound, CT chest, and neck and bone scan is warranted [10].   
14 
The limited treatment options for patients with refractory metastatic disease have 
provided a niche for the development of targeted chemotherapy and immunotherapy.  
Thyroid cancer treatment has been witness and participant to the evolution of targeted 
therapy. 
1.5.2 Tyrosine kinase inhibitor development 
Targeted therapy emerged as a novel concept in the late 20th century and was initially 
best exemplified through studies on Chronic Myeloid Leukaemia (CML).  CML, a 
clonal disorder where cells of the myeloid lineage undergo massive clonal expansion, 
occurs as a consequence of activation of the Abl kinase via its translocation to BCR in 
the Philadelphia chromosome. Imatinib was synthesized as a tyrosine kinase inhibitor 
acting through competitive inhibition at the ATP binding site of the enzyme.  Startling 
results in clinical trials at the turn of the century showed huge success for patients 
with the Philadelphia chromosome [50]. This paved the way for the generation of 
targeted therapy in many other cancers.  
Melanoma research is entwined with thyroid cancer research because both cancers 
have a high prevalence of BRAF mutations. BRAF is a serine/threonine protein kinase 
downstream of RAS (Figure 1.2).  
 
 
Figure 1.2 BRAF signalling pathway: BRAF is downstream of RAS and phosphorylation causes 
signalling along the MAPK pathway, sourced from Gild et al, Nature Reviews in Endocrinology, 2011. 
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More than 30 mutations of the BRAF gene have been identified and associated with 
different human cancers. A Glu-Val substitution at residue 600 (V600E) has been 
identified as the most common mutation. 80% of melanomas and ~44% of PTCs 
harbour this mutation [19].  Melanoma research has developed extensively from in 
vitro work with BRAF inhibitors, to recent clinical trials showing significant increase 
in survival following inhibition of the oncogenic kinase driver, BRAF, with a novel 
inhibitor, vemurafenib [51].   Combination treatment using a BRAF inhibitor 
(dabrafenib) and MEK inhibitor (trametinib) showed improved PFS than either drug 
alone [52].  In thyroid cancers, TKIs have been employed in Phase II and III trials 
(Table 1.3; 1.4) due to the relative high frequency of BRAF and RET mutations.  
1.6 RET in thyroid cancer 
1.6.1 The RET proto-oncogene 
The RET gene encodes a receptor tyrosine kinase that is mainly expressed in the 
precursor cells of the neural crest and urogenital tract (Figure 1.3).  RET is essential 
for the formation of the kidneys and nervous system, and spermatogenesis. 
Inactivating germline mutations of RET are found in Hischsprung’s disease, a 
congenital disease caused by absence of enteric neurons in the gastrointestinal tract.   
The RET proto-oncogene is involved in the regulation of growth, survival, 
differentiation, and migration of cells of neural crest origin. The RET gene is not 
normally expressed in thyroid follicular cells. The RET protein is a transmembrane 
receptor tyrosine kinase and consists of three separate domains: an extracellular 
binding domain, a transmembrane domain and a cytoplasmic tyrosine kinase domain 
(Figure 1.3). The extracellular domain contains four cadherin-like repeats and a 
cysteine rich region. This region is particularly important for the tertiary structure of 
the protein as it is involved in disulphide bond formation.  In 1996, the ligands for the 
RET receptor were identified as glial cell line derived neurotrophic factor (GDNF) 
family, a distant member of the TGF-beta family. The ligands include neurturin, 
artemin and persephin [53].   
It has long been established that inappropriate activation of the RET receptor tyrosine 
kinase causes development of both papillary and medullary thyroid cancers. Wild 
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type RET activation is induced by ligand induced dimerization (Figure 1.3).   RET 
gain of function point mutations are commonly found in MEN syndromes, FMTC 
and, loss of function in Hirschsprung disease. Here, activation is mediated by 
disulphide bond dimerization (Figure 1.3).  In papillary thyroid cancers, RET driven 
tumours are caused by chromosomal rearrangements where the RET gene is fused to 
heterologous genes, frequently in the setting of radiation.  The oncogenic properties 
of these RET/PTC fusion proteins, as they are termed, are derived from the 
constitutive activation of the tyrosine kinase domain. Activation is through coiled-coil 
induced dimerization (Figure 1.3).  Activation of the RET oncogene in PTC is the 
result of recombination events leading to the fusion of the RET TK with 5’fragments 
of heterologous genes, the most common being H4. This fusion provides an active 
promoter which drives the expression of the chimeric gene. These chromosomal 
errors are often due to radiation damage causing breaks in the double stranded DNA. 
The fusion gene is formed erroneously by the coding region for the C-terminus of 
RET to the promoter and coding region of the N-terminus of a constitutively 
expressed unrelated gene simply due to their close physical proximity.  These fusion 
genes encode for proteins that harbour the intracellular kinase domain of RET and the 
N-terminal domain of various proteins. This is significant because the N-terminal 
domains of these various proteins all have the property of allowing dimerization of 
the fusion protein. This leads to the autophosphorylation of tyrosine residues in the 
tyrosine kinase domain of RET and constitutive activation of RET.  There are more 
than twelve different fusion partner genes that are known to form, the most prevalent 
of which are the RET/PTC1 and the RET/PTC3 genes. There is evidence that in 
microscopic PTC, RET/PTC expression is highly prevalent, while in later stages of 
the disease the prevalence varies widely. This suggests RET/PTC is activated early in 
the disease [22].  
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Figure 1.3 Schematic representation of RET protein. TK1= Tyrosine Kinase domain 1 and TK2 = 
Tyrosine Kinase domain 2. Docking sites shown as blue circles. GFL GDNF ligand family in wild type 
RET induces dimerization. RET activation with gain of function point mutations (MEN2A mutations 
detected in the cysteine residues) is mediated by disulphide bond mediated dimerization. RET/PTC 
activation is mediated by coiled-coil induced dimerization. MEN2B mutations detected in the kinase 
domain of RET also appear to activate the RET protein without dimerization, probably due to a 
conformational change of its catalytic core region.  Adapted from Carlomagno, F; European Thyroid 
Journal, 2012 and De Groot, Endocrine Reviews, 2006. 
 
1.6.2 RET as the oncogenic kinase driver 
Reliance on RET for growth and proliferation in MTC cell lines and xenograft models 
has now been well established.  The dependence of MTC on RET tyrosine kinase 
activation is demonstrated in several preclinical studies. RET inhibition with 
vandetanib has been well documented in RET mutant MTC cell lines since 2002 [54] 
and more recently in exploring the mechanism and the relationship between RET and 
EGFR [55]. Another RET kinase inhibitor, NVP-AST487, has also been shown to 
have success in MTC xenograft models [56].  The dependence of these MTC cell 
lines on RET has been confirmed with siRNA techniques, where the specific knock 
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down of RET suppressed cell proliferation and increased apoptotic markers in TT cell 
lines [57]. Koga et al found that genetic knock down of RET profoundly improved the 
action of irinotecan, a traditional chemotherapeutic agent.  Recently, a novel 
compound, withaferin A, has shown in vivo RET kinase inhibitory activity and 
success in another MTC xenograft model [58].  Most of the in vitro model systems 
using RET kinase inhibitors show impressive in vitro results and tumour regression in 
in vivo studies. However there is little evidence on the induction of apoptosis in any 
model. 
The multikinase inhibitor sorafenib, (which includes inhibition of RET) has 
repeatedly shown a potent effect in orthotopic models of RET driven PTC [59] and 
RET mutant MTC [60]. Different kinases have also been compared to each other in an 
in vitro model [61]. Axitinib, sutinib, vandetanib and carbozantanib (XL184) were 
assessed in RET mutant PTC and MTC cell lines.  While all four inhibitors were able 
to reduce cell proliferation, carbozantanib and vandetanib (both known RET 
inhibitors) were more potent. Interestingly, it is these drugs that show progression-
free survival in phase III clinical trials [62, 63].  Clearly, when RET is specifically 
targeted, there is more inhibition of cell proliferation.  Results from this thesis 
confirm the specific effect of inhibiting the oncogenic kinase driver, RET with both 
genetic and pharmacological manipulation. 
1.6.3 RET kinase inhibitors 
TKIs are multikinase inhibitors, often inhibiting multiple targets simultaneously. 
When trials began in thyroid cancer, often all variants of the disease were grouped 
together as susceptible patient populations.  Table 1.3 shows earlier studies in both 
DTC and MTC patients as a reference guide to clinical trials of TKIs in thyroid 
cancer.  The results of these studies led to Phase III studies (Table 1.4). These recent 
advances have improved progression-free survival in patients with metastatic 
medullary thyroid cancer [62, 63].  It is unclear in the clinical studies which target’s 
inhibition exerted the clinical effect.   
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Table 1.3 Phase I and II clinical trial reports of kinase inhibitors in thyroid 
cancer 
Medullary Thyroid Cancer  
Author/year   Phase Drug  n CR (%)  PR (%)      SD ≥ 24 wk (%)   
Cohen/2008 [64]   II Axitinib  11 0 18  27  
Schlumberger/2009 [65]  II Motesanib 91 0 2  48       
Wells/2010 [66]  II Vandetanib 30 0 20  53 
Robinson/2010 [67] II Vandetanib 19 0 16  53 
Kurzrock/2011 [68] I Carbozantinib 37 0 29  41  
Ahmed/2011 [69] II Sorafenib 34 0 25  79 
Lam/2010 [70]  II Sorafenib 16 0 6.2  50 
Hong/2011 [71]  I Sorafenib & 13 0 38  31 
Tipifarnib   
Carr/2010 [72]   II Sunitinib 7 NA 50  46* 
 
Radioiodine refractory Papillary and Follicular Thyroid Cancer  
Author/year   Phase Drug  n CR (%) PR (%) SD ≥ 24 wk (%)  
Cohen/2008 [64]  II Axitinib  45 0 31 42 
Sherman/2008 [73] II Motesanib 93 0 14 35 
Gupta-Abramson/2008[74]II Sorafenib 30 0 23 53** 
Kloos/2009 [75]  II Sorafenib 41 0 15 56 
Ahmed/2011 [69] II Sorafenib 19 0 18 73*      
Carr/2010 [72]  II Sunitinib 28 1 28 46* 
Hong/2011 [71]  I Sorafenib & 22 0 4.5 36 
Tipifarnib  
 
CR= Complete response; PR= Partial Response; SD= Stable disease. * = SD not 
reported separately for DTC and MTC.  ** = trial reported SD lasting for 14-89+ 
week 
Table sourced from Gild et al, Nature Reviews Endocrinology, 2011. 
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Table 1.4 Phase III trials in thyroid cancer 
Author/year  Phase Drug       n PFS*   Hazard Ratio  
Elisei/2013 [62]      III Carbozantinib      330 11.2 v 4  HR 0.28 95% CI 0.19-0.40 
Wells/2011 [63]      III Vandetanib (ZETA) 331 30.5 v 19.3  HR 0.46, 95% CI 0.31-0.69 
DECISION trial [76]III Sorafenib     417 10.8 v 5.8 HR 0.587 95% CI, 0.45-0.76 
*PFS= progression-free survival, measured in months in patients receiving drug vs. 
patients receiving placebo 
 
At the time of submission, there have been two phase III studies of tyrosine kinase 
inhibitors in thyroid cancer completed. A sorafenib study abstract was presented at a 
clinical meeting but the publication was pending [76]. Both of these have shown an 
increase in progression-free survival [62, 63].  In November 2013, the FDA approved 
sorafenib for DTC following the DECISION abstract presentation. But these drugs 
are not without serious toxicities.  In the ZETA trial, nearly all patients experienced at 
least 1 adverse event, and over half experienced an adverse event of grade 3 or higher 
[63]. In the carbozantinib trial, 79% of patients required dose reductions and 65% 
required withholding of at least 1 dose.  Adverse effects led to treatment 
discontinuation in 16% of carbozantinib treated patients [62]. In the phase II studies, 
similar potent side effects were observed. Wells’ initial phase II study used a dose of 
300mg of vandetanib. Here, over 70% of patients suffered diarrhoea, 67% 
photosensitive rash, 63% fatigue and 63% nausea [66]. Later studies by Robinson et 
al titrated the dose of vandetanib to 100mg and saw proportionally less side effects 
but a similar disease control rate (68% at 100mg and 73% at 300mg) [67].  A 
summary describing the extensive debilitating side effects of the compounds is shown 
in Table 1.6.  Ensuring better patient tolerability of these drugs as essential as is 
increasing progression-free survival. This is especially so as survival is still 
comparably short, making quality of life crucial.   
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Table 1.5 Frequency of dose reduction or withdrawal of TKIs in clinical trials in 
thyroid cancer 
 
TKI 
 
Study 
 
Dose Reduction for 
toxicity (%) 
 
Withdrawal for toxicity 
(%) 
 
Vandetanib Wells (2010) 
Robinson (2010) 
Wells (2011) 
73 
15 
35 
23 
11 
12 
Carbozantanib Elisei (2013) 79 16 
Motesanib Schlumberger (2009) NA 14 
Sorafenib Lam (2010) 
DECISION trial (2013) 
76 
NA 
16 
18.8 
Sunitnib Carr (2010) 60 11 
Axitinib Cohen (2008) 38 13 
 
Table 1.6 Frequency of major adverse events noted in TKI use in thyroid cancer, 
from Phase II (if no Phase III) or Phase III clinical trials of patients with thyroid 
cancer  
 
Adverse Event 
 
 
Sorafenib 
(%) [76] 
 
Sunitinib  
(%) [72] 
 
Carbozantanib 
(%) [62] 
 
Vandetanib 
(%) [77] 
 
Motesanib 
(%) [65] 
Hypertension 40.6 3 33 32 27 
Long QT NE NE NE 14 NE 
Hand-foot syndrome 76.3 26 50 NE NE 
Stomatitis NE NE 29 NE NE 
Anorexia 31.9 3 46 21 27 
Weight loss 46.9 NE 48 10 22 
Diarrhoea 68.6 26 63 56 41 
Nasopharyngitis/Oedema NE 6 NE 11 NE 
Fatigue 49.8 26 41 24 41 
Rash 50.2 NE NE 45 NE 
Nausea 20.8 9 43 33 26 
Oral mucositis 23.2 6 NE NE NE 
NE= Not evaluated 
Other serious adverse events not described above due to <10% frequency included: 
GI perforation, venous thromboembolism and haemorrhage.  
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1.7 mTOR in human cancers 
mTOR is a pivotal signalling mechanism in many human cancers and has emerged as 
a successful target for disease control.  mTOR is a highly conserved protein belonging 
to the PI3K-related kinase family of serine/threonine protein kinases [78].  mTOR 
integrates various environmental cues which modulate its behaviour. Growth factors, 
nutrients and energy, together with cellular stresses, regulate its activity on protein 
synthesis, cell growth and proliferation [79].  mTOR signals through two distinct 
complexes.  mTOR complex 1 (mTORC1) or RAPTOR is sensitive to rapamycin and 
positively regulates mTOR [80].  The function of mTORC1 is regulated by the PI3K-
AKT and MAPK signalling pathways through TSC2 (Figure 1.4).  RICTOR or 
mTORC2 is upstream of the PI3K-AKT pathway, and phosphorylates AKT at Ser473. 
It is in a rapamycin insensitive complex with rictor and Sin1. AKT promotes cell 
survival by inhibiting apoptosis through phosphorylating and inactivating several 
targets. Aberrantly high mTOR activity is a hallmark of many cancers; many studies 
have shown rapamycin and its analogues to maximise the inhibition of mTORC1. 
This has led to clinical accomplishments in renal cell carcinoma, mantle cell 
lymphoma and endometrial cancers, and most recently in neuroendocrine tumours 
[81, 82].  However, following single inhibition of mTORC1, secondary pathways can 
be activated that perpetuate proliferation and disease progression.  A novel feedback 
inhibitory mechanism has been described whereby inhibition of mTORC1 leads to 
AKT activation through upregulation of RTKs, specifically through IRS-1 [83]. This 
group has also reported that mTORC1 inhibition leads to MAPK activation in patients 
with metastatic cancer [83].  
Aberrations in the PI3K signalling pathway play a notorious role in many human 
cancers [84]. PTEN mutations are associated with a wide spectrum of cancers 
including prostate, lung, bladder, melanoma, breast, endometrial, thyroid, brain, renal 
and many others making it one of the most frequent mutations in tumour suppressor 
genes [85]. Aberrant PTEN signalling leads to increased downstream AKT signalling 
with changes to cell survival, cell proliferation and metabolism. AKT phosphorylates 
multiple downstream targets enacting these effects (Figure 1.4). 
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Figure 1.4 AKT signalling network. AKT (Protein Kinase B) plays a key role in multiple cellular 
processes including growth and modulating of apoptotic pathways.  AKT activates a number of 
downstream targets, some which are outlined in this diagram; Casp9 = Caspase 9; Mdm2 = Human 
oncoprotein Mouse double minute 2; BAD= Bcl-2 associated death promotor; FOXO = Forkhead box 
protein; TSC2 is phosphorylated and inhibited by AKT.  AKT lies downstream of mTORC2 and 
upstream of mTORC1. mTORC1 phosphorylates S6K1 which in turn activates S6.  Rapamycin 
(everolimus) is an inhibitor of mTORC1.  INK128 (a compound utilised in this thesis and described in 
1.7.2) acts on mTORC1 and mTORC2 to inhibit AKT and its downstream targets.  
 
1.7.1 mTOR in thyroid cancer 
In immortalised non-transformed rat thyroid cell lines, thyroid stimulating hormone 
(TSH) induces mTOR activity through Protein Kinase A (PKA) [86]. Poorly 
differentiated thyroid cancers and thyroid cancer cell lines lose dependence on TSH 
for growth, yet they show increased mTOR activity [87]. mTOR is a critical effector 
in the MAPK and PI3K signalling network, both which have been shown to be 
deregulated in thyroid cancer [84].  The precise impact of the oncogenic drivers on 
mTOR is yet to be completely determined.  Thyroid cancers may have switched 
upstream control of mTOR activity from the TSH-cAMP-PKA system to the 
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oncogenic kinase driver, i.e. RET in MTCs.  Coexisting mutations of PI3K and 
MAPK have been reported in poorly differentiated and anaplastic thyroid cancers 
[22].  Unregulated output through both signalling networks may be important in 
mediating thyroid cancer pathogenesis and mTOR itself may be the integrator of the 
proliferative response.   
1.7.2 mTOR inhibitors 
mTOR inhibitors have demonstrated success in increasing median survival in 
pancreatic neuroendocrine tumours (pNET) [88]. pNET has a traditionally poor 
outcome with over 64% of patients presenting with metastatic disease with a median 
survival of 27 months [89].  Everolimus (rapamycin), an oral mTOR inhibitor was 
approved in May 2011 for the treatment of pNET.  A phase III study (RADIANT-3) 
demonstrated increased progression-free survival in patients treated with everolimus 
as compared with placebo [81].  As discussed in section 1.3.3, MTC shares a common 
neuroendocrine lineage with pNETs, which prompted a hypothesis tested in this 
thesis, that MTC might be similarly sensitive to mTOR inhibitors.   
Thyroid cancer cell lines containing RET or BRAF mutations have modest growth 
inhibition to rapamycin treatment [90, 91]. Grosinsky-Glasberg describes an effect on 
TT cells of up to 60% growth inhibition [91]. However there was no evidence of 
overwhelming inhibition or apoptosis in thyroid cancer cell lines or xenograft models. 
It is established that mTORC1 inhibitors like rapamycin lead to increased activation 
of AKT, which can lead to attenuation of the tumour response [92].  It may be 
important therefore to inhibit both mTOR complexes in order to completely obliterate 
PI3K signalling.  Indeed, when a PI3K/dual mTOR inhibitor was compared with 
rapamycin alone, there was a considerably more profound cellular response including 
a loss of cell viability [92].  INK128, developed by Intellikine (La Jolla, CA, USA), is 
a dual mTORC1/mTORC2 inhibitor with more potent activity against mTORC1 than 
rapamycin (Figure 1.4) [93].  Utilising these dual mTOR inhibitors is an approach to 
potentially avoid or at least delay secondary mutations and escape pathways, to aim 
for an extended progression-free survival. 
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1.7.3 mTOR inhibitors as part of combination therapy 
Despite targeted therapy increasing progression-free survival, durable responses are 
not common with single agents. One of the strategies to combat progression has been 
to use dual therapy simultaneously to inhibit multiple protumourogenic pathways.  
During this candidature, preclinical studies showed success in inhibiting mTOR 
together with upstream drivers.  One example showed impairment of growth in MTC 
and PTC cell lines through inhibition of mTOR and with a pan-RAF inhibitor 
(including inhibition of VEGFR2) [94].  A novel MEK inhibitor, RDEA119 was also 
shown to have a synergistic inhibitory effect when combined with the mTOR 
inhibitor temsirolimus in thyroid cancer cell lines and a xenograft model of a PTEN 
knock out thyroid cancer cell line [90].  Earlier, combinations of MEK inhibitors and 
rapamycin showed greater inhibition in anaplastic and papillary thyroid cancer cell 
lines [95].   
Recently, clinical studies have started to show the success of combining mTOR 
inhibitors with other pathway blockers.  Common combinations include receptor 
tyrosine kinase inhibitors and either PI3K/mTOR inhibitors or MEK inhibitors. The 
use of rapamycin alone triggers upregulation of S6K through the IRS-1 feedback 
loop, hence inhibiting targets along the amplified axis is appropriate.  In other 
malignancies, combination treatment (mTOR + other) has become standard.  In breast 
cancer, the BOLERO-2 trial showed increased progression-free survival with 
exemestane and everolimus (10.6 months on treatment vs. 4.1 months on placebo) 
[96].  In neuroendocrine tumours, standard therapy with octreotide was augmented 
with everolimus and also increased progression-free survival [97].  Renal cell 
carcinoma, particularly sensitive to mTOR inhibition, has shown clinical success with 
rapamycin [82] and preclinical studies show an augmentation of growth when 
rapamycin is combined with a TKI [98]. Others have confirmed the benefits of 
synergistic therapy in in vivo RCC models [99].  
There are two broad methods by which combined pathway inhibition can be 
exploited. Firstly, by inhibiting multiple points along the same pathway with lower 
doses which can achieve the same overall inhibitory effect; or secondly, by inhibiting 
parallel pathways to aim for an overwhelming inhibition of simultaneous proliferative 
pathways. In this thesis, the former method was examined with a RET and mTOR 
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inhibitor in combination. The latter method was employed with an HSP90 inhibitor, 
which acts to inhibit multiple parallel pathways simultaneously with a single 
destabilising compound and is discussed next.  
1.8 HSP90 inhibitors 
1.8.1 HSP90 mechanism 
Members of the heat shock protein family work as molecular chaperones, ensuring 
homeostasis and aiding in folding and trafficking of client proteins.  Found in the 
cytosol, HSP90 has been shown to mediate the folding of client proteins including 
signalling kinases.  It is well established that cancer cells exhibit deregulation of 
multiple pathways.  Heat shock proteins have become known as central regulators, 
whose actions are to control the activity of pathways such as cell proliferation and 
death, while preventing the aggregation of non-native proteins [100]. There are 
several reasons why HSP90 is an excellent therapeutic target.  Firstly, HSP90 is 
overexpressed in cancer cells. Secondly, documented HSP90 ATPase activity is 
approximately 100 times higher in malignant cells when compared to non-neoplastic 
counterparts [101].  Indeed, cancer cells appear to be more sensitive to inhibition of 
this chaperone’s activity, making it a more specific targeted therapy [102].  HSP90 
client proteins include many kinases involved in apoptosis and signalling. These 
include AKT (and in phosphorylated form), p53, Raf-1, Bcr-abl, BRAF; many of 
these well known in carcinogenesis (Figure 1.7) [103].  RET was recently classified 
as a direct client protein of HSP90 [104]. Mutant cells may even utilise HSP90 to 
compensate for their structural instability and it has been proposed that HSP90 is 
essential to the sustenance of these molecules, otherwise following mutation they 
would be hastily degraded [103, 105].   
HSP90 exists as three separate highly conserved domains; an N-terminal ATPase 
binding domain; a middle domain; and a C terminal dimerization domain. ATP 
binding triggers the closure of the ATP pocket lid and brings the N-termini close to 
each other, resulting in the formation of a compacted, ring-shaped HSP90 dimer 
[106]. These conformational alterations lead to a “closed” state to “clamp” client 
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proteins inside. The ATPase activity of HSP90 itself drives the chaperone cycle and it 
is this mechanism that is exploited when targeting its inhibition [105] (Figure 1.5). 
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Figure 1.5 Mechanism of HSP90 inhibitors. In tumour cells, HSP90 is overexpressed, exists in a co-
chaperone protein complex and has increased ATPase activity.  Tumour cells also have an increased 
affinity for HSP90 inhibitors.  HSP90, when ATP is bound, is involved in the correct folding and 
stabilisation of HSP90 client proteins. HSP90 inhibitors competitively bind to the ATP binding pocket, 
impairing the function of HSP90 and causing destabilisation which leads the proteins to the proteasome 
for degradation. Figure modified from Kamal, A, Discovery Medicine, 2009. 
1.8.2 HSP90 inhibitors in clinical use 
HSP90 inhibitors are categorised into several classes based on distinct modes of 
inhibition, including i) interruption of ATP binding; ii) disruption of co-
chaperone/HSP90 interactions; iii) antagonism of client/HSP90 associations; and iv) 
interference with post-translational modifications of HSP90 [100].  Current treatments 
explored in this thesis draw on the first mechanism as it is employed in the 
geldanamycin derivative, 17-AAG and the Novartis compound, AUY922. 
HSP90 has multiple ways of stabilising proteins which have been exploited in 
inhibitor development (reviewed in [107]).  Geldanamycin, a benzoquinone 
ansamycin antibiotic was the first HSP90 inhibitor to be thoroughly investigated.  It 
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binds to the ADP/ATP binding pocket of the protein through competitive inhibition. 
Its high potential for hepatotoxicity led to the development of its more commonly 
known derivative, 17-Allylamino-17-demethoxygeldanamycin (17-AAG). This drug 
entered clinical trials in 1999 and has had success in phase II trials in a number of 
cancers, including breast, melanoma and multiple myeloma, summarised in [100]. It 
has pertinent pharmacological limitations including low water solubility, instability in 
solution and low oral bioavailability [100].  As well as formulation difficulties, there 
are significant clinical toxicity issues when using 17-AAG as a primary therapy. 
These include hepatotoxicity and polymorphic metabolism [108].  Hence, newer 
compounds with similar inhibitory activity have been developed.  NVP-AUY922 is 
an isoxazole based compound that acts as a competitive inhibitor of ATP.  Its 
administration renders HSP90 inefficient thereby destabilising its client proteins. It 
has been used in preclinical studies of many recalcitrant cancers including most 
recently studies on prostate [109], non small cell lung cancer [110] and osteosarcoma 
[111].  It has both cytostatic and cytotoxic effects, depending on the origin of the 
malignancy.  
 
 
Figure 1.6 PyMOL cartoon showing NVP-AUY922 bound to the NH2-terminal domain of 
HSP90.  Reproduced from Eccles, S et al, 2008 [108]. 
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1.8.3 HSP90 inhibitors in thyroid cancer 
Investigation into the effectiveness of HSP90 inhibitors in thyroid cancer has 
commenced in the past few years. 17-AAG has showed an inhibitory growth effect in 
thyroid cancer cell lines, but no apoptosis was observed [112]. The drug 
BTIMNP_D004 acts through HSP90 destabilisation and shown anticancer activity in 
thyroid cancer cell lines in vitro [58].  Furthermore, treatment with 17-AAG reduced 
PTC-1 expression levels and increased radioiodine accumulation in PCCL3 thyroid 
cells where PTC-1 was induced by doxycycline [113].  This was determined to be 
independent of the sodium iodide symporter (NIS) and likely resulted from an effect 
of decreased iodide efflux through a PKA mechanism. Whilst significant, this data 
was performed in non-cancer thyroid cell lines and requires further certification in 
cancer cells.  Elisei et al have also shown that destabilising HSP90 prolongs the 
retention time for I131 in NIS transfected FRO-19 tumour cells [114].  Treatment with 
radioiodine in poorly differentiated refractory thyroid cancers is often inadequate due 
to resistance. Enhancing I131 uptake is a focus in thyroid cancer research. These 
compounds may be a novel mechanism of increasing uptake.  Recently another 
tyrosine kinase protein found prolifically in thyroid cancer, AXL, was shown to be a 
client protein of HSP90, and was downregulated after 17-AAG treatment [115]. 
1.8.4 HSP90 in RET driven cancers 
The rationale for pursuing HSP90 inhibitors in RET mutant cancer cells is not only its 
role as an HSP90 client protein [104].  In section 1.3.3, the close association and 
shared lineage of MTCs and neuroendocrine tumours have been explored.  In the last 
few years, clinical trials have shown improvements in outcomes with neuroendocrine 
tumours and drawing on their shared ancestry is a mechanism to develop new 
treatments in MTC [81]. Gloesenkamp et al showed preclinical data with HSP90 
inhibitors in NETs and the successful results of dual treatment with mTOR or AKT 
inhibitors [116].  Cohen et al showed inhibition of RET phosphorylation and 
proliferation in TT cells following 17-AAG treatment [117].  None of these studies 
showed apoptosis.  Just prior to submission, Zitzmann et al showed AUY922 treated 
neuroendocrine cell lines demonstrated apoptosis [118].  
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Advanced cancers have multiple genetic alterations that drive malignant growth. It is 
established that often, once the initial oncogene has been targeted, resistance develops 
to the treatment through further mutations.  The benefit of HSP90 inhibitors is the 
simultaneous inhibition of multiple targets along the signalling cascade (Figure 1.7).  
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Figure 1.7 HSP90 client proteins. Downstream RET signalling in thyroid cancer is closely linked 
with to HSP90 chaperone.  Components of the MAPK and PI3K pathways are established HSP90 
client proteins and are all susceptible to inhibition by AUY922. 
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1.9 The role of the tumour microenvironment 
As discussed above, there have been considerable developments in cancer research 
over the past decades with the advent of targeted therapy. However these gains, in 
terms of patient survival times, are still relatively modest.  An alternative path of 
therapeutic investigation is the tumour microenvironment. Stroma surrounding the 
tumour is now thought in many cases to moderate propagation of disease.  Aggregates 
of inflammatory cells in the stroma lead to a protumourogenic environment. The 
relationship between cancer and inflammation is recognised, but cross talk between 
microenvironment and tumour oncogenes is still being established. Polymorphisms in 
genes encoding proinflammatory chemokines are associated with an increased risk of 
certain cancers [119]. Cancer cells themselves secrete cytokines and chemokines 
promoting inflammation and recruiting leukocytes into the tumour sites.  An 
inflammatory microenvironment supports cell survival in stress conditions, as normal 
human epithelial cells prevent oncogene expression due to induction of apoptosis 
following excess growth signals and DNA stress [120]. Chronic inflammation induces 
aggregation of inflammatory cells including macrophages, neutrophils and 
lymphocytes coalesced by cytokines. This microenvironment may contribute to 
tumour progression through the presence of highly mutagenic agents like reaction 
oxygen species inciting DNA stress such as breaks, rearrangements and point 
mutations that lead to tumourogenesis [121].  
RET itself has a close association with inflammation.  RET/PTC induces the synthesis 
of many inflammatory proteins in epithelial thyroid cells [120].  In Tg-RET/PTC 
transgenic mice where RET/PTC is expressed solely in the thyroid, an inflammatory 
response is described [122, 123].   Others have found RET/PTC rearrangements in the 
immune inflammatory condition Hashimoto’s thyroiditis [124].  The RET/PTC3 
oncoprotein can even induce recruitment of immune cells into tumour sites, 
specifically CD8+ T-Cells [123].  This is through the recruitment of chemokines, 
cytokines, matrix degrading enzymes and adhesion molecules, all of which the 
oncogene is known to directly recruit [125].   
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1.9.1 TAMs in cancer 
The rich tumour stroma has pathologic actions in tumour progression by regulating 
tumour growth, invasion and metastasis.   An important component of the tumour 
stroma are leucocytes termed tumour associated macrophages (TAMs) (Figure 1.8).  
These macrophages, derived from the usual myeloid lineage are activated by 
cytokines and environmental cues to differentiate into an “alternatively activated” M2 
phenotype. This is opposed to M1 (classically activated) macrophages which are anti-
tumour [126]. M2 macrophages, or TAMs, found predominantly in tumours, are 
protumourogenic and are critical to progression in a variety of malignancies. They are 
involved in promotion of cancer cell motility and breed metastasis [127].  The 
molecular mechanisms that differentiate TAMs into their M2 phenotype are yet to be 
completely elucidated. However, some of their protumourogenic roles have been 
identified and are summarised in Figure 1.8.  As their role in tumour progression has 
started to be understood, pharmacological inhibitory targets have emerged as potential 
therapies [128].  
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Figure 1.8 Diagram of the microenvironment in cancer.  Key players of the microenvironment 
include monocytes which differentiate into TAMS through M-CSF.  TAMs also are involved in matrix 
remodelling through chemokines, antigen presentation and tissue damage leading to accentuation of 
tumour invasion and metastasis. MMPs= Matrix metalloproteinases, known for degrading the 
extracellular matrix (ECM); M-CSF= macrophage colony stimulating factor (a secreted cytokine); 
CXCL8; CXCL12 = interleukins produced by TAMs involved in the immune response. 
 
1.9.2 The microenvironment in BRAF mutant thyroid cancers 
In thyroid cancer, over half of the tumour stroma can be comprised of TAMs [129].  
A clear association between capsule invasion and extrathyroidal invasion is correlated 
with increased TAM infiltration [129].  A high density of TAMs also correlates with 
poor prognosis.  As shown in Table 1.1, BRAF mutant thyroid cancer is found in 30-
50% of PTCs. Patients with BRAF mutations also experience a more aggressive 
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clinical course. They have worse outcomes associated with refractoriness of 
radioiodine therapy and an increase in mortality [22]. The role of the 
microenvironment in BRAF tumours is only beginning to be understood. Mesa et al 
showed that in mutant BRAF rat thyroid cells, the expression of the matrix 
metalloproteinases (MMP 3, 9, 13) is upregulated [130].  The presence of these 
endopeptidases is correlated with chemokine and cytokine activation and degradation 
of fibrillar collagens, promoting metastasis. Others have looked at roles of integrins as 
mediators of extracellular matrix invasion in mutant BRAF driven cancer. This has 
been shown to have higher expression in mutant BRAF positive PTC compared with 
wild type BRAF PTC [131]. Hence the role of the microenvironment in mutant BRAF 
malignancies is suggestive of a tumour enhancement.  
The role of the tumour microenvironment in thyroid cancer is not well studied.  
Investigating critical components of the stroma may lead to novel therapies. In this 
thesis, the role of tumour associated macrophages is explored in in vivo models of 
BRAF mutant thyroid cancer.  Potential therapies include inhibiting CSF-1 
pharmacologically, which render TAMs ineffective.  The stroma is not merely a 
structural scaffold to moderate progression of disease, but a dynamic functioning 
component of cancer progression.  
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1.10 Summary and aims 
In summary, whilst new research has brought a number of targeted therapies to 
clinical trials in thyroid cancer, current TKIs are yet to achieve a consistent prolonged 
therapeutic response.  The increasing incidence and mortality of thyroid cancer is 
alarming.  Beyond initial surgical resection, refractory tumours with aggressive 
mutations are providing clinicians with limited options.  The approved TKIs for 
metastatic disease are accompanied by adverse side effects often requiring dose 
reductions or delays.   
The goal of this project was to identify alternative strategies for the development of 
targeted treatment of thyroid cancer. To address that goal, the specific aims of this 
project were: 
1. To determine the significance of the role of mTOR in mutant RET driven 
thyroid cancers in both in vitro and in vivo model systems 
2. To evaluate the anti-proliferative and apoptotic outcomes of inhibiting 
multiple components of signalling pathways though: 
a. A combination of lower doses of compounds along the same signalling 
axis (RET and mTOR). 
b. Use of a novel HSP90 inhibitor, AUY922. 
3. To explore the role of the tumour microenvironment in thyroid cancer, and 
specifically to investigate the role of a dominant cell type in the tumour 
stroma, the tumour associated macrophage (TAM), in thyroid cancer initiation 
and progression.   
  
 
Chapter 2. 
Materials and methods 
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2.1 Materials 
Information about materials, reagents and kits used are listed in Table 2.1 (section 
2.9). All were prepared according to the manufacturer’s instructions of the relevant 
kits. Table 2.2 (section 2.10) describes the sources of specialty equipment and 
software.  Section 2.11 describes the components of reagents prepared by the 
candidate. The suppliers of specific materials are listed when first described. Methods 
specific to each results section are found within that chapter.   
2.2 Cell Culture 
2.2.1 Cell line origins 
TT cells, derived from a medullary thyroid cancer, harbouring a gain of function 
RETC634W mutation, were from the American Type Culture Collection (ATCC); CRL# 
1803 (Manassas, VA, USA).  MZ-CRC-1 cells were derived from a malignant pleural 
effusion from a patient with metastatic medullary thyroid carcinoma with a RETM918T 
mutation (a kind gift from Massimo Santoro, Italy). TPC-1 cells are a papillary 
thyroid cancer cell line which harbours the RET/PTC1 rearrangement. This consists of 
a fusion gene between RET and H4 which causes constitutive RET activation (Fagin 
lab stores, USA). The SW1736 thyroid cancer cell line harbours a BRAF mutation and 
is wild type for RET (Fagin lab stores, USA). The FTC133 cell line was sourced from 
a lymph node from a metastatic follicular thyroid cancer (Fagin lab stores, USA). It 
has one PTEN allele deleted and has a p53 mutation.  All cell lines have been 
genetically fingerprinted by either Comparative Genomic Hybridization plus Single 
Nucleotide Polymorphism (SNP-CGH) or polymorphic short tandem repeat (STR) 
and verified to be unique [132, 133]. 
2.2.2 Maintenance of cell lines 
Cell cultures were grown in humidified conditions with 5% CO2 at 37°C (Sanyo 
Biomedical, Wood Dale, IL, USA) and were subcultured at 90% confluence.  TT cells 
were grown in F12 Ham’s media (Invitrogen Life Technologies, Carlsbad, CA, USA) 
supplemented with 10% Foetal Bovine Serum (FBS) (Invitrogen). MZ-CRC-1 cells 
were grown in Dulbecco’s Modified Eagle’s medium (DMEM) (Invitrogen), 
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supplemented with 10% FBS. TPC-1 cells were grown in DMEM - High Glucose 
media (Invitrogen) supplemented with 5% FBS.  SW1736 was grown in RMPI-1640 
(Invitrogen) with 10% FBS and 1% Non Essential Amino Acids. FTC133 were grown 
in 50% DMEM; 50% HAMS F12 media with 10% FBS.  All media were 
supplemented with glutamine and 100 units/ml penicillin-streptomycin unless 
specified (Thermo Trace, Noble Park, VIC, Australia).  
2.2.3 Subculture of cells 
All cells were harvested with Trypsin-EDTA (0.25%/2%) (Sigma-Aldrich, St Louis, 
MO, USA) after one wash with Phosphate Buffered Saline (PBS) (Invitrogen). Cells 
were incubated with sufficient trypsin to cover flask. Following 5 minute incubation 
or until cells were nearly suspended; trypsin was deactivated with 10ml of media 
containing FBS. The cell suspension was transferred to 15ml tube and centrifuged for 
5 minutes at 1200rpm. The supernatant was removed and cells were resuspended in 
predetermined volume of media.    
2.2.3.1 Mycoplasma detection 
The MycoAlert Mycoplasma Detection Kit (Lonza, Rockland, ME, USA) was used to 
routinely assess cultured cells for Mycoplasma contamination every three months.  
Antibiotic-free cell culture supernatant was aliquoted into a white opaque 96 well 
microplates. 100µL MycoAlert Reagent was added per well and allowed to incubate 
for 5 minutes. The Veritas Microplate Luminometer (Promega, Madison, WI, USA) 
was used to perform a 1 second integrated reading, then 100µL of MycoAlert 
Substrate was added to each sample. After 10 minutes incubation at room 
temperature, another 1 second integrated reading was performed. The ratio of the 
second to the first reading was calculated, with a result <1 negative, and >1 positive 
for Mycoplasma contamination.  
2.2.4 Cryopreservation of cells 
Long term storage for cells was in liquid nitrogen tanks. T150cm2 flasks were 
cultured until 90-100% confluent.  Cells were passaged as described above, and the 
cell pellet resuspended in 10mls of freezing media.  Freezing media contained 10% 
DMSO (Sigma-Aldrich), and 90% filtered FBS.  The suspension was evenly divided 
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into 10 cryovials (Cryotubes, Iwaki; Crown Scientific, NSW Australia). Vials were 
frozen at -80°C for 48 hours prior to transfer to liquid nitrogen.  To resuscitate frozen 
cell cultures, one vial of cells was rapidly thawed at 37°C and then added into 
warmed culture media. The culture medium was replaced after 24 hours. 
2.3 Drugs 
2.3.1 AST487 
NVP-AST487-NX, (AUY922) a protein tyrosine kinase inhibitor with the structure 1-
[4-(4-ethyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-3-[4-(6-methylamino-
pyrimidin-4-yloxy)-phenyl]-urea was analysed at Novartis Pharma AG (Basel, 
Switzerland) (Figure 2.1). It inhibits the intracellular domain of the RET kinase with 
an IC50 of 0.88µl/L [56].  The compound, in powder form, was stored at -80°C in its 
original shipping container for up to 2 years. The powder was weighed and using the 
formula mass of 529.55, appropriate concentrations of DMSO was added to make 
stocks of 10mM to avoid multiple freeze thaw cycles. Stocks were kept at -20°C for 
up to 6 months as per the manufacturer’s instructions.  In vivo preparation is described 
in section 4.2.4.3.  
2.3.2 INK128 
INK128 is an ATP competitive inhibitor of mammalian target of rapamycin (mTOR) 
complex 1 and complex 2.  Its structure is 3-(2-amino-5-benzoxazolyl)-1-(1-
methylethyl)-1H-Pyrazolo[3,4-d]pyrimidin-4-amine and has a formula weight of 
309.3 (Figure 2.1). Out of a panel of 222 protein kinases, it inhibited 5 kinases 
(including mTOR) greater than 80% at 1mM in SelectScreen Kinase Profiling, and 
had very low activity on RET [134].  INK128 was stored in a light sensitive container 
at -20°C, as per the manufacturer’s instruction.  10mM stocks in 2ml eppendorf tubes 
were generated, diluting the correct amount of compound with DMSO and stored at 
4°C.  In vivo preparation is described in 4.2.4.2. INK128 was provided as per a 
material transfer agreement with Intellikine (La Jolla, CA, USA). 
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2.3.3 AUY922 
AUY922 is an isoxazole based compound which competitively inhibits the ATPase 
activity of heat shock protein 90 (HSP90). AUY922 potently inhibits HSP90 with an 
IC50 of 30nM as measured in a fluorescence polarization assay [135]. The chemical 
name is 5-(2,4-dihydroxy-5-isopropyl-phenyl)-N-ethyl-4-
[4(morpholinomethyl)phenyl]isoxazole-3-carboxamide methanesulfonate (Figure 2.1) 
and documented molecular mass is 465.24.  Powder was stored at -20°C in a light 
sensitive container.  Powder was measured at 500µg and 107.38µl 100% DMSO 
added to stock concentration of 10mM. 10µl aliquots were stored at -20°C to avoid 
multiple freeze-thaw repetitions.  The HSP90 inhibitor AUY922 was kindly provided 
under a material transfer agreement with Novartis Institutes for Biomedical Research 
(Basel, Switzerland).  
 
 
 
 
Figure 2.1 Chemical structure of compounds utilised in this thesis. 
 
  
AST487' INK128' AUY922'
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2.4. Western Blotting 
2.4.1 Extraction of total cell protein 
Cells were washed once with PBS and scraped into 1.5ml eppendorf tubes on ice. 
Lysates were spun at 2,500rpm for five minutes and the pellet resuspended in 50µl of 
a modified RIPA lysis buffer (see 2.11). Lysates were spun at 4°C for 1 hour then 
centrifuged at 14,000rpm for 10 minutes. Protein quantification was determined 
through BCA protein assay (Thermo Scientific, Rockford, IL), with premade BSA 
standards. BSA standards were aliquoted according to the manufacturer’s instructions. 
Standards were pipetted in triplicate to determine a standard curve. Curves for 
determining concentration were only used if R value >0.99. Lysates were diluted 1:5 
and incubated for 30 minutes at 37°C. Concentrations were determined on the Tecan 
Sunrise microplate reader (Salzburg, Austria). 
2.4.2 Western gel electrophoresis 
Samples containing 20µg protein were separated by SDS-10% PAGE precast gels 
(Invitrogen) for all antibodies except pRET and RET, for which SDS-7.5% PAGE 
gels were analysed. A lane containing 10µL of Precision Plus Protein Standard 
Kaleidoscope Bio-Rad marker ladder (Bio-Rad Laboratories, Hercules, CA, USA) 
was included in each gel. Running buffer was generated by the candidate (see 2.11).  
Gels were run for 1 hour at 100V.  Proteins were transferred to a nitrocellulose 
membrane (Hybond-C, GE Healthcare) using Bio-Rad transfer apparatus (Hercules, 
CA, USA) for 40 minutes at 100 volts. Successful transfer of proteins was determined 
by clear identification of the pre-stained kaleidoscope marker ladder, and by staining 
the membrane with 0.1% (wt/vol) Ponceau S Red in 5% acetic acid (Sigma). The 
membranes were then washed in Tris-buffered saline with 0.1% Tween 20 [TBST] 
(Sigma). Membranes were blocked in 5% milk powder diluted in TBST (wt/vol) for 1 
hour. 
 
2.4.3 Antibody hybridisation 
The membrane was hybridised to the primary antibody that had been diluted in buffer 
(5% wt/vol nonfat dry milk in TBST).  10ml of this solution was added to each 
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membrane which was kept on an orbital shaker at 100rpm overnight at 4°C. 
Membranes were probed a maximum of three times.  The following day membranes 
were washed at room temperature in TBST, 3 times for 10 minutes on the orbital 
shaker, vigorously at 500rpm. Working solution consisted of 1x TBS and 1% Tween 
20 was added. The secondary antibodies were diluted in 5% BSA in TBST (wt/vol) 
which was hybridized for 1 hour with vigorous agitation at room temperature. Both 
anti-mouse and anti-rabbit antibodies were used at a 1:5000 dilution (GE Healthcare 
Pittsburgh, PA, USA). The membrane was then rewashed in TBST 3 times for 10 
minutes each prior to detection with Immobilon Western Chemiluminescent 
Horseradish Peroxidase Substrate (Millipore, Billerica, MA, USA) and images 
analysed with Molecular Imaging Software (Kodak, Rochester, MA, USA). For each 
western blot performed, a housekeeping protein was probed for to ensure equal 
loading and even transfer. Choice of the housekeeping protein varied between blots 
depending on the size of the nominated primary antibody. They included p85 (PI3K- 
p85 #06-195, Millipore); beta actin (#A2228 Sigma); and GAPDH (#2118 Cell 
Signalling). If the housekeeping protein did not distribute evenly across the samples, 
the blot was discarded.  Blots in chapter 3 were not normalised with digitisation as 
that was not the protocol in the lab during that time. Normalisation of other blots were 
achieved through MyImageAnalysis (Thermo Scientific, Rockford, IL). Briefly, blots 
were transferred to tiff image files and exported into the MyImageAnalysis. Density 
was calculated automatically using high sensitivity. Phospho proteins were then 
divided by total protein density.  The ratio values of the vehicle treated cells were 
analysed to 100%. Treated values were calculated against vehicle protein expression.  
The following rabbit antibodies were purchased from Cell Signalling Technology 
(Beverly, MA, USA): anti-phospho-Akt XP(Ser473, #4060), anti-Akt (#2938), 
phospho-p44-42 MAPK (Erk1/2; Thr 202/Tyr204 # 9101), anti-phospho-phospho-
MEK1/2 (Ser217/221 #9121), anti-phospho-S6 ribosomal protein (Ser235/236, 
#2211), anti-phospho 4EBP-1 (#9455), anti-4EBP-1 (#9452), anti-phospho RET 
(Y905 #3221), anti-RET (#3220). The mouse anti-cleaved PARP (#9544) and anti-S6 
ribosomal protein (#2317) were also from Cell Signaling Technology. Representative 
membranes are shown for each experiment.  
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2.5 Cell cycle analysis 
TT, MZ-CRC-1 and TPC-1 cells were plated at 1x106 wells in triplicate in a 6 well 
plate. The following day cells were incubated with fresh medium with either vehicle, 
INK128, AST487 or the compounds in combination. Cells were trypsinised at 72 and 
96 hours and treated with 20mg/ml Purelink RNAse A (Invitrogen) and 10mg/ml 
ethidium bromide (Promega). Following one hour incubation, cells were retreated 
with 2.5µl ethidium bromide and cell cycle analysis was performed on a 
FACSCalibur flow cytometer (Beckton-Dickinson, NJ, USA) in collaboration with 
the Memorial Sloan Kettering Flow Cytometry core.  Cell cycle analysis was 
achieved through FloJo Software (Treestar, Ashland, OR, USA). 
2.6 RNA methods 
2.6.1. Extraction of total cell RNA  
RNA was isolated from cell lines through PrepEase RNA Spin Kit (USB, Affymetrix, 
Santa Clara, CA, USA). Briefly, following treatment, 5x105 cells were harvested and 
bound to agent RA1 and β-ME. Cell lysate was added into PrepEase collecting tube 
and centrifuged for 1 minute at 11,000g for filtering. The RNA was prepared for 
binding by adding 350µl of 70% ethanol to elutent. RNA was then bound to a spin 
column and centrifuged for 30 seconds at 8000g. The spin column membrane was 
desalted by adding 350µl of Membrane Desalting Buffer and respun at 11,000g for 1 
minute. DNA was digested by adding 95µl of DNAse reaction mixture to column. 
The column was washed 3 times and pure RNA was eluted by adding 30µl of RNAse 
free water to the final column and centrifuging at 11,000g for 1 minute. RNA was 
quantitated on the Nanodrop spectrophotometer (NanoDrop, Wilmington, DE, USA). 
2.6.2. Reverse transcription 
Complementary DNA (cDNA) was synthesised by converting 0.4µg of RNA using 
converted to cDNA with the Verso cDNA Kit (Thermo Scientific). Each 20µl 
reaction included 5X cDNA synthesis buffer, 2µl dNTP mix, 1µl RNA primer, 1µl 
RNA enhancer, 1µl Verso Enzyme Mix then totalled to 20µl with PCR grade water. 
The reverse transcription cycling program had cDNA synthesis for 30 minutes at 
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42°C followed by inactivation at 95°C for 2 minutes. Samples were stored at -20°C. 
Quantitative reverse transcription-PCR was done using Power SYBD Green PCR 
Master Mix (Applied Biosystems, VIC, Australia) and primer pairs for RET (5’-
GCAACGGCCTTCCATCTGAA-3’ and 5’-ACTCGGGGAGGCGTTCTCTTT-3’) 
and GAPDH (5’-ACCATCTTCCAGGAGCGA-3’ and 5’-
GGCAGAGATGATGACCCTTT-3’).  The cycling conditions for samples analysed 
included an initial denaturation step (95°C for 15 minutes), 40 cycles of denaturation 
(95°C for 15 seconds), followed by annealing and extension (60°C for 30 seconds). 
Relative quantitation was determined using the comparative CT method and GAPDH 
gene was used as the endogenous control. The cycle threshold values for GAPDH and 
RET were determined with an eppendorf thermocycler (Eppendorf, Hamburg, 
Germany) and used to calculate the relative expression using the QGENE program 
(Kansas State University, Manhattan, Kansas, USA) [136]. 
2.7 In vivo experiments 
2.7.1 Mouse breeding 
The candidate was trained in animal husbandry and breeding through the Memorial 
Sloan Kettering Animal Core Facility. Mice were mated at 6-8 weeks when they were 
sexually mature. Mice were split into 1 male and 2 females per cage. Upon delivery of 
the pups, females were moved with the pups into their own cage.  Genotyping was 
performed by the Memorial Sloan Kettering Core Facility through PCR from tail 
DNA.  Mouse identification number was ascertained through toe clipping.  
2.7.2 Thyroid dissection  
Following the described treatment protocol, mice were sacrificed with CO2.  They 
were weighed before and after treatment.  Thyroids were dissected promptly after 
sacrifice. Paratracheal muscle was removed with surgical instruments as precisely as 
visually possible.  Thyroids were placed immediately in 4% paraformaldehyde 
(freshly made) (Sigma) and incubated overnight at 4°C on a rotating platform.  The 
following morning, tissue was washed twice in PBS for 30 minutes.  Tissue was then 
stored at 4°C in 70% ethanol (BDH).  The fixed tissue was embedded in paraffin 
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(Thermo Scientific) and sectioned into 5µM sections by the candidate (Discovery XT 
processor, Ventana Medical Systems, Tucson, AZ, USA).  Slides were prepared with 
three repeated sections of the indicated condition on one slide.    
2.7.3 Immunohistochemistry 
Immunohistochemistry was not performed by the candidate but in collaboration with 
the Memorial Sloan Kettering Cancer Center Molecular Cytology Core Facility.  
Tissue was analysed and immunostained with antibodies to Ki67 (VP-K541; Vector 
Laboratories); pS6 ribosomal protein (#2211, Cell Signaling Technology); anti-Akt 
(Cell Signaling #2938), phospho-p44-42 MAPK (Erk1/2; Thr 202/Tyr204 Cell 
Signaling #9101). Quantification of staining was performed using whole thyroid 
digitised images obtained from scanned slides, and analysed with Metamorph 
software (Olympus, Center Valley, PA, USA). Slides were also stained for H/E. 
These stained slides were reviewed by a pathologist experienced in the analysis of 
murine thyroid cancers (Dr R. Ghossein, Department of Pathology, Memorial Sloan 
Kettering Cancer Centre, NY, USA).    
2.8 Statistical Analysis 
Experiments were performed in triplicate and repeated three times unless otherwise 
stated. Data presented in this thesis was analysed by the candidate using the statistical 
software package for Microsoft Excel and GraphPad Prism version 5.2 and 6.0. 
Unpaired two tailed t tests were performed between groups as indicated. P values 
were considered significant if < 0.05. In each figure p values of <0.05 are identified as 
*; p values <0.001 as **. Results are expressed as mean ± standard deviation (SD) 
unless otherwise stated.  Statistics were reviewed by Dr Jillian Patterson (Statistician, 
Kolling Institute, Australia). 
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2.9 Chemicals, kits and reagents 
Table 2.1 Source of chemicals and reagents 
 
Materials Source 
2-Beta-Mercaptoethanol Sigma-Aldrich, MO, USA  
β-glycerophosphate  Millipore, Billerica, MA, USA 
4% paraformaldehyde Sigma-Aldrich, MO, USA  
5% acetic acid Sigma-Aldrich, MO, USA 
Acetone Sigma-Aldrich, MO, USA 
Ambion Silencer select siRNA Ambion, Austin, TX, USA 
Annexin binding buffer Invitrogen Life Technologies, Carlsbad, CA, 
USA 
Annexin V/PI Apoptosis kit Invitrogen Life Technologies, Carlsbad, CA, 
USA 
Anti-mouse antibody horseradish peroxidase DakoCytomataion, Denmark 0447 
Aprotinin Sigma Aldrich, MO, USA 
BCA protein assay Thermo Scientific, Rockford, IL, USA 
Bovine serum albumin (BSA) Invitrogen Life Technologies, Carlsbad, CA, 
USA 
BrdU Cell proliferation assay kit #6813 Cell Signalling Technology, Beverley, MA, 
USA 
Calcium chloride Sigma-Aldrich, MO, USA 
Cell culture flasks and plates Nunclon, Nalge, Nunc International, Denmark 
Cell Proliferation Assay 96 Aqueous One 
Solution  
Promega, Madison, WI, USA 
Cryovials Iwaki Glass, Canada 
Culture medium, DMEM powder, Gibco Invitrogen Life Technologies, Carlsbad, CA, 
USA 
Culture Mmedium, DMEM/F12 powder, 
Gibco 
Invitrogen Life Technologies, Carlsbad, CA, 
USA 
DakoCytomation serum-free protein block Dako, Carpinteria, CA, USA 
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DAPI Thermo Scientific, Rockford, IL, USA 
DilC(5)  Biotium Inc, Hayward, CA, USA 
Dimethyl sulphoxide (DMSO) Sigma-Aldrich, MO, USA 
Diphtheria toxin List Biologicals Laboratories, Campbell, CA, 
USA 
Doxycycline impregnated chow, 2,500ppm Harlan-Teklad, Haslett, MI USA 
EasySep Mouse mesenchymal stem cell kit Stemcell Technologies, Vancouver, Canada 
Easy Prep RNA spin kit Affymetrix, Santa Clara, CA, USA 
ECL Plus western blotting detection Amersham Pharmacia Biotech, 
Buckinghamshire, UK 
Ethanol BDH Chemicals, VIC, Australia 
Ethidium bromide Amresco, OH, USA 
Ethylene diamine tetraacetic acid (EDTA) BDH Chemicals, VIC, Australia 
Foetal Bovine Serum (FBS) Fisher Scientific, Pittsburgh, PA, USA  
Filter, 32 mm, 0.2 µM Millipore Cooperation, MA, USA 
Glycine Amresco, OH, USA 
Hanks buffer Invitrogen Life Technologies, Carlsbad, CA, 
USA 
HEPES Amresco, OH, USA 
Hybond ECL western blotting membrane 
GE Healthcare, Buckinghamshire, UK 
Iodine  PerkinElmer, Waltham, MA, USA 
Lipofectamine RNAImax Invitrogen Life Technologies, Carlsbad, CA, 
USA 
Loading dye solution Quantum Scientific, QLD, Australia 
Magnesium Chloride Sigma-Aldrich, MO, USA 
Marker, Precision Plus Kaleidoscope protein 
ladder  
Bio-Rad, CA, USA 
Mouse seroblock FcR AbD Serotech, Bio-Rad Laboratories, CA, 
USA 
MycoAlert Kit mycoplasma detection kit Cambrex Biosciences Rocklands Inc, 
Rocklands ME, USA 
NMP Sigma-Aldrich, MO, USA 
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NP40 Sigma-Aldrich, MO, USA 
OCT Sigma-Aldrich, MO, USA 
Optimem, reduced serum media Invitrogen Life Technologies, Carlsbad, CA, 
USA 
Penicillin / Streptomycin Invitrogen Life Technologies, Carlsbad, CA, 
USA 
Pepstatin Sigma-Aldrich, MO, USA 
Phenylmethylsulfonyl fluoride Thermo Scientific, Rockford, IL, USA 
Phenylmethylsulfonyl fluoride Thermo Scientific, Rockford, IL, USA 
Phosphate Buffered Saline, (PBS) Gibco Invitrogen Life Technologies, Carlsbad, CA, 
USA 
PNB blocking reagent PerkinElmer, Waltham, MA, USA 
Polyethylene glycol Sigma-Aldrich, MO, USA 
Ponceau S red  Sigma-Aldrich, MO, USA 
Potassium chloride BDH Chemicals, Kilsyth, VIC, Australia 
Potassium perchlorate Sigma-Aldrich, MO, USA 
Power SYBD Green PCR master mix  Applied Biosystems, VIC, Australia 
Primers - all used in thesis Sigma-Aldrich, MO, USA 
Propidium Iodide Merck Chemicals, Darmstadt, Germany 
Protease inhibitor, complete mini cocktail 
tablets 
Roche, Basel, Switzerland 
Purelink RNAse A Invitrogen Life Technologies, Carlsbad, CA, 
USA 
PVP Sigma-Aldrich, MO, USA 
RNA PrepEase kit  USB Corporation, Cleveland, OH, USA 
SDS Sigma-Aldrich, MO, USA 
Skim milk powder, Coles instant Coles Supermarkets, Tooronga, VIC Australia 
Sodium chloride Asia Pacific Specialty Chemicals, NSW, 
Australia 
Sodium citrate Sigma-Aldrich, MO, USA 
Sodium deoxycholate  Sigma-Aldrich, MO, USA 
Sodium flouride Sigma-Aldrich, MO, USA 
Sodium hydroxide Sigma-Aldrich, MO, USA 
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Sodium orthovanadate Sigma-Aldrich, MO, USA 
Tg-RET/PTC3 transgenic mice  Dr Jay Rothstein, Amgen Inc., Seattle, WA, 
USA 
Tris BDH Chemicals, VIC, Australia 
Tris-HCL Amresco, OH, USA 
Triton X-100 BDH Chemicals, VIC, Australia 
Trypsin – EDTA Sigma Aldrich, MO, USA 
Tween 20 Sigma-Aldrich, MO, USA 
Verso cDNA Kit Thermo Scientific, Rockford, IL, USA 
Vi-Cell series cell viability analyzer  Beckman Coulter, Fullerton, CA 
Western chemiluminescent horseradish 
peroxidase substrate 
Millipore, Billerica, MA, USA 
 
 
  
50 
2.10 Special Equipment and Software 
Table 2.2 Source of all equipment and software 
Equipment Source 
Applied Biosystems 7900HT Fast Real - Time 
PCR System thermal cycler 
Applied Biosystems, CA, USA 
 
Biorad transfer apparatus Hercules, CA, USA 
Cell Quest Pro BD BioSciences, Australia 
Centrifuge, benchtop GPR Beckman Instruments Inc, CA, USA 
Centrifuge, benchtop model 5415D Eppendorf, Hamburg, Germany 
Centrifuge, cell culture model 5702R Eppendorf, Hamburg, Germany 
Discovery XT processor  Ventana Medical Systems Tucson, AZ, USA 
Electrophoresis Cell Apparatus, Ready Gel Bio-Rad Laboratories, CA, USA 
Eppendorf Thermocycler  Eppendorf, Hamburg, Germany 
Flow cytometer FACSCalibur; Becton Dickinson, Franklin 
Lakes, NJ, USA 
FlowJo software Treestar, Ashland, OR, USA 
FUJIFILM Multi Gauge Software V3.0 FUJI Photo Film, Ltd., Tokyo, Japan 
Gamma counter PerkinElmer, Waltham, MA, USA 
GraphPad Prism 5.2 and 6.0 GraphPad Software, San Diego, CA, USA 
Immunoratio 
 
Institute of Biomedical Technology, University 
of Tampere, Finland 
Incubator, CO2 Quantum Scientific  Sanyo Biomedical, IL, USA 
Incubator, shaking Sanyo Biomedical, IL, USA 
Luminometer, Veritas 96-well plate reader Promega Corporation, WI, USA 
Metamorph software Sunnyvale, CA, USA 
Microscope, Inverted Fluorescence Olympus 
IX70 
Sci-Tech Imagining, VIC, Australia 
Microscope, Inverted Nikon Eclipse TS100-F 
with Digital Camera DS-5M-L1 
Sci-Tech Imaging, VIC, Australia 
Microscope, Inverted Olympus BH-2 OM 
System 
Sci-Tech Imagining, VIC, Australia 
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Mirax scanner Carl Zeiss, Germany 
ModFit software Verity Software House, Topsham, ME, USA 
Molecular Imaging software, Kodak and LAS 
4000  
FUJI film Ltd, Tokyo, Japan 
Motifolio Ellicott City, MD, USA 
MyImageAnalysis  Thermo Scientific, Rockford, IL, USA 
PCR Workstation, Aura PCR Bioair PC10000 Bio-Cabinets Australia, VIC, Australia 
pH meter Mettler-Toledo International, OH, USA 
Plate reader Sunrise, Tecan, Salzburg, Austria 
PowerPack, basic Bio-Rad Laboratories, CA, USA 
PrepEase RNA Spin Kit  USB, Affymetrix, Santa Clara, CA, USA 
QGene software Kansas State University, Manhattan, KS, USA 
Rotating wheel Salmond Smith Biolab LTD., Auckland, New 
Zealand 
Shaker, microplate Berthold Detection Systems, Pforzheim, 
Germany 
Shaker, orbital Paton Scientific P/L, SA, Australia 
Shaker, rolling Sanyo Biomedical, IL, USA 
Spectrophotometer, Model DU ® 650 Beckman Instruments Inc., CA, USA 
Spectrophotometer, NanoDrop ND-1000 Nanodrop Technologies, DE, USA 
Thermocycler, Dyad, DNA Engine Bio-Rad, CA, USA 
Veritas Microplate Luminometer  Promega, Madison, WI, USA 
Vi-Cell cell viability analyser Beckman Coulter, Fullerton, CA, USA 
VisualSonics, Vevo2100 ultrasound VisualSonics BD, Amsterdam, The 
Netherlands 
Waterbath, Julabo, SW-20C Julabo, Seelbach, Germany 
Zeiss Axio2Imaging microscope Carl Zeiss, Germany 
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2.11 Reagents 
RIPA Lysis Buffer for in vitro experiments 
50mM Tris HCL 
150mM sodium chloride 
1% NP40 
0.5% sodium deoxycholate 
0.1% SDS 
1mM EDTA 
RIPA Lysis Buffer for in vivo experiments 
20mM Tris [pH 7.4] 
135mM NaCl 
2mM EDTA 
1% Triton X-100 
25mM β-glycerophosphate 
1mM sodium orthovanadate 
1mM NaF 
1mM phenylmethylsulfonyl fluoride 
10µg/ml pepstatin 
10µg/ml aprotinin  
Running Buffer (2L) 
188g Glycine  
30.2g TRIS base 
0.5% SDS 
2L MQ H20 
Transfer Buffer (2L) 
188g Glycine  
30.2g TRIS base 
1.6L MQ H20 
400ml Methanol 
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Tris Buffered Saline (TBS) 10x 
24.23g Tris HCL 
80.06g NaCL  
900ml MQ H20 
Citric Saline (2x) 
270mM KCl 
30mM sodium citrate  
Sterilise by autoclaving for 45 min at 121°C. 
Flow Buffer 
100ml 1x PBS 
0.5g BSA
 
 
 
 
Chapter 3. 
Targeting mTOR in 
RET mutant medullary 
and differentiated 
thyroid cancer cells 
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3.1 Introduction 
3.1.1 RET in thyroid cancer  
RET is a tyrosine kinase receptor for neurotrophic ligands belonging to the glial cell 
line-derived neurotrophic factor (GDNF) family that regulate growth, survival, 
differentiation and migration of cells of neural crest origin [137]. RET also plays a 
crucial role in thyroid tumourogenesis.  RET is endogenously expressed in thyroid 
parafollicular cells. Mutations in RET are highly prevalent in medullary thyroid 
carcinomas (MTC) which arise from these cells.  Hereditary MTC syndromes are 
caused by germline RET point mutations that render the kinase function constitutively 
active, and can present as part of the multiple endocrine neoplasia syndromes 
MEN2A and MEN2B, or as familial medullary thyroid carcinomas (FMTC). Up to 
50% of sporadic MTC is associated with somatic versions of these RET point 
mutations. Conversely, ectopic expression of RET in thyroid follicular cells via 
somatic RET fusion genes, most commonly CCDC6-RET (PTC1) and NCOA4-RET 
(PTC3) are associated with sporadic and radiation-induced papillary thyroid cancer 
[138]. Proteins encoded by these fusion genes typically have coiled-coil domains, 
which induce constitutive dimerization of the oncoprotein and aberrant activation of 
RET kinase activity (Figure 1.3 and detailed in 1.3; 1.6). 
Upon activation, RET is autophosphorylated on numerous tyrosine residues, and the 
signalling pathways activated in response to this have been studied quite extensively 
[21, 139]. Phosphorylation of RET-Y1062 generates a docking site for the adaptor 
molecule Src-Homology 2 (Shc), which when engaged, recruits effectors that lead to 
activation of mitogen-activated protein kinase (MAPK) and phosphoinositol 3-kinase 
(PI3K) signalling.  Inhibition of the PI3K pathway with LY294002, a kinase inhibitor 
that also has effects on mTOR, has been shown to inhibit growth and induce apoptosis 
of the MTC cell line, TT [140, 141]. Recently, novel natural compounds called 
withanolides have been shown to induce apoptosis in MTC cell lines at high 
concentrations, which was suggested to be due to dual mTOR and RET inhibition 
[142]. In contrast, MAPK pathway inhibitors have only modest effects on growth of 
RET/PTC1 mutant thyroid cancer cells [141, 143] and RET mutant MTC cells [144].   
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3.1.2 The role of mTOR in medullary thyroid cancer 
The mTOR kinase is a component of the PI3K signalling pathway that regulates 
protein synthesis, metabolism and cell growth in response to growth factors and 
nutrients. mTOR is present in two multi-protein complexes: mTORC1, in which it is 
associated with raptor, and which controls cap-dependent translation, and mTORC2, 
in which the kinase is associated with rictor, and which phosphorylates AKT at Serine 
473 leading to enhancement of its catalytic activity [145]. AKT, the prosurvival 
protein, is a known therapeutic target (see Figure 1.4). Upregulation can attenuate 
tumour response [146].  mTORC1 is sensitive to rapamycin, whereas mTORC2 is not.  
It is well established that mTOR is dysregulated in pancreatic neuroendocrine 
tumours (pNET). The mTORC1 inhibitor rapamycin inhibits growth of NET cells in 
vitro [147], and one of its analogues, everolimus, was found to have significant 
activity in a clinical trial of patients with pNETs [81].  C cells also derive from a 
neuroendocrine lineage and interestingly, the growth of at least one MTC cell line, TT 
cells, has been shown to be mTOR-dependent [91].   
3.1.3 Current treatments 
MTC has a disproportionately high mortality compared to most other types of thyroid 
cancer, with early surgery offering the only chance for curative therapy.  Vandetanib 
(AZD6474) and cabozantinib (XL184) are ATP-competitive RET kinase inhibitors 
that were recently approved for treatment of metastatic medullary thyroid cancer by 
the FDA, based on significant extension of progression-free survival in patients with 
familial or sporadic forms of the disease [68, 77].  Vandetanib targets RET, epidermal 
growth factor receptor (EGFR) and vascular endothelial growth factor receptor 
(VEGFR) while carbozantanib targets RET, VEGFR and MET.  The extent to which 
the effects of these multikinase inhibitors are due to inhibition of RET is unclear.  
Other ATP-competitive small molecule multikinase inhibitors also targeting RET, 
such as sorafenib, are currently in clinical trials, and are showing promising results in 
patients with metastatic MTC [70].  However, while this is promising new data, these 
compounds are associated with significant side effects and patients often require dose 
reductions. Low-dose therapy with vandetanib has also shown efficacy [67], although 
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the extent to which the activity of the oncogenic kinase is inhibited in the MTC 
lesions with the lower dose of this drug is uncertain. 
3.1.4 Aims 
The goals of this chapter were to determine whether oncogenic RET regulates mTOR 
activity in MTC and PTC cells, and whether targeted inhibition of these two kinases 
shows cooperative effects on growth suppression and cell death. 
3.2 Methods 
Cell cycle, RNA extraction, qPCR methods and western blots are outlined in general 
methods.  
3.2.1 Cell lines and proliferation assays 
TPC-1 cells are a PTC cell line, harbouring the RET/PTC1 chromosomal 
rearrangement. TT and MZ-CRC-1 cell lines are MTC cell lines harbouring the RET 
C634W and M918T point mutations respectively. The FTC-133 cell line is a PTC cell 
line with a PTEN deletion (sources detailed in 2.2.1).  
3.2.1.1 Cell counts on Vi-Cell 
TPC-1, MZ-CRC-1 and TT cells were plated at a density of 50,000 cells/well, in 
triplicate, in six-well plates and treated with the indicated concentration of each 
specific compound the following day.  TPC-1 cells were trypsinised, resuspended in 
2mls of media and counted on day 4.  Due to their more prolonged doubling times, 
TT and MZ-CRC-1 cells were re-treated every 3 days and counted at 6 days.  Cells 
were counted in a Vi-Cell series cell viability analyser (Beckman Coulter, Fullerton, 
CA, USA).  The dose required to inhibit growth by 50% (IC50) was calculated using 
GraphPad Prism version 5.02 for Windows (La Jolla, CA, USA). Briefly, IC50 
analysis was derived from a ‘non linear regression’ with a dose response inhibition 
(log inhibitor vs. normalised response).  
Inhibition of cell growth was calculated as described below (Figure 3.4). Cells were 
plated in triplicate in 6 well plates on day -1 and were treated on day 0. TPC-1 cells 
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and TT cells were counted at 4 and 6 days after treatment with indicated doses of 
single and combination therapy (Vi-Cell counter).  Treated cell counts were 
normalised to the mean of the vehicle treated cells.  Each cell count was divided by 
the mean of the vehicle and converted to % to show relative cell growth inhibition as 
compared with vehicle.   
3.2.1.2 BrdU analysis 
Bromodeoxyuridine (BrdU Cell Proliferation kit, Cell Signaling, Boston, MA, USA), 
a synthetic thymidine analogue that is incorporated into a cell's DNA when the cell is 
dividing (during the S-phase of the cell cycle) was used to demonstrate changes in 
cell proliferation. A series of experiments were performed in each cell line to 
ascertain the best plating densities for the cell proliferation kit. A 96 well plate was 
used and cells were plated at the following densities: TT at 5000/well; MZ-CRC-1 at 
3000/well; and TPC-1 at 1000/well. Cells were treated with compounds and siRNA as 
described in 3.2.2. The following day, 20µl of BrdU was added to each well. 24 hours 
later, cells were washed and DNA denatured with fixing solution (100µl/well). BrdU 
mouse antibody was added to each well (100µl/well) and cells were kept at room 
temperature for 1 hour.  Wells were then washed three times. 100µl of 1xHRP 
conjugated secondary antibody solution was then added and plate kept at room 
temperature for 30 minutes. Plate was then washed three times and 100µl TMB 
substrate was added to each well. Stop solution (100µl) was added and plate was read 
at 490nm on a spectrometer. Data was analysed and presented with GraphPad Prism 
6.0. 
3.2.2 Transfections 
3.2.2.1 Source of siRNA 
Silencer Predesigned Validated siRNAs were purchased from Ambion (Austin, TX, 
USA). Two different RET Silencer siRNAs were purchased for evaluation of knock 
down effectiveness (Ambion siRNA ID’s #s11935, termed “RET 1” and #s11936 
termed “RET 2”). siRNA targeted to Cyclophilin B was used as a positive control in 
the initial experiments to validate the method (Ambion, #12935-142).  The sequence 
termed, “RET 2” was selected due to a greater knock down effect (Figure 3.2A) and 
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was used in all subsequent knock down experiments.  The sequence is as follows: 
(5’>3’) GGAUUGAAAACAAACUCUAtt (sense) and 
UAGAGUUUGUUUUCAAUCCat (antisense).  
3.2.2.2 Methods of transfection 
Cells were plated in antibiotic free media at 30% confluence in six well plates. The 
following day they were transfected with Lipofectamine RNAImax (Invitrogen) and 
siRNAs targeted to RET (“RET 2” selected, Ambion product #4392420), Cyclophilin 
B (Ambion) or a scrambled control (Scramble sequence, Applied Biosystems, 
#AM4611).  siRNA was diluted with 220µl OptiMEM (Invitrogen) to the desired 
concentration.  In a separate tube, the Lipofectamine RNAImax was diluted with 
220µl OptiMEM.  Table 3.1 shows the final concentrations for each cell type 
following titration experiments that maximised knock down and minimised toxicity 
(raw data not shown). Each concentration and time point was performed in triplicate.   
Both the diluted Lipofectamine and siRNAs were incubated for 5 minutes at room 
temperature.  Lipofectamine and siRNA were then mixed together by pipetting gently 
into a fresh tube, and incubated at room temperature for a further 20 minutes.  
Antibiotic free media was added to this solution (to a total of 2ml). Cells were then 
treated with this solution. Media was changed 6 hours later to avoid lipofectamine 
toxicity.  
Table 3.1 Concentration of siRNA used for each cell line 
Cell Line Concentration of 
siRNA/well* 
Amount of 
Lipofectamine RNAImax 
/well 
OptiMEM 
volume/well 
TT 25nM 5µl 440µl 
MZ-CRC-1 50nM 5µl 440µl 
TPC-1 5nM 5µl 440µl 
 * Concentration of scramble sequence siRNA was matched to that of RET siRNA 
used 
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Following transfection, both RNA and DNA were extracted (2.4.1 and 2.6) from 
separate wells. mRNA levels were measured with qPCR.  Results are shown in Figure 
3.2B.   
3.2.3 Apoptosis assessment 
Apoptosis was determined through Annexin V/PI kit (Invitrogen). In this assay, 
Annexin V is conjugated to green channel FITC and PI stains necrotic cells with red 
fluorescence. After treatment with both probes, live cells will show no fluorescence, 
and apoptotic cells will show fluorescence with both PI and Annexin V (red and 
green). 250,000 cells were plated in each well in triplicate. The following day, cells 
were treated with increasing concentrations of AST487 and INK128. The positive 
control was doxorubicin, a cytotoxic chemotherapeutic agent known to cause 
apoptosis in these cells [148].  Cells were harvested to 1 x 106 cells/ml and washed in 
PBS twice. Annexin V binding buffer solution included 25mM HEPES (Amresco, 
OH, USA); 140nM NaCl (Asia Pacific Specialty Chemicals, NSW, Australia); 1mM 
EDTA (BDH Chemicals, VIC, Australia); 0.1% BSA (Invitrogen). 5µl of Annexin V 
binding buffer and 1µl of PI (1mg/ml) was added to 100µl of each suspension. Cells 
were incubated for 15 minutes. 400µl of Annexin Binding buffer (Invitrogen product 
no: V13242, Carlsbad, CA, USA) was added. Cells were kept on ice.  Samples were 
analysed on FACSCalibur flow cytometer promptly (Beckton-Dickinson, NJ, USA).   
3.3 Results 
3.3.1 RET inhibition retards growth in RET mutant cell lines 
3.3.1.1 The RET kinase inhibitor AST487 decreases cell proliferation and mTOR 
signalling in RET mutant cell lines 
AST487 inhibited growth of all three RET mutant thyroid cancer cell lines, with IC50 
in the low nanomolar range for TPC-1 and TT cells and slightly higher for MZ-CRC-
1 cells (Figure 3.1A). As expected, the compound inhibited RET phosphorylation in a 
dose-dependent manner, shown through protein expression in western blots (Figure 
3.1B).   Notably, AST487 also inhibited phosphorylation of the mTORC1 substrate 
4EBP1, and of ribosomal S6, (which is phosphorylated by the mTORC1 substrate 
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p70-S6 kinase) in a dose-dependent manner (Figure 3.1B). This was consistent in all 
RET mutant cell lines in doses as low as 20nM.  By contrast, these mTOR effectors 
were not inhibited by AST487 in the FTC133 cell line, which harbours a homozygous 
PTEN loss-of-function mutation and is wild type for RET (Figure 3.1C).  In the TPC-
1 cell line following 20nM AST487 there was a decrease of cell growth of 76% as 
compared with vehicle treated cells (p<0.001) (raw data shown in Figure 3.1D). This 
increased to 92% following 1µM treatment (p<0.001) (Figure 3.1D). In the TT cell 
line a similarly potent effect was noted with 20nM AST487. It caused a 75% 
inhibition (p<0.001) which increased to 82% at the higher dose of 100nM (p<0.001). 
There was a less potent but still recognisable effect in the MZ-CRC-1 cells. At 20nM 
there was non-significant inhibition but at higher doses of 100nM there was 44% 
inhibition (p=0.02) (Figure 3.1D). 
 
 IC50 AST487 (nM) 
TPC-1 1.63 ± 0.29 
TT 1.15 ± 0.08 
MZ-CRC-1 41.30 ± 0.23 
 
 
 
  
A 
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Figure 3.1 Effects of AST487 on thyroid cancer cell lines with endogenous RET mutations. 
Pharmacological inhibition of RET decreases growth and signalling of downstream targets in PTC and MTC 
cell lines. (A) IC50 values (nM) for the RET Kinase inhibitor AST487 in thyroid cancer cell lines. (B) 
Western blots of lysates of cell lines treated with the indicated concentrations of AST487 for 24 hours and 
probed for the labelled antibodies. (C) FTC133 cells were treated with indicated doses of AST487 for 24 
hours. Western blots were performed for analysis of downstream targets of mTOR. (D) Summary of 3 cell 
lines, raw data from cell counts (ViCell) following AST487 treatment. TPC-1 cells were analysed at 4 days 
and MZ-CRC-1 and TT at 6 days. 
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3.3.1.2 siRNA targeted to RET inhibits mTOR signalling 
3.3.1.2.1 Selection of siRNA 
siRNA knockdown of RET was used to confirm that the observed effects of AST487 
on mTOR signalling were mediated specifically via RET inhibition.  Two RET 
siRNAs were run at different concentrations and assessed for knockdown efficacy: 
“RET 2” siRNA was selected for further experiments on the basis of consistently 
more potent RET knock down than “RET1” in the TPC-1 cell line (99% vs. 90% at 
5nM; Figure 3.3A).  For each experiment the appropriate concentration of a 
scrambled siRNA was used as control.   
3.3.1.2.2 Positive control 
Concurrent experiments with cyclophilin siRNA were done in TPC-1 cells as a 
positive control.  At 48 hours, 50nM siRNA targeted to cyclophilin, knocked down 
cyclophilin to 0.3% (± 2.1) of the scramble control (data not shown). Then in the next 
experiment, the siRNA targeted to cyclophilin had no effect on RET expression 
(Figure 3.2A).  This confirmed that the protocol was satisfactory and signalling 
effects could now be analysed. 
3.3.1.2.3 Effect of knockdown on mTOR signalling 
Cells were plated to achieve 30-40% confluence and treated the following day with 
siRNA targeted to RET, (“RET 2”).  Protein samples (from total cell lysates) were 
collected at 24, 48, 72 and 96 hours. Cells treated in parallel were harvested for RNA 
at 48 hours.  A representative western blot from a time-course experiment is shown in 
Figure 3.2C, and confirmed consistent RET knockdown in all cell lines at all time 
points. (In the TPC-1 cell line pRET is also shown as the clarity of total RET is poor.)  
Figure 3.2D shows a separate experiment in which the downstream targets of mTOR 
and MAPK were examined in the three cell lines 72 hours following siRNA 
treatment.   mTOR signalling through pRS6 and p4EBP1 was clearly impaired 
following RET knockdown.   
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Figure 3.2 RET knockdown with siRNA demonstrated inhibition of mTOR targets. (A) RET 
knockdown was achieved with difference concentrations of 2 different RET siRNAs. Cells were treated with 
allocated concentrations for 48 hours then RNA extracted. qPCR was performed and mRNA expression was 
normalised to corresponding doses of scrambled siRNA. Cyclophilin was the positive control.  (B) Three 
cell lines with RET mRNA levels following 48 hour RET knock down with siRNA, presented as percent of 
RET mRNA from scrambled siRNA treated cells. (C) siRNA time course. RET 2 was selected as the siRNA 
to assess RET knock down at the protein level. Each cell line was treated with the siRNA at 4 time points 
and western blots performed. Blots were probed for RET and demonstrate successful knockdown over 96 
hours. (D) Three cell lines shown at 72 hours post RET knock down with siRNA. Downstream targets of 
mTOR and MAPK are inhibited following knock down of RET. siSCR= siRNA with scramble sequence; 
siRET= siRNA targeted to RET. 
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3.3.2 Inhibition of mTOR kinase activity inhibits MTC cell growth 
3.3.2.1 Growth effects of INK128 
The contribution of mTOR to growth of RET mutant thyroid cancer cell lines was 
assessed by treatment with INK128, a kinase inhibitor that blocks mTORC1 and 
mTORC2.  As shown in Figure 3.3A, growth of all cell lines tested was inhibited with 
an IC50 of between 10-20nM.  Following 4 day treatment with 20nM INK128, TPC-1 
cells showed 48% inhibition of cell growth (p=0.003) which increased to 89% with 
100nM INK128 (p<0.001; Figure 3.3B). MZ-CRC-1 cells were treated for 6 days and 
demonstrated a cell growth inhibition of 52% with 100nM INK128 (p=0.004; Figure 
3.3B).  TT cells were also treated for 6 days and showed 35% inhibition of cell 
growth with 20nM INK128 (p=0.02) which increased to 65% at 100nM (p=0.001; 
Figure 3.3B).  
3.3.2.2 Signalling effects of INK128 
INK128 profoundly inhibited RS6 and 4EBP1 phosphorylation at low nanomolar 
concentrations (Figure 3.3C). There was no change in MAPK signalling shown 
through stable pERK expression in all three cell lines. Furthermore, a time course was 
performed on the TPC-1 and TT cell lines to investigate whether there was 
upregulation of pAKT, as has been observed in other cell types with mTORC1 
inhibitors. The time course in the TPC-1 cell line showed no increase in pAKT up to 
and including 72 hours of drug exposure (Figure 3.3D).  In the TT cell line there was 
abrogation of pAKT signalling for 48 hours showing no feedback upregulation 
(Figure 3.3D). Lastly, to ensure that INK128 had no effect on RET 
autophosphorylation, MTC cell lines were treated for 24 hours with increasing 
concentrations of INK128 and there was no change in pRET and pERK signalling 
following these treatments (representative MZ-CRC-1 blot shown in Figure 3.3E).  
 
 IC50 INK128 (nM) 
TPC-1 11.02 ± 0.22 
TT 18.29 ± 0.13 
MZ-CRC-1 23.10 ± 0.09 
A 
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Figure 3.3 Protein expression and growth effects of mTOR inhibition. The mTOR kinase inhibitor 
INK128 decreases the proliferation of RET mutant thyroid cancer cell lines and inhibits downstream targets 
of mTOR. (A) IC50  values (nM) for INK128 as determined by GraphPad version 5.02. (B) Summary of 3 
cell lines, raw data from cell counts (ViCell) following INK128 treatment. TPC-1 cells were analysed at 4 
days and MZ-CRC-1 and TT at 6 days.  (C) Cell lines were treated with the indicated concentrations of 
INK128 for 24 hours and Western blots probed with the indicated antibodies. (D) Time course of TPC-1 and 
TT cell lines following 500nM (TPC-1) and 100nM (TT) INK128 treatment to assess for pAKT feedback.  
(E) MZ-CRC-1 cell line was treated for 24 hours with increasing concentrations of INK128. Expression of 
pRET and downstream targets of mTOR are shown.  
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3.3.3 Pharmacological inhibition of RET and mTOR show synergy at low 
concentrations 
3.3.3.1 Combination therapy increases cell growth inhibition in TT and TPC-1 
cell lines 
Initially, TT and TPC-1 cell lines were treated with high doses well above the IC50 of 
both INK128 and AST487 (100nM) to ensure complete inhibition of targets.  Growth 
inhibition was assessed as a percent of mean vehicle treated cells in order to compare 
the TT and TPC-1 cell lines which have markedly different doubling times. Although 
the growth of TT cells were markedly inhibited by 100nM INK128, 100nM AST487 
was more potent (Figure 3.4A). Specifically INK128 treatment incurred a 32% ± 3.0 
growth inhibition and AST487 alone incurred a 15% ± 1.5 inhibition (p<0.001). In 
combination there was a clear reduction to 11.3% ± 1.4. However despite this lower 
recording in the combination therapy, it was only statistically significant when 
compared with INK128 alone (p<0.001) and marginally not when compared with 
AST487 (p=0.052). Hence, combined administration of 100 nM AST487 (>50-fold 
IC50) and 100nM INK128 (5 to 10-fold IC50) did not further inhibit cell growth more 
than with AST487 alone (Figure 3.4A), likely because at this concentration AST487 
already inhibits mTOR signalling profoundly.  In a similar fashion, following 100nM 
INK128 or AST487 treatment, TPC-1 cells were inhibited to degrees of 4.1% ± 0.6 
and 16.3% ± 2.0 (p<0.001). However dual therapy was more potent only when 
compared to individual AST487 (3.5% ± 0.8; p<0.001). 
It was not clear from the clinical trials with multikinase inhibitors whether full 
inhibition of RET kinase activity can be achieved at the maximal tolerated doses. 
Because of this, it was necessary to examine the effects of lower concentrations of 
AST487 and INK128 (i.e. at or close to the IC50 for each cell line), alone or in 
combination, on growth and signalling. At these lower doses, combination treatment 
showed greater growth inhibition in the RET mutant cell lines compared to that seen 
with each compound alone (Figure 3.4B).  Inhibition was normalised to vehicle 
treated cells.  TPC-1 cells were treated with indicated concentrations of INK128 and 
AST487 for 4 days while MZ-CRC-1 and TT cells were treated for 16 days in total, 
with retreatment every 3 days.  For the TT line, cell number increased to 8.03 ± 0.32-
fold above day 0 without drug treatment. Treating with AST487 and INK128 at low 
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doses (2nM and 5nM) reduced TT cell number by 62.5% and 52% respectively (i.e. to 
3.05 ± 0.16-fold and 3.82 ± 0.92-fold increase above baseline, respectively). 
Combination therapy resulted in 90% reduction in TT cells (i.e. to 0.82 ± 0.14-fold 
increase above baseline), significantly greater than for either treatment alone (Figure 
3.4B). Similar synergy was noted for combined low dose AST487 and INK128 
therapy in MZ-CRC-1 and TPC-1 cells (Table 3.2 and Figure 3.4B). 
Table 3.2: Cell number expressed as fold above day 0 growth following indicated 
treatment 
Cell Line Vehicle INK128 AST487 Combination 
TT 8.02 ± 0.32 3.05 ± 0.16 3.82 ± 0.92 0.82 ± 0.14 
MZ-CRC-1 8.11 ± 0.96 3.31 ± 0.13 4.49 ± 0.34 2.27 ± 0.11 
TPC-1 35.72 ± 4.35 21.00 ± 4.02 14.91 ± 1.83 6.27 ± 0.79 
 
3.3.3.2 Combination therapy inhibits signalling pathways 
TPC-1 and TT cells were treated with low dose individual and combined drugs for 24 
hours. Cells were harvested into lysates and western blots performed and probed for 
AKT and MAPK signalling targets. When used at these lower concentrations, 
AST487 (2nM) and INK128 (5nM) blocked mTOR signalling partially, whereas the 
combination showed a more profound inhibition, particularly of the direct mTOR 
substrate 4EBP1 (Figure 3.4C).  
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Figure 3.4 Combined pharmacological inhibition of RET and mTOR potentiates growth inhibition. 
(A) TPC-1 and TT cells were treated with 100nM INK128, 100nM AST487 or both. Data represents % of 
inhibition from vehicle treated. All treatment caused significant inhibition as compared with vehicle. (B) 
TPC-1, TT and MZ-CRC-1 cells were treated with the indicated concentrations of AST487 and INK128 
for 4 (TPC-1) and 16 days (MZ-CRC-1 and TT), then counted on a Vi-cell. Data represents fold cell 
number above Day 0. (C) Western blots of TPC-1 and TT cells treated with 2nM AST487 and/or 5nM 
INK128.  
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3.3.4 Knockdown of RET cooperates with INK128 in growth suppression  
To better define the role of mTOR on RET-dependent growth and signalling, the 
combined effects of RET siRNA-mediated knockdown and INK128 were examined.   
As described in 3.3.1.2.1, RET siRNA was used to demonstrate that the specific 
effects of AST487 were dependent on RET rather than off target effects. Effects on 
growth on the ViCell, were only evaluated in TPC-1 cells, as the growth rate of TT 
and MZ-CRC-1 cells was too slow to test effects of RNA interference because of the 
transient knockdown of RET.  TPC-1 cells were treated with or without 100mM 
INK128 one day following transfection with RET siRNA or scrambled siRNA.  Cells 
were then counted on the ViCell at 96 hours. As expected, INK128 treatment 
significantly inhibited cell growth after scrambled siRNA transfection (Figure 3.5A); 
however, even after RET knock down (which reduced cell growth to 29% ± 4.84 of 
control) the combination with INK128 significantly further inhibited cell growth to 
10.8% ± 0.93 of control (Figure 3.5A).  
In TT and MZ-CRC-1 cell lines, BrdU incorporation was measured in an attempt to 
overcome the difficulty in assessing growth following siRNA. The MZ-CRC-1 cell 
line showed a 39.4% decrease in cell proliferation following RET silencing (0.23 ± 
0.02 vs. 0.14 ± 0.04; p=0.03) and a 52.0% decrease following INK128 administration 
(0.23 ± 0.02 vs. 0.11 ± 0.01; p=0.002), but combined RET siRNA and INK128 
treatment was not observed to further inhibit cell proliferation (0.11 ± 0.02; Figure 
3.5B). Significance is as compared to scramble siRNA treated cells. In TT cells, BrdU 
uptake was not significantly changed by either RET siRNA or INK128, or by 
combination therapy (Figure 3.5B), most likely due to the slow growing nature of the 
cells and the time for effective RET knock down to induce a change in cell 
proliferation.   
The downstream effects of RET siRNA and/or INK128 treatment on mTOR 
signalling were examined by treating each cell line with 2nM INK128 for four hours 
the day after transfection with the RET siRNA.  Protein expression was determined 
through western blots.  In each cell line, expression levels of pRS6 were further 
blunted with dual treatment compared to either treatment alone (Figure 3.5C).   
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B 
Figure 3.5 RET knock down confirms synergy in inhibition of downstream targets of mTOR. (A) 
TPC-1 cells were treated with scrambled or RET siRNA. 6 hours post transfection 100nM INK128 was 
added. Cells were counted at 96 hours on the Vi-cell. (B) Following indicated transfections and INK128 
treatment; TT and MZ-CRC-1 cells were exposed to BrdU for 24 hours. Relative BrdU concentration was 
assessed through a spectrometer and analysed on GraphPad Prism. (C) TPC-1 and MZ-CRC-1 cells were 
treated with scrambled or RET siRNA for 48hours and then either treated with 2nM INK128 or vehicle 
for 4 hours. TT cells were treated with scrambled or RET siRNA for 96 hours and similarly treated with 
2nM INK128 or vehicle for 4 hours. Lysates were analysed through Western blots and probed to show 
synergy of inhibition. siSCR= siRNA with scramble sequence; siRET= siRNA targeted to RET. 
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3.3.5 Combination therapy enhances apoptosis in MTC cell lines  
3.3.5.1 Cell cycle effects 
Cell cycle effects of individual and combination treatment were analysed in the three 
RET mutant cell lines and an additional thyroid cancer cell line that is wild type for 
RET (SW1736) to ensure effects were RET-dependent.  High dose INK128 (100nM) 
was utilised to ensure maximum inhibition of the mTOR pathway. Following plating, 
each cell line was treated with 100nM of each compound. After 96 hours, results were 
analysed on a flow cytometer. A representative experiment is shown in Figure 3.6A 
for each cell line. TPC-1 cells treated with 100nM AST487 exhibited G1 arrest both 
with individual treatments and in combination. No cell death was evident in that cell 
line, as assessed by the population of cells with <2N DNA content (i.e. sub-G1).  By 
contrast, neither treatment affected cell cycle distribution of SW1736 cells (Figure 
3.6A).   
Figure 3.6B combines results from three separate experiments assessing the increase 
in % sub-G1 and highlights statistically significant results. In TT cells, AST487 
induced apoptosis such that 29.0% ± 2.6 cells in the sub-G1 region increased to 
37.2% ± 1.4 following combination therapy with INK128 (p=0.008).   A similar trend 
was noted in MZ-CRC-1 cells, although the effects were of lesser magnitude. 
Specifically, following AST487 treatment 4.06% ± 0.2 cells were in sub-G1 phase 
and this increased to 7.4% ± 0.3 with combination treatment (Figure 3.6B) (p<0.001).  
INK128 monotherapy did not increase the sub-G1 fraction in any of the cell lines, 
whereas it enhanced the apoptotic effects of the RET kinase inhibitor.  
To further assess this, apoptosis was also assessed by appearance of cleaved PARP on 
western blotting. In each case, cells were treated with high doses of INK128 and/or 
AST487, and doxorubicin (1 hour exposure 0.1µl/ml) was used as a positive control 
[148]. pRET was also probed as a positive control of consistent inhibition of RET 
signalling following treatment. In TT cells, abundance of cleaved PARP was 
markedly greater in cells treated with 100nM of both compounds (Figure 3.6C).  In 
MZ-CRC-1 cells, the effect of individual drug treatments on cleaved PARP was more 
subtle but high dose combination treatment still demonstrated an increase, consistent 
with pro-apoptosis findings as assessed by FACS in Figure 3.6B.   
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Figure 3.6 Apoptosis analysis in MTC cell lines. AST487 induces apoptosis in MTC cell lines which is 
augmented with INK128 treatment. (A) Three RET mutant cell lines and one WT RET cell line (SW1736) were 
treated with 100nM INK128 and 100nM AST487, alone or in combination for 96 hours and were then subjected 
to cell cycle analysis.  AST487 induced G1 arrest in TPC-1 cells but not in SW-1736. TT and MZ-CRC-1 cell 
lines showed an increase in the sub-G1 fraction following treatment. (B) AST487 induced apoptosis of TT and 
MZ-CRC-1 cell lines augmented by the mTOR inhibitor INK128 (doses and time as in A). Data represents 
percent of cells in sub-G1.  
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Figure 3.6 (C) TT cells were treated with the indicated concentration of compounds for 72 hours.  
Western blots were performed and probed for apoptosis indicator cleaved PARP. (D) MZ-CRC-1 
Cells were treated with low and high concentrations of INK128 and AST487 alone and in 
combination for 72 hours whereupon western blots were performed on the above antibodies. There 
was an increase in cleaved PARP demonstrating apoptosis at combination treatment at the higher 
doses.  
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3.3.5.2 Determination of apoptosis in TPC-1 cell line with AST487 
TPC-1 cells were treated with the compounds alone and in combination and assessed 
for apoptotic markers. Cleaved PARP levels increased following treatment with 
100nM AST487 but were not further increased by co-treatment with 100nM INK128 
(Figure 3.7A). Since FACS data in Figure 3.6A had suggested that combination 
treatment did not increase apoptosis of TPC-1 cells, another measure of apoptosis was 
employed to determine the presence of cytotoxic effects on the cells. A representative 
experiment is shown in Figure 3.7B, and graphically represented in Figure 3.7C. Cells 
were stained with Annexin V and PI following treatment with 500nM AST487 and 
20nM INK128 alone and in combination. Dying cells take up Annexin V as they 
apoptose, then start to take up PI as necrosis occurs. Dual stained cells are necrotic. 
There was a 4.3-fold increase in necrotic cells (17.67% to 76.72%) following a known 
apoptotic inducer, doxorubicin. Following high dose INK128 and/or AST487 
treatment, either individually or in combination, there was no increase in percent of 
apoptotic or necrotic cells.  
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Figure 3.7 Analysis of TPC-1 cells following combination treatment. (A) TPC-1 cells were 
treated for 24 hours with indicated concentrations of compounds and doxorubicin as positive 
control.  Western blots were performed and probed for apoptosis indicator cleaved PARP. (B) 
TPC-1 cells were treated with  500nM AST487 and 20nM INK128 individually and in 
combination. Annexin V/PI apoptosis kit was performed the following day and showed no increase 
in apoptosis after treatment. (C)  Graphic representation of results of Annexin V/PI kit showing 
increase in cell death only with the positive control.  
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3.4 Discussion 
3.4.1 The PTC and MTC cell lines described are addicted to the RET oncogene 
It is well established that cancer cells typically contain multiple genetic abnormalities 
that dysregulate many pathways. However, sometimes a cancer is fortuitously 
dependent on a dominant oncogene. Each of the cell lines examined in this chapter 
exhibited classic addiction to the RET oncogene.  As Weinstein described, such an 
“Achilles heel” represents a unique opportunity for targeted molecular therapy [149].  
For the RET mutant cell lines TPC-1, TT and MZ-CRC-1, RET inhibition mediated 
either by AST487 treatment or by siRNA silencing caused marked inhibition of cell 
growth (Figure 3.1A,D and Figure 3.5A) together with evidence of either growth 
arrest and/or apoptosis (Figure 3.6).    
3.4.2 INK128 has promising inhibitory effects on RET driven tumours 
The PI3K/AKT/mTOR pathways are known to be dysregulated in many cancers, and 
are partially controlled by upstream RTKs.  In some cancer types, constitutive 
activation of AKT/mTOR causes a feedback inhibition of upstream RTKs [146].  In 
this situation, inhibition of mTORC1 (by rapamycin or its analogues) is thought to 
cause release of feedback inhibition, thereby augmenting AKT signalling through 
mTORC2 and blunting any anti-cancer effect of such compounds.   
INK128 is a dual mTORC1/mTORC2 inhibitor and therefore potentially avoids this 
problem, as it is targeting AKT both upstream and downstream (see Figure 1.4 and 
section 1.7).  In this chapter, it is demonstrated that over an extended time course 
pAKT was not upregulated (Figure 3.3D). Moreover, there was clear inhibition of 
downstream mTOR targets using INK128 in RET mutant cell lines (Figure 3.3C). 
Furthermore, the positive response to INK128 in MTC cell lines (TT and MZ-CRC-1) 
may be consistent with a broad efficacy of mTOR inhibitors in neuroendocrine 
neoplasms [150]. 
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3.4.3 mTOR is the integrator of the proliferative response in RET driven tumours 
RET signals via multiple potential downstream mediators. These include: effects on 
cytoskeletal rearrangement; STAT3 at docking site Y752 and Y928; Src at Y981; and 
Phospholipase C-γ at Tyrosine 1015 [21]. In the case of the PI3K and mTOR 
pathway, Src Homology Collagen (Shc) docks at the Y1062 residue whose 
phosphorylation is essential in transforming activity of mutant RET [151]. Shc 
recruits the Grb2/son of sevenless multi-protein scaffold (SOS) complex and Grb2-
associated binding protein (GAB)1/2 resulting in the activation of the PI3K/AKT 
pathway.  There are other important proteins including ShcC (Rai), a neuron specific 
adaptor protein, which are involved in PI3K/AKT activation.  This chapter explores 
the role of this pathway as one of the primary outlets of RET oncogenic signalling. 
One hypothesis of this thesis was that mTOR is the integrator of the proliferative 
response.   
The experiments described in this chapter show the activity of mTOR is dependent on 
RET in thyroid cancer cells with endogenous mutations of the oncogene, either 
derived from C cells or from thyroid follicular cells.  This was shown using a potent 
RET inhibitor (AST487) that has no direct effects on components of the PI3K-AKT-
mTOR pathway, as well as by knockdown of RET by RNA interference.  Following 
either treatment there was a clear inhibition of downstream targets of mTOR.   
Other groups have also examined the role of mTOR in RET driven tumours. Rapa et 
al observed intense IHC positivity for pAKT, p-mTOR and p-p70S6K in MTCs, 
which was positively correlated with the presence of germline mutations of RET, 
whereas cancers with somatic RET mutations had a more heterogeneous pattern of 
staining, for reasons that were not investigated [152]. In this same study, everolimus 
inhibited the growth of a TT cell line, a finding that confirmed an earlier report [91]. 
Jin et al also found that TT cells were inhibited by the dual PI3K/mTOR kinase 
inhibitor BEZ235, and that the inhibition was synergistic with RAF265, a RAF kinase 
inhibitor which the authors had also discovered inhibited RET phosphorylation at low 
nanomolar concentrations [94].  
In immortalised, non-transformed rat thyroid cell lines, mTOR activity is induced by 
TSH acting via TSHR/protein kinase A (PKA) [153]. Poorly differentiated thyroid 
cancers and thyroid cancer cell lines lose dependence on TSH for growth, yet show 
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increased mTOR activity.  It seems that thyroid cancers, as part of the development of 
oncogene addiction, may have switched upstream control of mTOR activity from 
TSH-cAMP-PKA to either RET-RAF-RAF-MAPK and/or PI3K/AKT. It has become 
apparent through this research and others [142, 154, 155] that mTOR is pivotal in 
exerting the oncogenic potential of RET.  Further work, beyond the scope of this 
thesis, would include silencing mTOR to explore the hypothesis that RET inhibitors 
would be less effective in the absence of mTOR.     
3.4.4 Benefits of combination therapy regimens 
Multikinase inhibitors, such as vandetanib and cabozantinib, are new therapeutic 
options for patients with metastatic MTC.  Besides RET, vandetanib also inhibits 
EGFR and VEGFR kinase activities. Its mechanism of action in MTC patients is 
unclear, although it appears that patients with RET mutations may be preferentially 
responsive to the compound [77].  In the phase III trial, 12% of patients discontinued 
the drug, primarily due to adverse effects, and 35% required dose reductions [77].  
Although lower doses of the drug appear to exert a therapeutic benefit [67], it is not 
clear whether RET kinase activity is maximally inhibited with either dose, or to what 
extent the activity of the kinase driver needs to be blocked to obtain a biological 
effect.  
This chapter also addressed the hypothesis that combination of RET inhibition and 
mTOR inhibitor at submaximal doses might maintain therapeutic effect on 
downstream targets. When the RET kinase inhibitor was used at concentrations that 
were insufficient to abrogate mTOR signalling, addition of low dose INK128 further 
suppressed the pathway (Figure 3.4A). Together, the drugs also conferred greater 
inhibition of cell growth (Figure 3.4B).  At higher doses they conferred a greater 
degree of apoptosis (Figure 3.6B). This is clinically relevant since RET inhibitors 
often require dose reduction for systemic toxicities.   
Combination therapy may also provide a mechanism to prevent escape mechanisms 
and resistance. Blocking only one molecular target, despite the cancer being addicted 
to that activated oncogene, still allows for salvage or escape pathways to enhance the 
growth of cancer cells.  This is beginning to be understood in thyroid cancer. 
Montero-Conde et al examined inhibition of BRAF with vemurafenib in thyroid 
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cancer cell lines with BRAF mutations. They found a rebound increase in ERK 
signalling orchestrated by induction of ERBB3 (HER3) transcription following 
treatment. They proposed dual treatment with lapatinib, a HER3 inhibitor, as well as 
vemurafenib [156]. Dual therapy explored in this chapter provides an inhibition of the 
RET pathway and its downstream effectors. There are known interactions with RET 
and EGFR; specifically RET/PTC cell growth is mediated in part by EGRF activation 
[157]. Hence, if other pathways such as EGFR (or VEGFR) are also active in RET 
driven tumours, targeting more than one location in the signalling cascade can help to 
reduce escape mechanisms.  
Using more than one compound can also assist patients struggling with the toxicity of 
high dose single therapies.  Toxic side effects of TKIs often cause dose reductions.  
Common manifestations include: skin disorders; diarrhoea; and nausea (see Table 1.6) 
[158]. Most of these are due to off target effects on other tyrosine kinases. With 
regard to the thyroid, hormone dysfunction is seen in patients receiving sunitinib, 
where both thyrotoxicosis and hypothyroidism have been observed [159]. More 
seriously, cardiotoxicity is beginning to be observed in many of the TKIs in use. For 
example, imatinib has been shown to cause left ventricular dysfunction in mice and a 
recent report describes 10 individuals who developed severe congestive cardiac 
failure while on the drug [160].  These drugs have been in clinical use for a short time 
period, and in time, longer term side effects will become more apparent.  
In Phase II trials of vandetanib in MTC, 73% of patients receiving the 300mg dose 
required dose reductions, while in follow up studies using 100mg, only 15% had dose 
reductions [66, 67]. The concept of using multiple drugs at lower doses, while still 
achieving the same inhibition, can reduce the side effect profile. The data in this 
chapter provides a preclinical rationale to consider combination treatments with RET 
and mTOR inhibitors, to maximally suppress the activity of this pathway.    
3.4.5 Mechanism of inhibition in the PTC cell line is different to the MTC cell lines 
TPC-1 cells showed inconsistent results in examining the presence of apoptosis 
following AST487 administration.  Following cell cycle analysis (Figure 3.6A) it 
appeared that the growth inhibition seen in Figure 3.1B and 3.1D was due to a marked 
G-1 arrest rather than an increase in cell death. This was further investigated with 
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western blots probing for anti-cleaved PARP antibodies. There was a small increase 
in cleaved PARP density following AST487 treatment. This is consistent with the 
MTC data. Further investigation with the Annexin V/PI flow kit showed insignificant 
apoptosis.  It is unclear why there was a disparity in these assays and this requires 
further investigation.  The TT cells have a marked increase in cleaved PARP 
expression following AST487 treatment (Figure 3.6C) when compared to the positive 
control.  It appears that the primary mechanism of reduction in cell number seen in 
Figure 3.1 in TT cells is cytotoxic, while in TPC-1 cells it is cytostatic with a 
potential cytotoxic component.  Other groups have treated with TKIs and found a 
similar situation; Couto used a JAK1/2 inhibitor, AZD1480, and found a cytostatic 
effect in the TPC-1 cell line and cytotoxic effect in MTC cell lines [154].  This may 
be due to the origins of the cell lines, namely a rearrangement in TPC-1 and point 
mutation in the MTC cell lines.  
3.5 Conclusion 
mTOR activity was exquisitely RET dependent in all cell lines tested. Treatment of 
RET mutant thyroid cancer cell lines with the RET kinase inhibitor AST487 
profoundly inhibited their growth. Similar effects were noted when these cells were 
treated with the mTOR kinase inhibitor INK128. However, their combination at high 
concentrations showed no added effect, pointing to a possible overlapping mechanism 
of action. Indeed, when combined at lower concentrations, the RET and mTOR kinase 
inhibitors showed strong cooperativity. These results point to a critical role of mTOR 
signalling in RET-induced cell growth, and identify the potential use of combination 
therapies at submaximal doses to maintain therapeutic efficacy and avoid dose-
limiting toxicity. 
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4.1 Introduction 
Mouse models are ideal organisms with which to explore the effects of novel 
compounds. Mice have a genetic and physiological similarity to humans and their 
genome is easily adapted and manipulated.  Data from chapter 3 demonstrated the 
pivotal role of mTOR in RET signalling and the augmentation of apoptotic effect 
when both RET and mTOR were inhibited pharmacologically and genetically.  This 
chapter utilises a RET/PTC3 transgenic mouse model to further explore this 
hypothesis. 
4.1.1 Introduction to the RET/PTC mouse models 
The RET/PTC3 mouse model employed in this chapter provides a working model of a 
mutant RET driven PTC.  This model uses a rearrangement specific to papillary 
thyroid cancer and is shown in Figure 4.1 [161]. Tg-RET/PTC3 mice develop thyroid 
hyperplasia and solid tumour variants of PTC with metastatic spread in occasional 
cases [162] thus making it a good candidate for study. Furthermore, the RET/PTC3 
oncogene is highly prevalent and associated with more aggressive forms of cancer 
than other RET rearrangements in PTC [163].   
The in vitro data in chapter 3 utilised the TPC-1 cell line which expresses a 
RET/PTC1 rearrangement.   That model was not used for this study for the following 
reasons.  Cho et al generated a transgenic mouse of PTC with targeted expression of 
RET/PTC1 in the thyroid gland using the bovine thyroglobulin (Tg) promoter [164]. 
The Tg promoter is known to be active from embryological day 14.5 [165] 
whereupon the thyroid glands begin to form follicles in murine models.  The time of 
tumour onset in RET/PTC1 mice depends on the level of expression of RET/PTC1 and 
thus has a particularly irregular penetrance of disease.  These RET/PTC1 transgenic 
mice are also known to develop follicular hyperplasia and carcinoma without invasive 
cancer [162].  Hence, the RET/PTC3 mouse provides a better model with which to 
analyse the effects of a RET and mTOR inhibitor. The candidate did not pursue a 
MTC mouse model for reasons described in the discussion section 4.4.2. 
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4.1.2 mTOR in in vivo models of thyroid cancer 
mTOR plays a significant role in thyroid signalling in both non-neoplastic and 
neoplastic conditions. In non-neoplastic cells, TSH can stimulate S6 kinase, 
downstream of mTOR, thereby regulating DNA synthesis in normal follicular cells 
[153]. In thyroid cancers, aberrant pathway signalling includes increased mTOR 
activity (reviewed in [166]).  Recent work has shown high output by the mTOR 
pathway in human MTC tumours [152].  Others have shown activation of mTOR 
pathway in primary MTC as well as lymph node metastasis, further confirming 
increased mTOR activity [155].   
In thyroid cancer preclinical models, mTOR inhibitors have been used with moderate 
success [167].  In murine models of thyroid cancer, mTOR inhibitors have shown 
regression of tumour alone and in combination with other drugs [90]. In another 
study, combination therapy with a MEK inhibitor inhibited growth of an FTC133 cell 
xenograft. This PTEN knock out thyroid cell line xenograft has implicit high activity 
of the PI3K/AKT/mTOR pathway, which was diminished with combination therapy.    
There was also success with rapamycin, the mTOR complex 1 inhibitor in xenograft 
models [95, 168]. BEZ235, a dual mTOR/PI3K inhibitor which acts through G0/G1 
cell cycle arrest and apoptosis, was shown in in vitro models of thyroid cancer to 
cause inhibition and cytotoxicity [168].  This chapter uses the dual mTOR inhibitor 
INK128 to assess the effect of signalling and cell proliferation in mutant RET 
transgenic mice.  This, to the candidate’s knowledge, is the first time data has been 
presented with a transgenic RET/PTC mouse analysing the effects of an mTOR 
inhibitor.   
4.1.3 RET inhibitors in murine models of thyroid cancer 
There is also limited data on the effect of RET inhibitors in mouse models.  Most 
published studies have used xenograft models as opposed to transgenic mice to show 
effects of RET inhibitors. Samadi et al employed a novel compound derived from 
withaferin A to demonstrate RET inhibition and showed tumour regression [58].  A 
novel RET kinase inhibitor, ponatinib, also showed a reduction in tumour size in a 
xenograft model following treatment [169].  There is no data of RET mutant 
transgenic mouse models with a RET kinase inhibitor.  Even in the preclinical data for 
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vandetanib, none of the models included transgenic mice, only xenograft models after 
in vitro work [54, 60]. AST487 has been used in mutant RET xenograft models 
previously. TPC-1 xenografts are notoriously difficult to enact, so TT cells were 
employed to demonstrate that following oral gavage of AST487 there was a decrease 
in mean tumour volume as compared with control mice [56]. An important result of 
this in vivo treatment was that treatment with this RET kinase inhibitor directly 
mediates a physical pathway controlling calcitonin secretion.  AST487 administration 
caused a reduction in calcitonin levels independent of tumour volume. Calcitonin is 
routinely used as an indicator of progression in patients with persistent or recurrent 
MTC, as it is believed to be roughly proportional to tumour mass [10].  
4.1.4 Aims 
To explore the effect of the novel mTORC1 and mTORC2 inhibitor, INK128, in a 
transgenic mouse model, alone and in combination with the RET kinase inhibitor 
AST487.  
Firstly to recapitulate the effects of the compounds as shown in the in vitro system 
described in chapter 3 and assess for a reduction in tumour size through ultrasound 
technology and/or histologically through cell proliferation markers.   
Secondly, to perform experiments using combination treatment of the above 
compounds to determine tolerability of dual treatment in an in vivo model.   
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4.2 Methods 
4.2.1 General mice methods  
Mice were not generated by the candidate. Tg-RET/PTC3 transgenic mice were kindly 
provided by Dr Jay Rothstein (Amgen, Seattle, WA, USA). These mice express the 
RET/PTC3 oncoprotein in thyroid follicular cells under the control of the 
thyroglobulin gene promoter, and develop solid-variant papillary thyroid cancers 
(Figure 4.1A).  Preparation of thyroids including fixing and sectioning is described in 
chapter 2.7.2.  Western blots practice is described in general methods section 2.4. 
 
 
 
4.2.2 Mice ultrasound and analysis 
Mice were randomly selected to each different treatment group.  Pre-treatment, mice 
were weighed and an ultrasound was performed on their thyroid.  Mice were 
anaesthetised with a combination gas of 3ml/minute of isofluorane (MSKCC Animal 
Core) and 2.5ml/minute of oxygen.  Gas was fed into a clear sealed box for 
approximately 1 minute until mice were unconscious. Mouse neck hair was removed 
with Nair hair removal cream (Church & Dwight, USA) to ensure minimal 
interference on the ultrasound. Mice were placed supine with a hose secreting the 
anaesthetic gas attached to their snout. Limbs were secured with electrode cream and 
Tg-­‐RET/PTC3 
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Figure 4.1 Genesis of Tg-RET/PTC3 mice. This diagram shows the location of fusion of 
RFG-RET (RET/PTC3) including breakpoints, oligonucleotides and neucleotide positions. 
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tape (MSKCC Animal Core, provided). The platform position was adjusted according 
to the size of the mouse. Ultrasound gel was applied on the probe. Visualsonics Vevo 
2100 Imaging system (VisualSonics BD, Amsterdam, The Netherlands) with 3D 
assessment of small animal organs was used as the assessment tool. 3D motor process 
was started on the computer. 25-30 scans were ascertained for each mouse. 
“Brightness mode” was utilised to acquire 2 dimensional images of the thyroid gland.  
Following completion of the study, the ultrasound files were analysed with the 
candidate blinded to treatment. The volume of each thyroid carcinoma was outlined as 
shown in Figure 4.3A. Volume was measured automatically through the X point. 
Results and statistics were compiled on GraphPad Prism version 6.0 (GraphPad 
Software). 
4.2.3 Thyroid digestion for western blots 
Following thyroid dissection, fresh thyroid tissue was snap frozen in liquid nitrogen 
and stored at -80°C.  Lobes were then homogenised in RIPA lysis buffer (described in 
2.11) (Sigma). Homogenised tissue was transferred to eppendorf tubes and incubated 
for 1 hour at 4°C. Cell debris was removed by centrifugation at 14,000g for 20 
minutes at 4°C, and the supernatant protein concentration was determined by BCA 
assay (Pierce). Equal amounts of total protein were resolved by SDS-PAGE and 
immunoblotted with the primary antibodies indicated (see section 2.4.3).  
4.2.4 Drug treatments for in vivo studies  
All compounds were administered to the mice through oral gavage. The oral gavage 
technique involves sterile feeding needles with a maximum of 100µl liquid volume. 
Mice were firmly restrained in order to immobilise the head. The animal was 
maintained in an upright position and the gavage needle inserted gently into the 
mouth and syringe emptied.  
4.2.4.1 Vehicle solution 
A solution containing 15% Polyvinylpyrrolidone (PVP, Sigma P5288), 5% N-Methyl-
2-pyrrolidone (NMP; Sigma) and 80% MQ water was formed as per company 
instructions and stored at room temperature in a sterile container. 
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4.2.4.2 INK128 
Intellikine protocols advised commencing in vivo doses at 1mg/kg with a maximum 
of 10mg/kg.  The compound was kept at -20°C until prepared for use. A master mix 
of 10ml was prepared with the above concentrations, 15% PVP, 5% NMP, and 80% 
MQ water. Specifically, 1.5mg of PVP was dissolved in MQ water. 4.5g of INK128 
was mixed in 500µl NMP. Both solutions were mixed together. Sample was vortexed 
at each stage.  Final concentration was 0.45mg/100µl in vehicle, based on mean mass 
of mice. Solution was kept at room temperature in a sterile container for 1 week then 
discarded.   
4.2.4.3 AST487 
Previous data suggested targeting doses at 30-50mg/kg [56]. AST487 vehicle 
comprised 10% NMP and 90% Polyethylene glycol (PEG300, Sigma 81160). Vehicle 
was premade, vortexed, and AST487 was added fresh daily before treatment to a 
concentration of 0.45mg/100µl, as per mean mass of pre-treated mice.  
4.2.5 Immunohistochemistry (IHC) 
IHC technique was not performed by the candidate. Slides were prepared as per 
general methods.  Quantification of Ki67, pS6 staining was performed using whole 
thyroid digitised images that were obtained from scanned slides as above and with the 
assistance of the Molecular Cytology Core Facility. Automated image analyses were 
done using Metamorph software (Sunnyvale, CA, USA) as follows. Using the tool 
“set colour threshold” in Metamorph, brown pixels were selected by clicking on all 
the brown labelled cells for each representative immunostain until all the brown 
pixels were appropriately highlighted. Likewise, the blue counterstaining was selected 
by clicking on the blue labelled cells until the entire thyroid area was selected. 
Finally, each respective immunostain threshold was applied, in an automated-batch 
manner, to all samples for that respective immunostain. The software exported the 
data in an Excel sheet as the total area represented by brown pixels (positive area) and 
the total area represented by blue pixels (total tumour area). The percent positive area 
was calculated and plotted using GraphPad Prism 6.0. pAKT and pERK staining was 
performed at a later stage once the candidate had left MSKCC. This was quantified 
through Immunoratio [170]. Mechanism was as described above.  First, the positive 
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stain as brown was identified in a control thyroid section.  Then the ratio of positive 
stain to blue (background) analysed automatically through the program, in a batch 
format. Where possible, multiple levels of different mice receiving the same treatment 
were grouped together once normalised for the individual experiments, to ensure 
reproducibility.  
4.3 Results 
4.3.1 Compound effects were recapitulated in in vivo models 
Initial experiments assessed whether the compounds would inhibit the same 
molecular targets as described in chapter 3. Mice were treated with each compound 
alone, and in combination, initially for 6 hours.  Following treatment, mice were 
sacrificed and thyroids dissected. Thyroids were digested and proteins extracted to 
determine difference in overall expression through western blots (Figure 4.2A).  In 
this representative experiment, there were n=2 wild type; n=3 vehicle treated; n= 4 
INK128 3mg/kg and n=4 30mg/kg AST487 mice.  There was wide variation in 
measures of various target proteins and therefore signalling targets were expressed 
relative to β actin expression (Figure 4.2B). An alternative experiment was performed 
with fewer mice where the phosphorylated proteins were normalised to the total 
proteins expressed but there were no consistent results (data not shown). 
Figure 4.2B shows the results of the normalised protein expression following 
treatment. This graph demonstrates large standard deviations due to irregular 
expression of the proteins in the amalgamation of tissue extracted.  However, there 
was an overall reduction in protein expression of signalling targets following INK128 
treatment.  The expression of the pRS6 protein was decreased by 41.1% (87.3 ± 27.54 
vs. 51.45 ± 22.76) (p>0.05).  The expression of p4EPB-1 had a relative reduction of 
50.3% (77.54 ± 1.52 vs. 39.8 ± 3.15) (p<0.001).  In addition pAKT expression 
reduced to 64.1% as compared with vehicle (73.30 ± 3.28 vs. 26.26 ± 15.27) (p<0.05).  
Following AST487 treatment there was no significant or trending inhibition of targets 
seen through analysis of protein expression.   
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Figure 4.2 Protein expression in Tg-RET/PTC3 mice following indicated drug treatment. Mice were 
treated for 6 hours with indicated compounds. Following sacrifice, thyroids were harvested and prepared for 
western blotting.  (A) A representative western blot is shown above. There is a discrepancy in each of the 
triplicate samples.  (B) Western blots were normalised to β actin protein expression and analysed on Thermo 
Scientific MyImageAnalysis. Density of each band was determined with high sensitivity. There was a 
reduction in pAKT, p4EPB1 and pS6 following INK128 treatment. 
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4.3.2 Pilot experiment 
In order to determine the safety and effectiveness of ultrasound, a single pilot 
experiment was performed. Three cohorts were treated for 2 weeks.  The regime 
consisted of: daily oral gavage from days 1-5 inclusive; 2 days off; daily oral gavage 
from days 8-12 inclusive. The treatment groups were: vehicle; “low dose” AST487 
(30mg/kg); and a combination 3mg/kg INK128 and 30mg/kg AST487.  In this pilot 
experiment, the other aim of the combination arm, was to determine tolerability of 
dual therapy.  There were no mice deaths due to toxicity in this pilot.  
4.3.2.1 Ultrasound analysis  
Before treatment, mice were anaesthetised and ultrasounds performed to determine 
volume of each tumour (Figure 4.3A).  A representative image is shown in Figure 
4.3A.  Two weeks later, after the mice were sacrificed, ultrasound was again 
performed, and the results of change in volume, graphed in Figure 4.3B.  In the small 
number of mice used, there were no significant or consistent findings of changes in 
thyroid tumour volume (Figure 4.3B).  Some mice did not survive the anaesthetic 
and/or the ultrasound experience and died afterwards from tracheal compression, and 
therefore were excluded from the study.  Hence the total number of mice included in 
this single experiment was 6. The fragile nature of the mice with their size and their 
poorly penetrant tumours meant that it was not feasible to continue with ultrasound 
assessment, as the high casualties leading to low numbers meant insignificant results, 
at a high cost.  
  
93 
  
A 
B 
m
m
3
Ve
hic
le 
 
AS
T4
87
  
Co
mb
ina
tio
n
-10
0
10
20
30
Figure 4.3 Representative ultrasound image of mouse thyroid pre-treatment. (A) 
Ultrasound of mouse thyroids on the Vevo2100 Imaging System (Visualsonics) pre- and 
post-treatment in a preliminary experiment. Volumes were measured on 3D motor process.  
(B) Graph demonstrating the absence of change in thyroid volume after 2 weeks of 
treatment. None of the measurements were significant due to low number of mice examined.    
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4.3.2.2 Confirmation of pRET inhibition in vivo 
The next aim was to confirm that over the prolonged treatment regimen, RET, the 
oncogenic kinase driver was inhibited by AST487 in vivo.  A pRET antibody 
generated by the Fagin lab was utilised.  It had previously been validated by the 
MSKCC IHC core (data not shown). Following the 2 week experiment, IHC was 
performed and Figure 4.4 shows a representative section showing a reduction in 
pRET signalling at both 10x and 40x magnifications.  Once this inhibition of the 
oncogenic kinase driver had been confirmed (Dr R. Ghossein, Senior Pathologist 
MSKCC), other effects including phenotype changes and downstream signalling 
targets could be investigated.  
  
40x 40x 
10x 10x 
Vehicle AST487 
pRET 
Figure 4.4 anti-pRET IHC following AST487 treatment. A novel pRET antibody generated by the 
Fagin lab was utilised. Mice were treated with 30mg/kg AST487 for 5 days on, 2 days washout and 
then a following 5 days. IHC was performed and demonstrated a clear reduction in pRET signalling, 
low and high magnifications shown for effect.   
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4.3.3 Final Experiment  
17 mice were randomised into 5 treatment arms. Over two weeks, mice received oral 
gavage of either: vehicle; 3mg/kg INK128; 10mg/kg AST487 “AST low”; 30mg/kg 
AST487 “AST high”; a combination dose which entailed 3mg/kg INK128 and 
10mg/kg AST487, “Combination”. 
There was no significant difference between the mice weights in each randomised 
group before treatment.  Mice were weighed pre- and post-treatment. After 2 weeks of 
drug treatment via oral gavage, there was no significant difference between the 
change in body weight of mice in any group (p>0.05) (Figure 4.5A).   
Following sacrifice mice thyroids were dissected and weighed (Figure 4.5B). There 
were 2 cohorts with significant reduction in thyroid mass (g); INK128 as compared 
with the vehicle (0.0159 ± 0.0013 vs. 0.0237 ± 0.0057; p=0.03) and the combination 
treatment (0.0156 ± 0.0015 vs. 0.0237 ± 0.0057; p=0.026).  There was no difference 
between the individually treated INK128 and the combination group (p>0.05). 
  
Figure 4.5 Mass of thyroid and body weight following treatment.  (A) Mice were weighed pre- and post-
treatment and the change graphed above.  (B) Following sacrifice, mice thyroids were dissected and weighed. 
There was a significant reduction in thyroid mass in the INK128 and combination treatment groups.   
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4.3.3.1 IHC shows a more differentiated phenotype following RET inhibition 
IHC was employed to assess the degree of inhibition of the same targets as the in vitro 
data.  IHC staining of MAPK and mTOR targets was performed to determine 
recapitulation of signalling effect in vivo. As the penetrance of PTC in this model is 
variable, it was not possible to determine effects on tumour phenotype in a rigorous 
manner. However, in the AST487 treatment group a consistent regression of tumour 
phenotype was observed at both low and high doses (Figure 4.6).  In these 
representative H/E images there is a more follicular, well-differentiated phenotype 
following the 2 weeks of RET inhibition.  Particularly the follicles in the high dose 
AST487 are well formed and more regular than any other treatment arm (Dr R. 
Ghossein, MSKCC). 
 
 
  Control Vehicle INK128 
30mg/kg 	  AST487 10mg/kg 	  AST487	  +	  INK128 
10mg/kg 	  AST487 
Figure 4.6 Representative H/E IHC for each described condition. Thyroid were sectioned and 
prepared for IHC staining following 2 week treatment regimen. H/E stains applied and slides were 
fixed. Magnification is 4x. Following AST487 treatment, the phenotype of the papillary carcinoma 
returns to a more differentiated follicular pattern.  
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4.3.3.2 MAPK signalling was measured through anti-pERK IHC 
Treatment with both low and high dose AST487 reduced signalling through the 
MAPK pathway shown by reduction in pERK stain, visually in Figure 4.7C-E and 
quantified in Figure 4.7F. Compared with vehicle, which showed a positive stain of 
45.9% ± 11.1 pERK expression, high dose AST487 (4.7D) expressed a mean positive 
stain of significantly less; 16.5% ± 4.9 (p=0.009). There was no change in pERK 
staining after INK128 treatment which recapitulates what was seen in the in vitro 
setting, confirming no upregulation of alternative pathways with a dual mTOR 
inhibitor. However, when INK128 was treated in combination with low dose AST487 
there was an augmentation of inhibition of pERK as the percent positive stain 
decreased to 15.5% ± 7.2 (p=0.004).    
 
   
A B C 
D E 
Figure 4.7 Representative anti-pERK IHC for each described condition. Anti-pERK IHC 
antibody was applied to slides of specified treatment	  (A) Vehicle (B) INK 128 3mg/kg (C) Low 
dose AST487 (10mg/kg) (D) High dose AST487 (30mg/kg) (E) AST487 10mg/kg and INK128 
3mg/kg combination. 10x magnification. (F) Quantification of expression using Immunoratio and 
graphed in Graphpad Prism. 
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4.3.3.3 IHC showed no change in pAKT expression 
IHC stain with a pAKT antibody showed no significant difference in expression 
following any treatments despite a trend of reduction following combination therapy 
(Figure 4.8F). Vehicle positive stain was 83.4% ± 4.5 which reduced to 67.6% ± 11.9 
after dual treatment (p=0.09) (Figure 4.8E). 
  
A B C 
D E 
Figure 4.8 Representative anti-pAKT IHC for each described condition. Anti-pAKT IHC 
antibody was applied to slides of specified treatment.	  (A) Vehicle (B) INK 128 3mg/kg (C) Low 
dose AST487 (10mg/kg) (D) High dose AST487 (30mg/kg) (E) AST487 10mg/kg and INK128 
3mg/kg combination. 10x magnification.  (F) Quantification of expression using Immunoratio 
software and graphed in Graphpad Prism. 
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4.3.3.4 mTOR signalling was assessed with pS6 expression  
Expression of pS6 in vehicle treated mice was quantified at 2.6% ± 1.9. Following 
INK128 treatment, 0.7% ± 0.9 of the thyroids were positively stained for pS6, which 
was a relative reduction of 73.1%, as compared with vehicle (p=0.002) (Figure 4.9F). 
Following high dose AST487 there was a 0.32% ± 0.1 expression of pS6, a relative 
reduction of 87.7% (p=0.04). There was no significant changes either of the other 
conditions. Visual representative sections are shown in Figure 4.9 A-E. 
  
A B C 
D E 
Figure 4.9 Representative anti-pS6 IHC for each described condition	  Anti-pS6 IHC 
antibody was applied to slides of specified treatment.	  (A) Vehicle (B) INK 128 3mg/kg (C) 
Low dose AST487 (10mg/kg) (D) High dose AST487 (30mg/kg) (E) AST487 10mg/kg and 
INK128 3mg/kg combination. 10x magnification. (F) Quantification of pS6 through 
Immunoratio and graphed in Graphpad Prism. 
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4.3.3.5 Ki67 analysis   
The proliferation index, as determined by Ki67 staining, was reduced by both drugs 
shown in Figure 4.10. Here, following treatment there is a mean of 55.2% relative 
reduction in Ki67 positive stain following 10mg/kg AST487 (p>0.05). When this is 
increased to 30mg/kg AST487, it has a mean of 57.8% reduction in stain as compared 
with vehicle but was statistically significant (p=0.02). There is a mean reduction of 
55.1% following INK128 treatment (p>0.05).  However when low dose AST487 and 
INK128 were combined a 57.8% reduction in positive stain was confirmed (p=0.008). 
  
A B C 
D E 
Figure 4.10 Representative Ki67 IHC for each described condition	  (A) Vehicle (B) INK128 
3mg/kg (C) Low dose AST487 (10mg/kg) (D) High dose AST487 (30mg/kg) (E) AST487 
10mg/kg and INK128 3mg/kg combination. 10x magnification. (F) Quantification of Ki67 with 
Immunoratio, graphed on Graphpad Prism. 
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4.4 Discussion 
4.4.1 Results from in vitro study are recapitulated in vivo 
Downstream signalling targets of mTOR and MAPK were inhibited in the Tg-
RET/PTC3 mouse model following INK128 and AST487 administration. This 
recapitulated much of what was seen in the cell culture studies of chapter 3. Initially, 
western blots were performed to ensure the direct targets were inhibited. However, 
there were limitations when assessing differences in protein expression following 
treatment.  β actin, as part of the actin family, functions as one of the main 
components of microfilaments. β actin from humans and mice are identical, hence it 
was used as a loading control in both the human cell lines (chapter 3) and the in vivo 
experiments (Figure 4.3A). The disparity between β actin expression in each 
condition was likely due to the heterogeneous nature of the tissue digested.  Due to 
the minute size of the thyroids, often paratracheal muscle and other tissue in the 
region of the thyroid was also digested within the selected sample. To overcome these 
difficulties associated with Western blot analysis, immunohistochemistry was 
employed to confirm that the treatments were accurately inhibiting the signalling 
targets and this technique demonstrated more consistent findings (Appendix 5) [171].  
Immunohistochemistry demonstrated a reduction in pRET, pERK, pAKT and overall 
pS6 staining following corresponding treatment, albeit using small numbers of mice.   
The low percentage of positive stain reflecting pS6 expression was surprising in the 
mouse model (Figure 4.9). mTOR is highly active in RET driven tumours [152] and 
the effect of the compounds on pS6 in vitro was clear (Figure 3.3C, 3.1B).  One 
potential explanation is an inappropriately low concentration of antibody.  
H/E stains were able to show differences in the histology of the thyroid tumours. The 
potent effects of AST487 altered the thyroid follicular tumour phenotype towards a 
more differentiated pattern. This observation was confirmed in both low and high 
dose therapy by a pathologist specialising in mouse thyroid histology (Dr R. 
Ghossein, MSKCC).  This follows the expectation that inhibiting the oncogenic 
kinase driver amends the development of tumourogenesis in the mouse model and 
may confer a better prognosis.    
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Finally, there was a reduction in Ki67 staining in all of the described conditions. This 
reduction in cell proliferation confirmed that inhibiting the oncogenic kinase driver 
with AST487 caused a reduction in proliferation, which was augmented with INK128.  
The initial Ki67 index was low in the vehicle so the absolute differences are small.  
4.4.2 Limitations of the mutant RET transgenic mouse 
There were a number of difficulties with performing experiments with this mouse 
model.  The main issue was the variable penetrance of the disease. This is an issue in 
many of the documented transgenic mice with RET mutations [172, 173].  Increasing 
the number of mice would have ensured more statistically significant data.  However 
their slow breeding due to their hypothyroidism and general runt-like habitus made 
the numbers low, and that coupled with their fragility made the investigations 
difficult. Three sets of experiments were performed over the course of 6 months and it 
was deemed unfeasible, expensive and unnecessary to continue to generate more 
mice.  To the candidate’s knowledge, this is the first data of a transgenic mouse 
model, as opposed to a xenograft, showing evidence of a signalling effect with a RET 
inhibitor.  
Other options of mutant RET transgenic mice were explored. The Tg-RET/PTC1 mice 
were not used because the thyroid tumours developed in them are not completely 
representative as human PTCs [172]. Ideally, following the success of the in vitro data 
in chapter 3, an MTC mouse model would have been valuable to confirm induction of 
apoptosis and possibly survival advantage using these treatments.  There are two well 
known MTC mice: RET/MEN2A and CT (Calcitonin)-MEN2B. Demonstrating 
apoptosis in either model would have assisted in streamlining these compounds into a 
clinical trial.  However, none of the published transgenic models of MTC have 
consistent penetrance of the disease [173, 174]. For example, in CT-MEN2B 
transgenic mice only 3 of 8 animals developed MTC at 20-22 months of age [173].  
This persistent problem with the mutant RET transgenic mice suggests why there is 
such limited data using them with TKIs (4.1.3) [66].  
4.4.3 Combination of INK128 and AST487 in the in vivo model 
A secondary goal of the mouse studies was to test whether sub-therapeutic doses of 
AST487 cooperated with INK128 on mTOR inhibition. A series of experiments were 
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performed with the goal of addressing the effect of combination treatment. In both, 
the RET kinase inhibitor alone potently inhibited mTOR activity as determined by 
pS6 IHC. There was also a reduction of cell proliferation. Addition of INK128 
augmented the effects in the reduction in cell proliferation, but not signalling, in this 
model.  In the pS6 IHC data, the combination data was not significant when compared 
with vehicle treated mice.  Additional experiments were performed to identify optimal 
subtherapeutic doses of AST487 that could be used in combination with INK128 to 
test for cooperativity. However, it appeared dual treatment failed to demonstrate an 
additive effect by virtue of the potent effects of each individual compound. Lower 
doses of each were attempted but the results were inconclusive, in part because of the 
variable penetrance of the disease and the difficulties with the mouse model as 
described above.    
The effect of the combination treatment is significant despite the lack of complete 
clarification in these experiments.  Many have shown the success of combination 
treatment in preclinical models of thyroid cancer [95].  Feedback loops and escape 
pathways are emerging as important considerations in targeted therapy regimens.  
Inhibition of mTOR with a dual PI3K/mTOR inhibitor can cause an increase in 
MAPK signalling, thereby potentially negating the positive effect of cytotoxity of 
compounds [168]. It is well established that inhibition of mTOR can initiate a 
feedback loop concurrently activating MAPK [83]. Hence, dual treatment regimens 
are now becoming standard to prevent the establishment of these secondary pathways 
[95].  In the data presented in chapter 3, there was no corresponding activation of 
MAPK following mTOR inhibition (Figure 3.3D). In these in vivo models there was 
also no combination of effect, and nor was there any increase in pERK signalling after 
2 weeks of treatment (Figure 4.7). As discussed previously, titration of each 
compound is the next necessary step in working out the effect of these drugs in vivo.  
Lastly, the tolerability of these compounds together in the mouse model is significant. 
No mice died or were visibly ill following combination therapy.  Hence in this 
preliminary setting toxicity is not an acute issue in this regimen.  
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4.4.4 Pre-clinical and clinical applications of this proposition 
This is the first presentation of INK128 in thyroid cancer models. INK128 has been 
used in vivo with success in other cancers. Pre-clinical models in breast and prostate 
cancer have showed reduction in metastases and xenograft size following INK128 
administration [175, 176].  INK128 has also shown success in combination treatments 
in other cancers. In preclinical breast cancer murine models, INK128 was combined 
with the HER2 inhibitor lapatinib, and it was demonstrated that this synergistically 
inhibited the AKT/PI3K/mTOR pathway and the MAPK pathway, and thereby 
induced cell death and tumour regression in cancer models refractory to single 
therapy [177].   
Recent clinical data has also added weight to the hypothesis of this thesis. A recent 
abstract at American Society of Clinical Oncology meeting showed the effect of the 
mTOR inhibitor everolimus combined with the TKI sorafenib in patients [178].  
Sorafenib is a known RET inhibitor. The data showed that within the group of 
patients with refractory disease, MTC patients had particularly good outcomes. It 
would be worthwhile investigating the subgroup of patients, both MTC and PTC with 
RET mutations to see if they respond better than the RET wild type cohort.   
4.4.5 Limitations in experimental design 
A large part of the limitations described in this experiment may be due to the short 
duration of this treatment regimen and the small number of mice.  It would be useful 
to extend this experiment past two weeks of treatment to assess a prolonged treatment 
effect.  This would also recapitulate more accurately what might be seen in a clinical 
setting. However, caveats explained in section 4.4.2 illustrate limitations of these 
mice.  Lack of concrete data from assessment of thyroid size, mouse body weight and 
the volume assessed through ultrasound, was primarily due to the low numbers of 
mice.  
4.5 Conclusions 
Despite a lack of evidence for certain signalling targets and size of tumours there are 
some key conclusions that can be drawn from these results. Firstly, INK128 and the 
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AST487 were tolerated over a two week period, alone and in combination in a mouse 
model of thyroid cancer.  Using the transgenic model Tg-RET/PTC3, following 
treatment with AST487 and INK128 there was reproducible inhibition of the 
downstream targets of mTOR, which recapitulated the in vitro data. The lack of 
inhibition of pERK (for AST487) and pAKT (for both compounds) was most likely a 
reflection in the limitations of this mouse model. The variable penetrance of the 
disease and the difficulty in breeding the mice, meant that the numbers were low for 
all arms of the experiment.  Overall, there was significant inhibition in certain targets 
and reduction in cell proliferation.  
Combination treatment failed to show a consistent additive effect in these 
experiments. This was due to the limiting factors outlined above, and also the short 
duration of the experiment. In the future, exploring an extended experiment with 
MTC models is precarious, but may be a better way to titrate doses and observe the 
success of the combination that was observed in the in vitro studies.  
 
  
 
Chapter 5. 
Destabilising RET with 
HSP90 inhibitors 
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5.1 Introduction 
5.1.1 Overview 
The results presented in chapters 3 and 4 of this thesis explored the effects of RET 
and mTOR inhibitors on RET driven thyroid cancers in vitro and in vivo.  mTOR was 
shown to be activated by RET in a PTC and 2 MTC cell lines.  This data provides a 
novel mechanism for effective treatment by identifying mTOR as a treatment target in 
RET-dependent thyroid cancer.  An approach using a combination of drugs at 
submaximal doses was shown as another potentially important therapeutic avenue.  
This may be particularly helpful when currently available TKIs show dose-limiting 
toxicities. Additionally, it further highlights the benefit of targeting more than one 
point of the signalling cascade.  
 
The advantages of a multi-targeted approach to treating cancer were discussed in 
chapter 1 [179].  Moreover, a benefit has been seen from concurrent use of multiple 
targeted inhibitors in thyroid cancer [95, 180]. The goal of this chapter was to look 
more broadly at multiple signalling inhibition, through exploiting heat shock protein 
90 (HSP90), a ubiquitous chaperone protein involved in multiple aspects of the 
signalling cascade.  The candidate hypothesised that the inhibition of HSP90 would 
lead to downstream simultaneous inhibition of multiple proliferation and anti-
apoptotic pathways due to their reliance on the chaperone protein.   Recently RET 
itself has been identified as a client protein of HSP90 [104]. Its role and mechanism is 
detailed in chapter 1.8.1.   
 
HSP90 inhibitors have been exploited as cancer treatments due to the overexpression 
of the vital regulator HSP90 in cancer cells [100].  Furthermore, malignant cells may 
be more sensitive to HSP90 inhibition than normal cells [101]. Malignant cells are 
inherently unstable.  The cells therefore rely on HSP90 more than their normal 
counterparts in the context of their hostile, acidotic, nutrient poor, and hypoxic 
tumour microenvironment [181].  The field of HSP90 inhibitors has developed from 
initial use of Geldanamycin derivatives, specifically 17-AAG.  Data in this thesis is 
presented with a novel compound AUY922, provided by Novartis. 
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5.1.2 NVP-AUY922 
NVP-AUY922 is a novel HSP90 inhibitor which acts to competitively inhibit the 
ATPase and cause destabilisation of HSP90 in cells leading to their degradation by 
the proteasome (Figure 1.5).  Detailed description of AUY922 is found in chapter 1.  
The destabilising effect is distinct in different cancer types [109-111, 182]. There is 
evidence both of cytostatic and cytotoxic effects. Some reports demonstrate apoptosis 
alone or with combination treatments.  There is no data with thyroid cancer cell lines 
and AUY922 at the time of submission of this thesis.   
5.1.3 Preclinical data in thyroid cancer 
There are no preclinical or clinical studies of thyroid cancer with AUY922 at the time 
of thesis submission. However, there is data utilising a different HSP90 inhibitor, 17-
AAG in vitro [112]; and in a clinical setting. There is a phase II clinical trial for 
“Advanced Medullary and Differentiated Thyroid cancer” which began in 2005 but 
has stopped recruiting participants.  At this time, there are no published results. 17-
AAG has already demonstrated significant problems in the clinic, with toxicity and 
side effects (see 1.8.2). There is a demand for alternative HSP90 inhibitors, both 
potent and tolerable [108]. This chapter demonstrates for the first time the cytotoxic 
effect of an HSP90 inhibitor in medullary thyroid cancer cells.  
5.1.4 Radioiodine treatment 
Most differentiated thyroid cancers (DTC, excluding medullary) maintain TSH-
inducible radioactive iodine (RAI) uptake, thereby ensuring RAI is the mainstay of 
detection and treatment of recurrent DTC [113].  Tumours that are refractory to RAI 
have a poorer prognosis (detailed in 1.5.1.1). They also show a higher prevalence of 
oncogenic BRAF mutations [22].   It has been recently reported that RAI uptake and 
retention can be enhanced by drugs that inhibit the MAPK pathway, particularly in 
patients with mutant RAS disease [44]. An additional hypothesis of this chapter was 
therefore to examine whether HSP90 inhibition with AUY922 would increase 
radioiodine uptake or retention in the RET mutant TPC-1 papillary thyroid cancer cell 
line [113].   
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5.1.5 Aims 
The aims of this chapter were to: (a) investigate simultaneous pathway inhibition 
using AUY922, a novel compound in thyroid cancer, and evaluate its potential as a 
therapeutic option in mutant RET thyroid cancers; (b) investigate apoptosis of MTC 
cell lines as a consequence of treatment and (c) assess any functional effects of the 
drug through increased RAI uptake or retention in a PTC cell line. 
5.2 Methods 
5.2.1 General methods 
Cell lines and culture conditions are detailed in chapter 2.  
The HSP90 inhibitor NVP-AUY922 was kindly provided under a material transfer 
agreement with Novartis Institutes for Biomedical Research.   Description of its 
preparation is detailed in chapter 2.  
5.2.2 Cell cycle assessment 
Cell cycle analysis was performed using propidium iodide (PI) (Merck Chemicals, 
Darmstadt, Germany) to differentiate each phase through DNA mass. Cells were 
plated in triplicate in 6 well plates at 1 million cells per well. The following day, cells 
were treated with increasing concentrations of AUY922.  Cells were exposed to the 
compound for 72 hours.  Cells were washed twice in PBS, spun at 300g for 2 minutes 
and vortexed between each wash.  Cells were resuspended in 700µl of PBS.  Each 
sample was treated with a master mix containing 50µl RNAse A (20mg/ml 
Invitrogen), 200µl 2% Triton X-100 (Sigma-Aldrich), and 200µl 10mg PI. Cells were 
incubated at 4°C for 30 minutes and then analysed on the FACSCalibur flow 
cytometer (Beckton-Dickinson, NJ, USA). Cell cycle distribution (G0/G1, S, G2/M) 
analysis was subsequently performed using Modfit LT software (Verity Software 
House, Topsham, ME, USA) to model mathematically the DNA histogram and thus 
objectively determine the percentage of cells in each phase.  
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5.2.3 Cell viability and apoptosis assessment  
5.2.3.1 MTS 
The CellTitre 96 Aqueous One Solution Cell Proliferation Assay kit was utilised as 
per the manufacturer’s instructions, (Promega, Madison, WI, USA). MZ-CRC-1 and 
TT cells were plated at 10,000 cells per well in 96 well plate. TPC-1 cells, due to their 
faster doubling time were plated at 5,000 cells per well, all in triplicate.  The 
following day, cells were treated with different concentrations of AUY922.   The next 
day, 20µl of a solution containing 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) was added and 
cells were incubated for 3 hours at 37°C.  The conversion of MTS into the aqueous 
soluble formazan product is accomplished by dehydrogenase enzymes found in 
metabolically active cells. The quantity of formazan product as measured by the 
amount of 490nm absorbance, is directly proportional to the number of living cells in 
culture. This experiment was repeated at 4 time points (24, 48, 72 and 96 hours) to 
determine the greatest inhibitory effect of the drug. The Sunrise Tecan microplate 
reader (Tecan Group, Mannedorf, Switzerland) was used to read the plate at 490nm.  
Absorbance data was imported into GraphPad Prism where the half maximal 
inhibitory concentration IC50 was determined through GraphPad software analysis 
version 6.0 (GraphPad Software) 
5.2.3.2 Apoptosis assessment 
Cell viability was assessed using the mitochondrial membrane dye DilC(5), 
propidium iodide with FACS analysis [183]. DilC(5) is a cationic cyanine dye which 
accumulates in response to membrane potential. The dye accumulates in mitochondria 
with active membrane potentials.  Cells that take up DilC(5) have functioning 
mitochondria and are termed “live” cells.  Propidium iodide (PI) is membrane 
impermeant and is excluded from live cells.  
TT and MZ-CRC-1 cells were plated on day 0 at 50,000 cells per well in a 12 well 
plate. The following day cells were washed with PBS and treated with increasing 
concentrations of AUY922. Cells were kept in an incubator at 37°C for 6 days 
whereupon they were prepared for flow analysis. 
111 
Media was removed and cells were washed once with PBS. All media and PBS were 
transferred to previously labelled flow tubes. 100µl citric saline (see 2.11) was added 
to each well for 10 minutes. Cells were resuspended in PBS and transferred to the 
same flow tube. Tubes were spun at 1,400rpm for 5 minutes. Excess PBS was 
removed. 2µl of 2µM DiLC(5) (1,1 dimethyl-3,3,3’3,3’-
tetramethylindodicarbocyanine iodide, 10mg/ml Biotium Inc, Hayward, CA, USA) 
was added to each tube. Cells were vortexed and incubated for 20 minutes in the dark. 
2µl of PI (10mg/ml; Sigma) was added and incubated for 2 minutes.  DilC(5) was 
excited by laser at 633nm and detected on the FL4 channel.  PI was excited by laser at 
488nm and detected on the FL-2 or FL-3 channel. Cells were analysed with 
FACSCalibur flow cytometer (Becton Dickinson) and results analysed by Cell Quest 
Pro (BD Biosciences). By determining the flow cytometer had a constant flow rate 
throughout each period of data acquisition and fixing the acquisition time to 20s per 
sample it was possible to quantify the number of cells.  Experiments were done in 
triplicate and results were normalised to the vehicle treated cells in each experiment.  
All results are expressed as a percentage relative to vehicle treated cells. For each 
experiment, live cells, namely those fluorescing DilC(5) and not PI were gated as R2.  
R3 was determined to be DilC(5) negative, PI positive cells or the necrotic cells.     
5.2.4 Radioiodine experiment  
Radioactive iodine (125I) has a 60 day half life and was ordered fresh at an optimal 
time to ensure sufficient specific activity for each replicate experiment. TPC-1 cells 
were plated in triplicate at 25,000 cells per well in a 12 well plate. 2 separate plates 
(also in triplicate) were prepared.  The first, for addition of perchlorate (KClO4) 
(Sigma) and the second for cell counting, (after identical treatments) to adjust the 
gamma count to the amount of cells to avoid inflation of the data. The following day 
the cells were treated with indicated concentrations of the drug.  Cells were incubated 
for 24 hours with treatment at 37°C.  Next, Na125I (Iodine-125 radionuclide in 0.1M 
NaCl, PerkinElmer) was administered to cells. Concentration was determined from 
stock concentration 4MBq/µl (original activity). Original activity was determined 
through online radioactive decay calculator 
(http://www.radprocalculator.com/Decay.aspx). A representative example of working 
concentration was 5.26µCi/µl (0.195 MBq/µl). The composite solution was diluted by 
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20.5.  Cells were washed once with warm Hanks buffer solution (Invitrogen). Cells 
were then incubated with 500µl Na125I mix at 37°C for 1 hour. In the representative 
example, final mix consisted of 3.59µM NaI and 0.21µCi Na125I in 500µl 1x Hanks 
solution. The alternative plate was then treated with KClO4. Perchlorate is a 
competitive inhibitor of the sodium-iodide symporter (NIS).  Cells were then washed 
twice with 500µl ice cold Hanks solution. Cells were then solubilised with 500µl 
NaOH (Sigma) per well overnight at 4°C. The following day, 400µl of each solution 
was aliquoted and counted on the gamma counter (PerkinElmer).  The final reading 
was adjusted to mean cell number in each treatment group.  
5.3 Results 
5.3.1 The HSP90 inhibitor AUY922 impairs cell growth MTC cell lines 
The effect of AUY922 on growth of RET mutant MTC cell lines was assessed by 
MTS assay after treatment for 48 hours and 72 hours. AUY922 inhibited the growth 
of TT and MZ-CRC-1 medullary thyroid cancer cell lines at doses above 25nM 
(Figure 5.1A). In the MZ-CRC-1 cell line, AUY922 inhibited cell growth by 45.8% ± 
1.45 at 25nM (p=0.002) and by 56.1% ± 2.79 at 100nM treatment (p<0.001). In the 
TT cell line, AUY922 inhibited cell growth by 64.3% ± 3.15 at 25nM (p<0.001), 
which was not further enhanced at higher concentrations of the drug. Figure 5.1B 
shows a graph of log (inhibitor) vs. response to determine IC50 calculations for both 
cell lines. IC50 calculations are shown at 48 and 72 hours (Figure 5.1C).   
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Figure 5.1 The HSP90 inhibitor AUY922 inhibited cell viability in the MTC cell lines. (A) 
Cells were treated for 48 and 72 hours with increasing concentrations of AUY922.  After 2 
hours of MTS incubation, absorbance was read at 490nm.  Representative experiment 
performed in triplicate at 72 hours. Percent growth inhibition was calculated. Inhibition was 
statistically significant in both cell lines in concentrations 25µM and above (p<0.002)  (B) 
Graphs of log (inhibitor) vs. response and analysis of non linear fit are shown at 72 hours for 
both cell lines.  (C) IC50values were calculated on GraphPad Prism version 6 and are expressed 
in nM.  
 
 IC50 48hr IC50 72hr 
TT 14.30 11.98 
MZ-CRC-1 27.27 41.30 
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5.3.2 Cell cycle analysis of MTC cell lines shows limited effect after treatment with 
AUY922 
Cells were treated for 72 hours with an empirically high dose of AUY922 (250nM), 
then incubated with PI and analysed on the FACSCalibur flow cytometer.  Modelling 
of cell cycle distribution was performed using ModFit software. There was a 
significant difference in the proportion of cells in the G0/G1 phase following 
AUY922 treatment in MZ-CRC-1 cells.  Control MZ-CRC-1 cells had 68.5% of cells 
in G1, which increased to 83.8% in treated cells (p=0.01) (Figure 5.2C, 5.2D).  
However in the TT cells, there was no significant difference in the G0/G1 proportion 
following treatment with AUY922, 87.8% vehicle vs. 92.4% treated (p=0.80) (Figure 
5.2). There were no significant differences in the S or G2/M proportions in any of the 
cell lines following treatment (p>0.05; Figure 5.2E, 5.2F). A representative diagram 
for each cell cycle is shown in Figure 5.2 (A-D).  
 
  
	   
G0/G1 
G0/G1 
G0/G1 
G0/G1 
S G2/M 
S G2/M 
S G2/M 
S G2/M 
Figure 5.2.  Cell cycle analysis of MTC cell lines after AUY922 treatment. (A) TT cells 
untreated. (B) TT cells treated with 250nM AUY922.  Cells demonstrates no change in cell cycle 
components following treatment of compound.  (C) MZ-CRC-1 cells untreated. (D) MZ-CRC-1 
cells treated with 250nM AUY922 for 72 hours. There is an increase in G-1 proportion following 
treatment.  Modelling of cell cycle distribution was performed using ModFit LT software. There 
was only a significant difference (*p<0.05) in G0/G1 proportion in MZ-CRC-1 cells following 
treatment. 
 
A B 
C D 
TT  G0/G1 S G2/M 
Vehicle 87.76 12.24 0 
AUY922 92.38 7.08 0.54 
SD 13.22 3.73 2.95 
p-value 0.80 0.48 0.92 
 
MZ-CRC-1 G0/G1 S G2/M 
Vehicle 68.49 29.62 1.89 
AUY922 90.85 8.84 0.31 
SD 11.54 9.86 7.07 
p-value 0.01* 0.21 0.33 
E F 
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5.3.3 AUY922 inhibits signalling through MAPK and mTOR pathways 
The effect of AUY922 on signalling via MAPK and mTOR pathways was examined 
through protein expression in western blots. TT and MZ-CRC-1 cells were plated at a 
density of 70%. The following day, cells were treated with increasing concentrations 
of AUY922, and then harvested for protein 24 hours later.  Following treatment with 
AUY922, RET signalling was inhibited, seen through a reduction of total and pRET 
protein levels in MTC cell lines. A representative blot is shown in Figure 5.3. In the 
TT cell line, concentrations of AUY922 above 10nM resulted in inhibition of total 
RET protein, whereas AUY922 at or above 100nM was required to inhibit total RET 
in MZ-CRC-1 cells (Figure 5.3). The downstream targets of RET, namely the MAPK 
and mTOR pathways showed a similar dose-dependent decrease following AUY922 
treatment. There was complete ablation of the signal of pS6, pAKT and pERK at or 
above 100nM AUY922 in both cell lines, which corresponded with the strong 
inhibition of total and pRET at these concentrations.  Interestingly, both total ERK 
and AKT protein (known client proteins of HSP90) were unchanged following 
AUY922 treatment suggesting that the reduction in pERK and pAKT was due to 
upstream RET inhibition.  
 
  
Figure 5.3 Protein expression in MTC cell lines following AUY922 treatment. Cells were 
treated with increasing concentrations of AUY922 for 24 hours. Cells were lysed and prepared 
for western blotting.  Membranes were probed by antibodies, for RET and downstream targets of 
mTOR and MAPK pathway. There is clear inhibition of pRET, pERK, pRS6 and pAKT in a 
dose responsive trend.  
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5.3.4 Treatment of MTC cell lines with AUY922 leads to apoptosis 
To explore the effect of AUY922 on apoptosis, TT and MZ-CRC-1 cell lines were 
treated with increasing doses of AUY922 for 6 days. Following treatment cells were 
incubated with DilC(5) and PI and analysed on a flow cytometer.  A representative set 
of experiments is shown for TT cells (Figure 5.4A) and MZ-CRC-1 cells (Figure 
5.4B). Consistently, following treatment there was an increase in apoptosis 
(characterised by cells expressing less DilC(5) and increased expression of PI), gated 
as R3 in Figure 5.4A, B.  There was a corresponding decrease in live/viable cells, 
gated as R2 in Figure 5.4A, B.  Figure 5.4C, D shows a dose response of both 
measures. After treatment with AUY922 at 100nM, live MZ-CRC-1 cells were 
reduced to 48.6% ± 14.5 as compared to vehicle treated cells (p=0.02). This was 
further reduced to 41.3% ± 14.0 of live cells when 1µM AUY922 was administered 
(p=0.018).  These results were even more potent in the TT cells. Following 100nM 
treatment live cells comprised of 24.8% ± 13.9 as compared with vehicle treated 
(p=0.011) and reached a plateau at higher concentrations (21.3% ± 11.7 as compared 
with vehicle, p=0.007) (Figure 5.4C, D).   
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Figure 5.4 DilC(5) vs. PI flow cytometry analysis on MTC cell lines. (A), (B) DilC(5) vs. PI 
flow cytometry analysis on MTC cell lines A: TT and B: MZ-CRC-1 show increased apoptosis 
following AUY922 treatment. Cells were treated with increasing concentrations of AUY922 for 
6 days. Cells were stained with DilC(5) and PI and analysed on a FACSCalibur flow cytometer.  
Analysis was performed by Cell Quest Pro.  (A) and (B) are representative examples of 
individual experiments which were completed three times. (C), (D) Combined flow cytometry 
results for dose response of AUY922. Each individually treated cohort was normalised to vehicle 
treated cells on that experiment.   
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5.3.5 AUY922 treatment in RET/PTC1 cell line inhibits RET signalling targets 
Similar analyses were conducted to assess the effects of AUY922 on a RET mutant 
papillary thyroid cancer cell line, TPC-1.  Metabolic activity was measured in the 
MTS assay (Figure 5.5A) and showed potent IC50 results (13.19nM). Inhibition of 
downstream targets of RET was also observed after 24 hour treatment with AUY922 
(Figure 5.5B). There was marked inhibition of mTOR and MAPK pathways including 
pERK (at 100nM) and pRS6 signal (from 50nM) (Figure 5.5B). There was some 
residual pAKT expression detected at 50nM but it was absent at 100nM AUY922 
(Figure 5.5B).  In contrast to the medullary thyroid cancer cell lines, both total AKT 
and ERK protein expression was also reduced following treatment with AUY922 
(Figure 5.5B).    
  
Figure 5.5 Protein expression and cell viability in the TPC-1 cell line following AUY922 
treatment. (A) Cells were treated with increasing concentrations of AUY922 for 24 hours.  After 2 
hour MTS incubation, absorbance was analysed at 490nm. Graphs of log (inhibitor) vs. response and 
analysis of non linear fit are shown at 24 hours. IC50values were calculated on GraphPad Prism 
version 6. (B) Cells were treated with increasing concentrations of AUY922 for 24 hours. Cells were 
lysed and prepared for western blotting.  Membranes were probed for antibodies to RET and 
downstream targets of mTOR and MAPK pathway.  There is clear inhibition of pRET, pERK, pRS6 
and pAKR in a dose responding trend. There is also clear inhibition of total proteins AKT and ERK 
despite even loading (GAPDH).   
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5.3.6 Radioiodine uptake is enhanced by AUY922 treatment on the PTC cell line 
TPC-1 cells were treated with increasing concentrations of AUY922 for 24 hours.  
The following day, cells were incubated with I125 for 1 hour with an identical 
triplicate set further incubated simultaneously with potassium perchlorate (KClO4). 
Following cell lysis the next day, radioactivity was measured on a gamma counter and 
showed a dose responsive increase following AUY922 treatment. Radioactive iodine 
uptake was increased up to at 100nM to 141% (1.93 ± 0.14 vs. 2.79 ± 1.23 cpm 
normalised to cell number); 163% at 250nM (1.93 ± 0.14 vs. 3.22 ± 1.44) and at 
1000nM to 284% (1.93 ± 0.14 vs. 5.85 ± 1.5) as compared to vehicle treated cells.  
However, only the 1µM cohort was statistically significant (p=0.015) (Figure 5.6).   
The cells treated with KClO4 also demonstrated a statistically significant increase in 
RAIU following 1µM AUY922 (p=0.002). The treated group without KClO4 was not 
statistically different from the group which received the competitive inhibitor 
(p=0.06), consistent with the observed effect of AUY922 on iodine uptake and/or 
retention being independent of the sodium-iodide symporter. 
   
Figure 5.6 Radioiodine uptake is increased in TPC-1 cell lines following AUY922 
administration. Cells were plated to 70% confluence and then treated with increasing 
concentrations of AUY922 in triplicate.  The following day cells were incubated with Na125I  or 
Na125I  and KClO4 at 37°C for 1 hour. Cells were washed with 1x Hanks Buffer and solubilised 
with NaOH overnight at 4°C.  The following day cells were counted on gamma counter.  There is 
significant increase in uptake at1µM AUY922 in both conditions (p<0.05).  
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5.4 Discussion 
5.4.1 The wide range of HSP90 activity is exploited in RET driven tumours 
Targeted therapy focusing on inhibition of single oncogenes has made significant 
inroads into promising cancer treatments, recently epitomised with the vermurafenib 
data [51].  However, in some cases it seems despite an initial promising response, 
these malignancies develop secondary mutations and form resistance to targeted 
chemotherapy drugs through escape pathways and feedback loops [51, 83].  The data 
in chapters 3 and 4 show the promising effects of dual mTOR and RET inhibition in 
RET driven tumours.  HSP90 inhibitors represent another strategy to inhibit 
proliferation pathways in these cancer cells.  They simultaneously target multiple pro-
oncogenic proteins leading to the inhibition of pro-malignant pathways.  
The novel compound AUY922 destabilises known client proteins of HSP90 including 
RET, AKT, and components of the MAPK pathway.  mTOR itself may also be a 
client protein of HSP90 [184].  In chapter 1 the successful role of mTOR inhibitors in 
neuroendocrine tumours was discussed [116] and the hypothesis was proposed that 
their shared lineage properties made mTOR inhibitors a viable proposition in MTC 
therapeutics. Chapter 3 provides data to support this hypothesis using a small 
molecule inhibitor (INK128).  HSP90 is an important molecular biomarker of 
neuroendocrine tumours (NET) [185].  Cell cycle arrest and/or apoptosis were both 
found to be employed in NET cell lines following inhibition with AUY922 and the 
HSP90 inhibitor IPI-504 (geldanamycin derivative) [116].  This thesis shows a novel 
HSP90 inhibitor demonstrating significant reduction in signalling and an increase in 
apoptosis measures in MTC cell lines (Figures 5.3 and 5.4), thus providing a new 
potential therapeutic option for patients. 
5.4.2 Inhibition of cell growth is achieved with AUY922 
In both the PTC and MTC cell lines there is growth inhibition following AUY922 
treatment (Figures 5.1A and 5.5A).  The IC50 for both MTC cell lines are very similar 
(Figure 5.1C) despite differences in the transforming ability of each mutation within 
the cell line; and are broadly consistent with effects on other cancer cell lines [110, 
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186].  The mechanism of reduction in cell growth which was seen in MTS assays was 
next explored in this chapter. 
5.4.3 Mechanism of loss of cell viability in MTC cell lines 
The TT and MZ-CRC-1 cell line have slow doubling times. This presented some 
difficulties when performing cell cycle analysis. In order to demonstrate drug effects, 
many experiments in this thesis have used prolonged treatments in the MTC cell lines. 
AUY922 was shown to have significant effects on both signalling and cell death on 
RET driven thyroid cancer cell lines.  In MTC cell lines there was an unambiguous 
decrease in cell viability (Figure 5.1). In the MZ-CRC-1 cell line there was an 
increase in G1 arrest following treatment with AUY922, while in the TT cell line the 
cells remained in proportionally the same phase after treatment (Figure 5.2). One 
reason for this may be because MZ-CRC-1 harbours the RETM918T mutation and has 
an enhanced transformative capacity as opposed to the TT cell line, harbouring the 
RETC634W mutation [151].  Also, naive TT cells have an extended phase G0/G1 
(Figure 5.2A). Therefore there is little capacity for any increase in G0/G1 with 
treatment, despite a clear reduction in viability (Figure 5.1). It became necessary to 
explore an alternative reason for the mechanism of decrease in cell viability, so the 
FACS apoptosis measure PI/DilC(5) was employed.  
An extended treatment approach was taken to assess for apoptosis. Cells were treated 
for 6 days with increasing concentrations of AUY922 and then prepared for analysis 
of mitochondrial membrane function as detailed in section 5.2.3.2.  There was a 
decrease in live functioning cells and a corresponding increase in dead cells following 
treatment (Figures 5.4C and D).   Cells staining for low DilC(5) and for low PI are in 
the current phase of apoptosis, as opposed to necrosis. In these experiments, there 
were negligible cells in that region.  These cells have non-functioning mitochondria 
but have not yet endorsed PI uptake into the nucleus.  It would have been ideal to 
have an earlier time point showing an increase in this quadrant, timing exactly when 
the cells were apoptosing, but when earlier time points were performed (at 24 and 72 
hours - data not shown) there was no significant increase in apoptosing cells.  Due to 
the difficult nature of this cell line it was thought best to show an overall increase in 
dead cells at a longer time point to demonstrate the effectiveness of the compound.  
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The precise mechanism through which apoptosis arises following treatment is likely 
due to inhibition of the pro-survival factors, including AKT (Figure 5.3). The MAPK 
pathway, inhibited here by AUY922, has also been shown to promote cell survival.  
Hence, the destabilisation of RET by AUY922 ensures these pro-survival components 
are inhibited, and apoptosis ensues.   
5.4.4 AUY922 treatment causes inhibition of mTOR and MAPK pathways 
Figure 5.3 shows inhibition of signalling in the mTOR and MAPK pathways in the 
MTC cell lines. Similarly in the TPC-1 cell line (Figure 5.5B) it is clear that at even 
lower concentrations of AUY922 there was disruption of these pro-oncogenic 
pathways. Interestingly, the effect of total ERK protein and total AKT protein 
following AUY922 administration was different between the MTC and the PTC cell 
lines.  In the PTC cell line, not only was there a clear dose response in the 
phosphorylated proteins following treatment, but there was also a clear inhibition of 
total protein. This demonstrates an increase in ubiquitination of both ERK and AKT 
(Figure 5.5B). This suggests that in the PTC cell line the HSP90 inhibitor is working 
effectively on its known client proteins ERK and AKT directly [184]. However, in the 
MTC cell lines, inhibition of the proliferative pathway MAPK, and the pro-survival 
pathway AKT, was due to inhibition of an upstream target as the total proteins 
remained stable.  Destabilisation of RET in the MTC cell lines and the data from the 
previous chapters confirming RET oncogene addiction, showed RET to be the 
architect of the downstream inhibition.  Furthermore it is clear that RET itself was 
destabilised in this treatment in all cell lines (Figure 5.3 and Figure 5.5B).  The 
difference between the effect in the PTC vs. MTC cell lines could be due to the slower 
growth of the MTC cell lines. Their turnover is far less than the TPC-1 line. This may 
be due to the inherent differences in the cell line genesis, specifically point mutations 
versus chromosomal rearrangement.  Total RET is also clearly destabilised in each 
cell line (Figures 5.3 and 5.5B) and the downstream targets abrogated. 
5.4.5 Radioiodine uptake is enhanced with AUY922 treatment 
Following thyroidectomy, patients with PTC receive radioiodine ablation therapy to 
eliminate any residual thyroid tissue.  Aggressive malignancies, most often mutant 
BRAF positive, have a reduced avidity rendering this treatment less effective.  Due to 
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their poor outcome, and the success of the TKIs, the pairing of TKIs with enhanced 
avidity has been investigated [44, 187].  This chapter presents data showing a dose 
dependent increase in the uptake of radioiodine in the TPC-1 cell line following 
treatment with AUY922 (Figure 5.6).  To the candidate’s knowledge, this is the first 
time radioiodine avidity has been increased with an HSP90 inhibitor in a PTC cell 
line. If these results were recapitulated clinically, patients may be able to ensure 
extended progression-free survival, with enhanced ablation of tissue. However, in 
these results, the corresponding increase in avidity following perchlorate 
administration was unexpected.  Perchlorate acts as a competitive inhibitor to NIS.  If 
the uptake was mediated by NIS, the expectation would be an absence of a dose 
dependent increase with AUY922 treatment.   In this case, there was a similar 
statistically significant dose dependent increase.  This suggests a NIS independent 
mechanism of increased iodine uptake.  Marsee et al show treatment of 17-AAG on a 
thyroid cell line increases radioiodine uptake [113] through the mechanism of 
decreased iodide efflux. Future work, beyond the scope of this thesis, will be to 
confirm the mechanism by which the uptake is enhanced.  Interestingly, this group 
also demonstrated no effect on the TPC-1 cell line in terms of uptake.  This further 
highlights the importance of translating these results to AUY922 clinical trials as the 
only clinical trial of HSP90 inhibitors at time of publication of this thesis was with 
17-AAG.  
5.4.6 Tolerability of AUY922 
Studies with 17-AAG have confirmed a difficult translation to the clinic. The poor 
aqueous solubility of the drug, coupled with side effects including hepatotoxicity have 
complicated its translation.  A recent Phase I clinical trial of AUY922 suggests this 
drug may be more tolerable than its competitor [188].  AUY922 is currently in 
clinical trials of non-small cell lung cancer and breast cancer (www.clinicaltrials.gov). 
If tolerable, it may be able to be streamlined into clinical trials in thyroid cancer. 
5.5 Conclusion 
In examining the effects of AUY922 on mutant RET thyroid cancer cell lines, it is 
clear that using this HSP90 inhibitor has anti-tumourogenic effects. It impairs 
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signalling through RET in all three cell lines and is associated with apoptosis in MTC 
cell lines.  AUY922 increased radioactive iodine retention in the PTC cell line in a 
NIS independent mechanism. This data suggests a potential therapeutic role for this 
compound in treating thyroid cancers. 
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6.1 Introduction 
6.1.1 Increasing awareness of the role of the tumour microenvironment  
The results presented in the previous chapters of this thesis focus on mapping the 
intrinsic genetic pathways and signalling defects in RET driven thyroid cancers.  The 
success of vandetanib for MTC patients has continued progressive research on RET 
driven signalling pathways.  But, as significant as the intrinsic signalling is to the 
genesis of the tumour, it is becoming apparent that the microenvironment also plays a 
vital role in its progression. In fact, the microenvironment is often itself driven by the 
oncogenic kinase driver.  In thyroid cancer research, little focus has been given to 
examining the stroma of these tumours and the role it plays in pathogenesis.   It is 
pertinent to understand the context of how these tumours metastasise and survive in 
their environment in order to advance treatment.    
The data presented in this thesis has focused on the consequence of RET mutant 
events in thyroid cancer.  Recent data has shown that oncoproteins have a complex 
strategy in recruiting the host’s immune system to enhance tumour progression. The 
tumour secretes chemoattractants which demand recruitment of protumourogenic 
stromal cells.  RET/PTC1 is known to directly enhance the recruitment of 
inflammatory cells providing a rich environment for the malignancy to flourish [123, 
189]. This oncogene recruits CD8 T-cells directly for this purpose [123].  In the same 
fashion that RET/PTC1 directly recruits other inflammatory cells, so do BRAF mutant 
tumours.   
The candidate used a BRAF mouse model to study the PTC microenvironment rather 
than the RET/PTC1 mouse model from chapter 4 for a variety of reasons.  The 
RET/PTC1 mice are small, hypothyroid and breed poorly. They also have established 
tumours in the foetal period and at 6 weeks have fully penetrant PTCs.  Using an 
established inducible model with a different oncogene, namely BRAF, which acts 
similarly to RET in protumourogenic inflammatory cell recruitment, meant that the 
role of the microenvironment could be studied in a more dynamic manner.   
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6.1.2 A mouse model of mutant BRAF in thyroid cancer 
As discussed in chapter 1, BRAF mutations are found in a variety of human cancers.  
The highest prevalence includes thyroid, melanoma and colorectal.  BRAF mutations 
render the kinase constitutively active thereby ensuring the constant activity of 
downstream MAPK targets (reviewed in [131]). The relationship of BRAF and the 
tumour microenvironment is beginning to be understood.  VEGF, a major regulator of 
angiogenesis in the stroma, has been shown to be unregulated in BRAF mutant PTCs 
[190].   Additionally, metalloproteinases (known for their protease action) are induced 
by BRAF and conditional expression of BRAF has been associated with increased 
invasion, possibly through the MMP mechanism [130].  It is also well established that 
PTCs harbouring the BRAF mutation are more aggressive, with greater extrathyroidal 
extension [131].  A better understanding of how BRAF promotes tumour progression 
and increases mortality is required for the rational development of strategies to 
combat the disease.  In this chapter a conditional BRAF mouse model is used to 
explore effects on initiation and progression of papillary thyroid cancer (Figure 6.1).  
Following treatment with doxycycline, the BRAF oncoprotein is expressed, causing 
complete infiltration with PTC after one week (see 6.4.1). 
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Figure 6.1 A mouse model for conditional regulation of BRAFV600E activity in thyroid follicular 
cells. Constructs to develop dox inducible thyroid specific expression BRAFV600E. Reverse tetracycline 
activator is cloned downstream of the bovine thyroglobulin promotor (Tg-rtTA).  Myc tagged BRAF 
cDNA is cloned downstream of multimerized tetO-minimal CMV promotor (pCMVmi); tetO-
BRAFV600E. The crossed mice have offspring which express oncogenic BRAF exclusively in thyroid 
cells. The addition of doxycycline impregnated chow activates expression of the Myc-BRAFV600E 
exclusively in the thyroid. This overexpression induces fully penetrant PTCs in 1 week. These mice 
were maintained in a FVB/N background.  bT=Bone tag agent. Figure adapted from Dr Debyani 
Chakravarty. 
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6.1.3 The role of TAMs in thyroid cancer 
Beyond activating signalling cascades, another mechanism for PTC progression is 
through the protumourogenic role of the stroma. Over half of thyroid cancer tumour 
stroma can be composed of tumour associated macrophages (TAMs) [129]. These 
infiltrating inflammatory cells have been established as critical components in nearly 
all types of malignancies.  As key proponents of inflammation, they have the ability 
to enhance tumour progression through angiogenesis, remodelling of the environment 
and suppressing the host’s anti-tumour immune response.  They have been shown to 
be tumour promoters through enhancing cancer cell motility and augmenting hypoxic 
stromal components to stimulate angiogenesis [127].  TAMs may be impelled into a 
tumour promoting phenotype by the presence of chemoattractants namely MCP-1 and 
CSF-1 which act on corresponding leukocytic receptors expressed on TAMs. These 
can include: F4/80; CSF-1; CCR2; Ly6C; and Mac-2 (Figure 6.2A).  Multiple lines of 
evidence show an association between these tumour derived macrophage 
chemoattractants and TAMs on tumour invasion and growth [128].   
Macrophage infiltration is seen in transgenic mice with thyroid specific expression of 
both RET/PTC3 and BRAF [130].  In thyroid cancers, infiltration of TAMs has been 
observed but their role is not well understood.  In patients with advanced thyroid 
cancers a higher proportion of TAMs has been shown to correlate with decreased 
survival and increased extrathyroidal invasion [129].  This data suggests that 
examining the cooperativity of TAMs in BRAF mutant thyroid cancers may shed light 
on the pathogenesis of this malignancy.  This chapter looks at selective targeting of 
TAMs in a BRAF mutant thyroid cancer mouse model.  Two genetic strategies were 
employed to deplete TAMs. This was part of a larger study where pharmacological 
inhibition of TAMs was also performed (Appendix 4).  Depletion of TAMs through 
the genetic strategies outlined in the methods below, showed impairment of PTC 
initiation, progression and reversed aspects of the classical papillary phenotype. 
Interestingly, there was also reduction of the stromal component, cancer associated 
fibroblasts (CAFs). 
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6.1.4 TAMs are depleted in established mice models 
Mice with an inducible expression of oncogenic BRAF were crossed with a mouse 
expressing a TAM receptor depletion mechanism. This provided a model to study the 
role of TAMs in PTC genesis. Transgenic mice were previously generated by Dr 
Debyani Chakravarty (Figure 6.1) [187].   After 7 days of doxycycline administration, 
murine thyroid tumours induced by BRAFV600E phenotypically resembled high grade 
human PTCs.  They were exquisitely dependent on the activation of the BRAF 
oncoprotein to ensure progression.  These mice were demonstrated to have fully 
penetrant, poorly differentiated papillary thyroid cancers which regressed after 
doxycycline removal (confirmed but not initially performed by the candidate).  These 
mice were crossed with Black 6 mice who had the simian Diphtheria Toxin (DT) 
receptor expressed downstream of the macrophage specific CCR2 (or CD11b) 
promoter (Figure 6.2B).  Mice generated using this strategy can be induced with 
doxycycline to express classical PTCs in which infiltrating CCR2 positive bone 
marrow derived TAMs can be selectively depleted with diphtheria toxin.   The net 
result was that the mice that expressed all three genotypes were able to have thyroid 
cancer induced in one week, and simultaneously deplete the TAMs from the growing 
tumour during initiation. This provided an evolving model in which to study the role 
of TAMs in PTC development.  
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Figure 6.2 Genesis of mice with genetically targeted inhibition of diphtheria toxin receptor. (A) 
Diagram of tumour associated macrophage with associated leukocytic receptors relevant for 
discussion in thesis. TAMs express CD11b; F4/80; CCR2; CSF-1; Ly6C markers, all of which can be 
exploited for analysis (flow conjugation) or mouse model development (DTR). (B) Doxycycline 
inducible mice (Figure 6.1) were crossed with mice where the simian diphtheria toxin receptor was 
targeted downstream of leukocyte receptors CD11b or CCR2.  Following diphtheria toxin treatment 
(2nd daily IP injections), cells expressing those markers are depleted, specifically TAMs.  
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6.1.5 Aims  
To explore the role of the tumour microenvironment in thyroid cancer mouse models. 
Specifically, to (a) investigate the role of one of the dominant cell types in the stroma, 
the TAMs, on PTC initiation using mouse models that are richly infiltrated with 
TAMs and (b) observe the effect on the tumour phenotype and invasive capacity 
following TAM depletion.  
6.2 Methods 
6.2.1 Mouse models 
Tg-rtTA/tetO-myc-BRAFV600E mice express oncogenic BRAF in thyroid cells in a 
doxycycline dependent manner and were maintained in a FVB/N background (Figure 
6.1) [187].  CCR2-DTR mice express the DTR under the control of the 
monocyte/macrophage specific CCR2 promotor and were maintained in a C57/B6 
background [128] (Figure 6.2).  CD11b-DTR mice express the DT receptor under the 
control of the leukocyte marker CD11b promoter (Figure 6.2). All animal husbandry 
and experimental procedures were approved by the Memorial-Sloan Kettering Cancer 
Center (MSKCC) Institute for Animal Care and Use Committee.  The mice were not 
generated by the candidate. Mouse genotyping required tail clipping and DNA 
analysis was performed by animal technicians at MSKCC.  Mouse breeding, ensuring 
young 6-8 week old males were bred with multiple females, was performed by the 
candidate.  
6.2.2 Doxycycline and DT administration  
PTCs were induced following introduction of doxycycline impregnated chow 
(2,500ppm, Harlan-Tekard) on day 0 to both control and DT treated mice.  TAM 
depletion was performed with the knowledge that wild type mice do not express the 
diphtheria toxin receptor. Hence, following DT administration, only those cells 
downstream of the genetically modified DT receptor (i.e. those expressing 
macrophage markers CCR2 or CD11b) are abrogated. 1mg of powdered diphtheria 
toxin (List Biologicals, Campbell, CA, USA) was reconstituted in 1.0ml of sterile 
water. 1:400 dilution was performed in sterile PBS to achieve a working 
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concentration of 2,500ng/ml. 20ng/g of DT was injected intraperitoneally on alternate 
days (Day 0,2,4,6) for 7 days. Control mice received intraperitoneal sterile PBS.  24 
hours after the last dose of DT mice were euthanised by CO2 inhalation.  The thyroids 
were removed, one lobe saved for IHC and the other for FACS analysis (Becton 
Dickinson).  
6.2.2.1 Peritoneal lavage 
Mice were euthanised by CO2 inhalation. A 5ml syringe was filled with sterile PBS. 
A 23-gague needle was attached and PBS injected into the peritoneal cavity. The mice 
were gently agitated to ensure adequate distribution of PBS.  The needle was then 
used to pierce into the peritoneum 4-5 times. The PBS was then removed by allowing 
it to drip it into a sterile 14ml conical tube.  Product was centrifuged at 1,200rpm.  
Samples were then washed three times with ice-cold media supplemented with 10% 
FBS followed by reconstitution in FACS buffer (PBS/1% BSA). Samples were 
blocked with mouse Seroblock FcR (AbD Serotech, Raleigh, NC, USA) for 10 
minutes on ice followed by a 30 minute incubation with the following fluorescently 
conjugated antibodies: Cd11b:APC, Gr-1:FITC (BD Pharmingen, San Diego, 
CA,USA) & F4/80:FITC (AbD Serotec). Data collection was obtained using the 
FACSCalibur flow cytometer through the MKSCC Flow Core and data analysis was 
performed using FlowJo 7.2.5 software (Treestar, Ashland, OR, USA). 
6.2.3 Immunofluorescence  
Murine thyroids and spleens post treatment were immediately fresh frozen in OCT 
(Sigma). OCT is an established water soluble glycols and resins compound that 
provides an excellent specimen matrix for cryostat sectioning at -10°C and below. It 
leaves no residue during the staining procedure.  5µM sections of thyroids from 3-4 
levels each over 150µM apart were obtained by the candidate (Discovery XT 
processor, Ventana Medical Systems). Slides were air dried for 15 minutes, fixed with 
ice cold acetone (Sigma) for 30 minutes, redried and then placed in PBS. 3 washes for 
5 minutes each were undertaken. Sections were blocked with DakoCytomation serum-
free protein block (Dako, Carpinteria, CA, USA) for 30 minutes followed by PNB 
blocking reagent (PerkinElmer, Waltham, MA, USA) for 60 minutes. Slides were 
again washed for 5 minutes twice with PBS. The CD68 unconjugated mouse antibody 
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was incubated with the slide for 1 hour at room temperature. A secondary antibody 
Alexa-Fluor488 (BD Pharmingen) was applied for 1 hour in the dark. DAPI (50µl in 
50ml deionised water) (Thermo Scientific) was applied for 5 minutes in the dark.  A 
further PBS wash was performed. Antifade media (Applied Biosystems) and coverslip 
was applied and kept at 4°C in the dark until imaged later that day. Sections were 
imaged on an upright Zeiss Axio2Imaging microscope (Carl Zeiss, Germany) at 
MSKCC molecular cytology core facility (New York, USA).  
IHC is outlined in general methods 2.7.3. 
6.3 Results 
6.3.1 CCR2-DTR mice: Treatment with DT was effective in depleting TAMs 
6.3.1.1 FACS analysis of peritoneal lavage  
Mice were sacrificed after treatment with doxycycline with concurrent DT daily IP 
injections. Peritoneal lavages of mice were subsequently prepared for FACS analysis 
(Figure 6.3).   CCR2-DTR mice treated with DT have depletion of bone marrow, 
circulating and resident monocytes.  Figure 6.3 shows FACS analysis of a 
representative peritoneal lavage using Cd11b, anti-F4/80 (macrophage markers; A, C) 
and anti-Gr-1 (neutrophil marker; B, D) in the absence (A, B) or presence (C, D) of 
DT.  Here, in the control group (A), resident macrophages were present with 84.32% 
having a high expression of CD11b and F4/80. There were also few neutrophils 
(0.08%) in the vehicle cohort (B) which corresponded to the CD11b low/Gr-1 high 
population.  Following DT treatment, TAMs were completely depleted (C) (only 
0.53% of all cells) and there was an influx of neutrophils at 71.88% (D).  
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Figure 6.3 Representative diagram of FACS analysis of peritoneal lavage after DT treatment. Mice 
were sacrificed after treatment with doxycycline and concurrent DT daily IP injections. Peritoneal lavages 
of mice were subsequently prepared for FACS analysis. FACS analysis of a representative peritoneal 
lavage using Cd11b, anti-F4/80 (A, C) and anti-Gr-1 (B, D) in the absence (A, B) or presence (C, D) of 
DT.  TAMs (CD11b high, F4:/80 high) were depleted following DT treatment. 
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6.3.1.2 IHC shows changes in thyroid tumourogenesis 
Figure 6.4 shows Tg-rtTA/teto-BRAFV600E/CCR2-DTR mice that have been treated 
with doxycycline and DT concurrently.  Thyroids have been prepared for IHC and 
stained with the indicated antibodies.  Following DT treatment, there was a significant 
reduction in the expression of the macrophage marker Mac-2; cell proliferation 
marker Ki67 and cancer associated fibroblast marker; αSMA (A, C, D, E).  The 
percent of positive stain of Mac-2 recorded by Metamorph software without DT 
treatment equates to a mean of 21.68% ± 9.14. By contrast, following DT treatment 
the mean is 3.23% ± 1.64, clearly showing a depletion of TAMs (p<0.001).  Analysis 
of Ki67 staining in the control group shows 11.50% ± 1.32 positive staining.  After 
DT treatment, 2.91% ± 1.34 incur a positive stain (p<0.05). This shows that DT is 
effective in depleting resident CCR2 macrophages in tissue through depletion of 
centrally derived CCR2 positive macrophages in the bone marrow.  Cancer associated 
fibroblasts (CAFs), a dominant cell type in the stroma express αSMA.  There was also 
a significant reduction in αSMA percent positive staining following DT treatment 
(Figure 6.4F) (p<0.05).  This showed an indirect reduction of CAFs through depletion 
of TAMs.   
Figure 6.4B is a representative H/E stain of the murine thyroids with PTCs with and 
without DT administration. Following TAM depletion the phenotype of the PTC was 
more follicular and differentiated.  Dr R. Ghossein, a pathologist at MSKCC 
specialising in murine models of thyroid cancer, confirmed the attenuated phenotype 
in multiple repetitions of this experiment.  
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Figure 6.4 Representative IHC and analysis following TAM depletion. Targeting CCR2-expressing 
cells in BRAF-induced PTC mice resulted in fewer TAMs, smaller PTCs and reduced CAFs.  
Representative sections from Tg-rtTA/tetO-BRAFV600E/CCR2-DTR mice treated with doxycycline for 7 
days with or without intraperitoneal DT every other day: (A) IHC with anti-Mac-2 shows dense brown 
staining within the stroma surrounding thyroid cancer follicular cells in control PTCs (left) that is 
significantly attenuated in DT-treated mice (right). (B) PTCs from DT-treated mice were smaller and had 
a more preserved follicular architecture. (C) IHC with Ki67 shows reduced cell proliferation, primarily 
within the stroma, of PTCs from DT-treated mice. (D, E) IHC with αSMA showed reduced positivity in 
tumour capsule and inter-tumoural stroma. (E) Higher magnification (40×) shows marked thinning of 
tumour capsule and depletion of αSMA positive cells in inter-tumoural spaces of DT-treated mice. (F) Bar 
graph depicting changes in Mac-2, αSMA and Ki67 in control (n=5) vs. DT-treated (n=6) mice.  
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6.3.2 CD11b-DTR mice: Treatment with DT was effective in depleting TAMs 
6.3.2.1 FACS analysis of peritoneal lavage  
Figure 6.5 is a representative diagram of repeated experiments where FACS analysis 
confirmed the depletion of TAMs following DT in the CD11b-DTR mouse models.  
Here, CD11b is stained with the fluorochrome APC which is detected on FL4 and 
F4/80 or Gr-1 is stained with FITC and read on FL-1. In the control mice, the lavage 
product contains 33.24% of cells that express CD11b high/F4/80 high, which is 
consistent with the TAM phenotype (Figure 6.5B). This same population co-stains 
with CD11b and Gr-1 in Figure 6.5C. Here, 35.16% of cells are negative for Gr-1, 
confirming their status as TAMs.  In vehicle mice, the peritoneal lavage product has 
no cells expressing the neutrophil marker Gr-1 as it is composed of TAMs. Following 
DT treatment, there was a decrease in the TAM population. In Figure 6.5E, the 
population has shifted to the left. The majority, 61.14%, do not express the TAM 
markers CD11b and F4/80. The low CD11b/Gr-1 neutrophil population has now been 
recruited.  Figure 6.5F shows 78.27% of collected cells are now expressing neutrophil 
markers. 
 
  
Figure 6.5 FACS analysis of CD11b-DTR mice following treatment. CD11b is conjugated to APC 
read on the FL-4 channel (y axis) and F4/80 and Gr-1 are conjugated to FITC seen on the FL-1 (x axis). 
(A) Control lavage, no stain. (B) Vehicle treated mice have a large TAM population expressing high 
CD11b/F4/80.  (C) A population depicting high CD11b but low Gr-1 is shown (the same population as 
in B). (D) DT Lavage unstained shows no bleeding into different channels. (E) After DT treatment there 
was a loss of the TAM population and (F) an increase of the Gr-1 high/CD11b low neutrophil 
population. 
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6.3.2.2 CAFs were reduced following TAM depletion 
CD11b-DTR mice were used as an alternative genetic strategy to confirm that 
depletion of TAMs leads to changes in thyroid tumourogenesis and a reduction in 
recruitment of CAFs.   IHC was performed and similar results to the CCR2-DTR 
model were found (Figure 6.6). Specifically, the percent of positive stain of anti-Mac-
2, specifying the presence of TAMs, was reduced from 34.40% ± 2.61 to 24.04% ± 
3.58 (p<0.001) following DT treatment.  Furthermore, the percent of positive stain of 
αSMA (expressed by CAFs) reduced from 8.15% ± 1.27 to 5.28% ± 1.46 (p<0.001) 
after DT (Figure 6.6B).   
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Figure 6.6 Representative IHC and analysis following TAM depletion. (A) Representative 
sections from Tg-rtTA/tetO-BRAFV600E/CD11b-DTR mice treated with doxycycline for 7 days with 
or without intraperitoneal DT every other day: IHC with anti-Mac-2 shows dense brown staining 
within the stroma surrounding thyroid cancer follicular cells in control PTCs (left) that is 
significantly attenuated in DT-treated mice (right). H/E stain of PTC from DT-treated mice has a 
more preserved follicular architecture. αSMA IHC showed reduced positivity in inter-tumour 
stroma. (B) Bar graph showing quantification of positive staining in n=7 DT and n=8 vehicle mice.  
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6.3.2.3 IF shows depletion of TAMs in murine spleen 
Tg-rtTA/teto-BRAFV600E/CD11b-DTR mice were treated for 7 days with doxycycline 
and alternate day intraperitoneal DT. 6 hours after the last DT dose, mice were 
sacrificed and murine spleens, (known sequesters of macrophages) were snap frozen 
for IF.  Figure 6.7 shows a representative example of a murine spleen, incubated with 
a CD11b antibody.  There was a significant reduction in CD11b+ fluorescent staining 
(red) of TAMs following DT treatment, which is consistent with the peritoneal lavage 
and thyroid tissue findings. 
 
  
Vehicle DAPI Cd11b DT 
Figure 6.7 Immunofluorescence in TAM depleted thyroid cancer. Tg-rtTA/tetO-BRAFV600E/CD11b-
DTR mice were treated for 7 days with doxycycline impregnated chow and alternate day intraperitoneal 
DT (right) or PBS (left). 6 hours after the last DT dose mice were sacrificed and spleens snap frozen for 
IF. Anti-CD11b antibody was incubated and shows depletion following DT (positive red stain). 
 
142 
6.3.2.4 TAM depletion recruits neutrophils and contracts the peritumoural 
stroma 
FACS analysis had previously confirmed neutrophils are recruited to the thyroid 
tumour following TAM depletion (Figure 6.5F).  Figure 6.8A shows representative 
H/E stains of vehicle and DT treated murine thyroids of Tg-rtTA/teto-
BRAFV600E/CD11b-DTR. There was an increase in neutrophils sequestered in the 
thyroid tumours after the DT treatment. Figure 6.8B shows another representative 
section of the same experiment. Here, following TAM depletion, there was a 
reduction in peritumoural stromal thickness, possibly due to the indirect depletion of 
CAFs (seen in Figure 6.6A).   Furthermore, similarly to the CCR2 model, depletion of 
TAMs led to a more favourable differentiated phenotype which has been associated 
with a better prognosis [191].   
  
Figure 6.8 Representative H/E stain of stroma after TAM depletion. (A) H/E stain of murine 
thyroids of rtTA/tetO/BRAFV600E/CD11b-DTR mice following depletion of TAMs in inducible 
model showed increase in neutrophils (arrows). (B) 10x H/E stain of murine thyroids, showing 
the TAM depletion in the peritumoural stroma. Thinning of the capsule is indicated (arrows). 
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6.3.2.5 TAM depletion shows a reduction of invasion foci  
Extra thyroidal skeletal muscle invasion, a key component of metastasis [192] was 
also reduced following TAM depletion. The pathologist was blinded to the treatment 
and assessed the H/E stained slides for foci of invasion which was scored as either 
positive or negative.  A representative H/E section is shown in Figure 6.9A. In one 
representative cohort, 33% of mice with TAMs depleted showed skeletal muscle 
invasion while in the untreated group 66% had clear invasion (Figure 6.9B).  In some 
cases there were multiple foci of invasion within one tumour.  Following TAM 
depletion there was a 33% reduction in gross foci of invasion.  Due to the low 
numbers assessed there was no statistical significance.  Furthermore, in examining 
gross macroscopic effects of TAM depletion, it was clear that there was thinning of 
the peritumoural stroma (Figure 6.8B). Peritumoural stroma is composed of 
fibroblasts. This observed reduction confirms the conclusion set out in sections 
6.3.1.2 and 6.3.2.2 above, that TAM depletion causes a reduction in CAFs.  Future 
directions beyond the scope of this thesis involve quantifying the reduction in 
peritumoural stroma and increasing the amount of mice to ensure statistical 
significance in the quantification of foci of invasion.  
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6.3.3 TAM depletion reduces thyroid and body weight of transgenic mice 
Changes were also noted in thyroid and animal weight following TAM depletion. 
Thyroid were smaller following DT administration in both mouse models, but 
because the glands are particularly small the results were not significant (Figures 
6.10B, D). Following TAM depletion the mice weights also trended lighter (Figures 
6.10A, C). The mass of the CCR2 mice was reduced with TAM depletion from 
25.83g ± 2.57 to 23.42g ± 1.89 (p<0.05) and also in the CD11b mouse 31.45g ± 3.74 
in control and 27.55g ± 2.57 in DT treated mice (p=0.11).  The absence of 
significance in much of this data is likely because treatment was only one week, 
providing little time to observe a large difference in weight due to the inherently small 
sizes of the mice and their thyroids. 
  
Figure 6.9 Representative H/E stain and analysis of invasive capacity of tumours. Tg-
rtTA/TetO-BRAF/CD11b-DTR mice treated with 1 week of DT showed less invasive capacity. 
(A) Representative H/E section demonstrating invasion through extrathyroidal skeletal muscle 
was reduced following TAM depletion (right).  Clinician was blinded to treatment and scored 
H/E sections on invasive capacity, results of representative cohort graphed in (B).  
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Figure 6.10 Body weight and thyroid mass post TAM depletion. (A)-(D) Following one week 
of PBS or DT treatment, rtTA/TetO-BRAF/CD11b-DTR and rtTA/TetO-BRAF/CCR2-DTR mice 
were weighed after sacrifice.  Thyroids were dissected with removal of the strap muscles and 
weighed. Results are graphed above and are expressed as mean and SD. (E) Photograph of 
murine thyroid with PTC. 
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6.3.4 Treatment with DT does not decrease MAPK signalling 
It was critical to determine that these effects of TAM depletion in phenotype and 
progression were not due to an abrogation of the strength of the oncogene.  IHC for 
pERK was performed on thyroid follicular cells in treated and untreated CD11b and 
CCR2 mice and there was no difference in uptake in either mouse model (Figure 
6.11). Therefore BRAF expression is constant in the presence or absence of TAMs 
and thus any changes in phenotype, progression and invasion are effects of TAM 
depletion.    
 
  
Figure 6.11 anti-pERK IHC confirming oncogene activity. This shows activity of the BRAF 
oncogene is consistent irrespective of confirming that the results are due to TAM depletion rather 
than abrogation of the strength of the oncogene. 
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6.4 Discussion 
6.4.1 The inducible PTC mouse is a model for exploring factors in tumour 
initiation 
Murine models of tumourogenesis are well suited to exploring the initiation and 
development of malignancies in the context of their microenvironment.  One of the 
most established and frequently used is the polyoma middle T-antigen [193, 194]. 
Here, four identifiable stages from pre-malignancy to metastasis are observed together 
with a leukocytic infiltration, corresponding closely with the human model.  They 
also show TAMs facilitating angiogenesis and lung metastases [195]. In the thyroid 
cancer tumour models that are described in this chapter, the doxycycline inducible 
system produces standard functioning mice whose thyroid cancer can be initiated and 
ceased upon addition of doxycycline.  The tetracycline transactivator protein rtTA 
binds to DNA at the specific TetO (operator) sequence only in the presence of 
doxycycline (Figure 6.1).  The introduction of doxycycline initiates transcription of 
mutant BRAF exclusively in the thyroid.  Thus the exact timing of oncogene addiction 
can be determined and compounding factors analysed.  
In this chapter, the role of the TAMs has been explored in PTC initiation.  TAMs are 
dominant cells in the microenvironment and have been shown to correlate with 
severity of the thyroid cancer [129].   The TAM depletion occurred simultaneously 
with the PTC initiation.  TAM depletion in two transgenic mouse models 
demonstrated a change in the aggressive nature of the BRAF driven tumours. This was 
seen in several measured outcomes.  The profound remodelling of the tumour stroma 
led to less extrathyroidal invasion; less tumour cell proliferation; and an observed 
change in the phenotype to a more follicular, well differentiated pattern.  Collectively, 
this shows the protumourogenic role of TAMs in PTC progression.  In the clinical 
context, this is even more relevant as these pathological features confer survival 
advantages [191].   
The experiments assessing extrathyroidal invasion (Figure 6.10) produced very small 
and thus not statistically significant numbers.  Reduction in metastasis and invasion 
are critical end points in examining the efficacy of treatment as metastases are the 
primary cause of poor outcomes [192]. The finding that TAM depletion led to 
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decreased invasion is consistent with the data showing the increase in differentiated 
phenotypes in the mouse models presented (Figures 6.4A, 6.6A).  However a larger 
study of these mice would need to be undertaken to confirm this result with statistical 
significance.  Figure 6.9 shows preliminary data (that was repeated) but due to the 
short time frame that these mice had to generate the PTC, there was little time for 
extensive invasion.  The Tg-BRAF mouse model closely recapitulates aggressive 
human mutant BRAF PTCs which develop into poorly differentiated thyroid cancers 
[196].  In this model there was a significant decrease in poorly differentiated foci 
following TAM depletion [128].  The benefits of the inducible model are that one can 
analyse initiation of PTC.  However, clearer results may be obtained by examining the 
effect of invasion in models with established PTC. Future directions include utilising 
murine models of thyroid cancer which metastasise [197] and using alternative 
methods of depleting TAMs which would precisely assess the propensity for invasion. 
6.4.2 TAM depletion causes an increase in neutrophil sequestration 
In both mouse models, following TAM depletion there was an increase in 
sequestration of neutrophils.  This was seen in IHC and FACS data (Figure 6.3D, 
6.5F) where a population expressing high Gr-1 increased following TAM depletion. 
These cells, termed “tumour infiltrating neutrophils” in other cancers, have caused a 
rescue of the PTC phenotype after their collection at the tumour site [198].  In the 
murine model of cervical cancer described in [198], the corresponding increase in 
neutrophils was seen as an alternative strategy by the malignancy to ensure its 
survival.  However, in thyroid cancer, TAM depletion confers a compensatory surge 
in neutrophils but without altering the phenotype.  
6.4.3 The oncogenic driver causes recruitment of protumourogenic stromal factors 
The mouse models described in this chapter have overexpression of mutant BRAF in 
the thyroid.  Activation of the BRAF-MAPK pathway induces known TAM 
chemoattractants [130].  Following BRAF activation, thyrocytes express CSF-1 and 
CCL2 which is associated with the recruitment of TAMs expressing those receptors 
[128].  Monocytes generated in the bone marrow require signalling through the 
CCL2/CCR2 pathway to mature into macrophages.  The mouse models which deplete 
CCR2 expressing leukocytic cells act to ensure these monocytes become trapped in 
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the bone marrow.  They are unable to recruit CAFs and differentiate into TAMs to 
promote tumourogenesis at the site of the malignancy [199].  Depleting CCR2 
positive cells with diphtheria toxin results in a near complete depletion of TAMs.  
CCR2 expression is not exclusively on TAMs; it is also found in NK cells and some 
endothelial cells [128].  However, in PTCs, CCR2 expression is restricted to 
leukocytes expressing CD45 and CD11b which is consistent with the literature 
regarding TAM characteristics [128].  Hence, one can be confident that the cells 
depleted with this genetic manipulation of the diphtheria toxin receptor are TAMs.   
6.4.4 In mutant RET tumours, the microenvironment is an alternative strategy for 
tumour augmentation 
In thyroid cancers with RET mutations, the function of the microenvironment is only 
beginning to be understood. It is known that RET/PTC rearrangements can 
functionally alter the expression of genes involved in the immune or inflammatory 
response [189, 200].  Specifically, RET/PTC3 recruits CD8 T-cells at the early stage 
of tumour progression and causes myeloid derived CD11b+ Gr1+ cell influx [123]. It 
is the influx of these inflammatory cell types which, it has been proposed, engineers a 
protumourogenic environment [189].   
In Ryder et al, that activation of oncogenic BRAF in murine thyroids resulted in an 
increased expression of the chemoattractants CSF-1 and CCL2 [128].  Exogenous 
expression of RET/PTC1 in primary normal human thyrocytes induces the expression 
of a set of genes involved in immune responses including that of CCL2 and CSF-1 
[189].  Hence, because of the similar way these common thyroid oncogenes recruit 
cells within the microenvironment, a similar theory of invasion and progression may 
occur in tumours with oncogenic RET as with oncogenic BRAF.  Melillo et al showed 
that the three most common oncogenes in thyroid cancer (RAS, BRAF and RET) all 
signal predominantly through a common transcriptional program utilising MAPK and 
ERK signalling, and that PTCs are associated with a strong inflammatory reaction 
[122].  Their group described how genes that were common to all three mutations 
included the inducible expression of MMPs. This same cascade for all three mutations 
drives PTC initiation and stimulates the overexpression of several chemokines, which 
are known to recruit immune cells including macrophages [122].  There seems to be a 
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strong relationship between inflammation and thyroid cancer in which the tumours 
manipulate the host’s immune system to their advantage. 
As discussed previously, the BRAF model was selected over the RET/PTC model for 
a variety of practical reasons. The penetrance of the syndrome in the BRAF mice is 
complete and predictable whereas in the RET/PTC model it is much less so. 
Moreover, the inducible model is the only inducible oncogene system in thyroid 
cancer literature, and this was required to explore the mechanisms of TAM 
recruitment as well as their role in transformation.   
The next stage of this research could involve tailoring experiments to explore the 
depletion of TAMs in RET mutant tumours. This may involve crossing the RET/PTC3 
mice with CSF-1 knock-out mice and confirming impairment of PTC progression.  
Alternatively a pharmacological inhibitor of TAMs may be used for this purpose 
[128].  
6.4.5 The presence of TAMs conferred a reduction in CAFs 
Most interestingly, following TAM depletion there was an unexpected reduction in 
CAFs, shown by a reduction in αSMA positive staining in IHC.  This work showed 
for the first time, the presence of CAFs in PTCs are exquisitely dependent upon the 
presence of TAMs. This reduction in CAFs was unexpected and suggests the 
hypothesis that TAMs are the direct recruiter of this component of the stroma.  This 
augments their protumourogenic role and starts to explain how they exert these 
effects.  CAFs themselves demonstrate protumourogenic features, including 
angiogenesis and enhancing invasive capacity of malignancies [201].  It therefore 
appears that TAMs have both a direct and indirect action on ensuring the progression 
of the tumour.  This link has not been previously identified in oncology and is a novel 
finding in understanding the interrelationships of the microenvironment.   
Once the link between TAMs and CAF recruitment became clear, the mechanism was 
next explored.  Identifying the progenitors of CAFs is unclear in the literature.  
Direkze et al demonstrated that bone marrow derived progenitor cells reconstituted 
25% of stromal αSMA+ myofibroblasts in pancreatic tumours of RIPTag mice [202]. 
Therefore it follows that CAFs are likely to be derived from bone marrow.  Human 
mesenchymal stem cells (MSCs) co-cultured with tumour conditioned media from 
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breast cancer cells differentiate into CAF like cells [203]. Furthermore in vivo human 
bone marrow derived mesenchymal stem cells engraft in tumour xenografts. The 
stromal compartment containing the engrafted MSC have increased expression of 
αSMA and other fibroblast protein markers [204]. The collated evidence infers that 
bone marrow derived mesenchymal stem cells differentiate into CAFs and are 
recruited to the PTC, all of which is mediated by TAMs.  
The candidate performed multiple experiments aiming to isolate murine mesenchymal 
stem cells from the bone marrow utilising isolation and enrichments kits (EasySep 
Mesenchymal stem cell kit, Vancouver, Canada).  The aim was to co-culture them 
with TAMs yielded from PTCs, and demonstrate their differentiation into CAFs.  
However there were multiple technical issues which caused this to be unsuccessful. 
Initially the yield of plated bone marrow cells was never enough to actively ascertain 
if the cells were MSCs. This was to be confirmed through expression of CD44 and 
through differentiation into osteoblasts, adipocytes and chondrocytes. Future 
directions of this research would be to continue to pursue this hypothesis and 
overcome the technical difficulties.  It would be interesting to research alternative 
ways to isolate and enhance murine MSCs or to adapt the experiments to in vitro 
work with the established human mesenchymal stem cell; 0P9.   
6.4.6 TAMs depleted pharmacologically and with alternative genetic strategies 
confirm hypothesis 
The role of TAMs in tumour maintenance and progression was further explored with 
a Tg-BRAF mouse model (Dr M. Ryder). Here, tumours are generated in the foetal 
period.  TAM depletion during advanced stages of this malignancy induced tumour 
regression [128].  Later in this study a novel compound GW2580, a c-FMS/CSF-1 
tyrosine kinase inhibitor, was utilised to pharmacologically inhibit TAM recruitment 
and activation. It showed a reduction in thyroid tumour weight and more 
differentiated thyroid architecture. This confirms TAMs as pivotal in the sustenance 
of PTCs and as a therapeutic target for patients with advanced disease. 
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6.5 Conclusion  
This chapter has explored the role of TAMs in PTC initiation.  Multiple lines of 
evidence suggest that TAMs are critical in the remodelling and maintenance of the 
tumour niche. When CAFs, which are exquisitely dependent upon the presence of 
TAMs, were depleted, the result was a contracted tumour stroma.  The stroma 
conferred less invasive ability and a more follicular, less aggressive phenotype.  The 
evidence of the tapered tumour stroma was most apparent at the margins of the 
tumour where following TAM depletion there was a clearer demarcation between 
PTC and muscle.  This data shows for the first time a possible causal relationship 
between TAMs and CAFs in the tumour microenvironment.  These two genetic 
strategies for depleting TAMs show a consistent result. The other Tg-BRAF and 
pharmacological treatments outlined in [128] are further confirmation of this 
hypothesis.  TAMs may be an important therapeutic target in patients with refractory 
PTC, particularly poorly differentiated and anaplastic thyroid cancers.  
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7.1 Overview: Thyroid cancer treatment and challenges 
The incidence and mortality of thyroid cancer is on the rise in the developed world.  
Key cancer-associated mutations identified over the past two decades have directed 
development of novel drug targets.  Current clinical challenges relate to resistance 
that often develops after a comparatively short course of treatment, and drug 
intolerance that limits optimal inhibition of the oncogenic kinase driver.  
Use of small molecule kinase inhibitors has proved highly successful in many other 
cancers. Over the past decade, patients bearing the BCR-Abl fusion gene in CML and 
those with the EGFR mutation in non-small cell lung cancer (NSCLC) have better 
outcomes following TKI treatment [50, 205].  Understanding the signalling pathways 
of RET and other kinases mutated in thyroid cancer (such as BRAF), has been at the 
forefront of thyroid cancer research.   During the time of candidature, two RET 
inhibitors were seen in phase III trials to extend progression-free survival (PFS) in 
patients with advanced thyroid cancer.  Patients with aggressive unresectable locally 
advanced MTC treated with vandetanib had 30.5 months PFS, compared with 19.3 
months for placebo treated patients [63].  In another study, patients treated with 
carbozantanib had an increase of 7.2 months PFS as compared with placebo [62].   In 
both cases, evidence of improved overall survival is lacking.  Nonetheless, the 
availability of effective systemic treatment is a significant advance for clinical care of 
advanced MTC.  
7.2 mTOR is a novel therapeutic target for RET driven thyroid cancers 
At the commencement of this thesis, the role of mTOR in RET mutant cancers had yet 
to be completely established. In the last few years, neuroendocrine tumours, once fatal 
with minimal treatment options, have started to show a response to targeted therapy 
[81].  Furthermore, mTOR has become an important therapeutic target in many 
cancers (reviewed in [206]). Once mTOR inhibitors were shown to increase 
progression-free survival in pancreatic neuroendocrine tumours, the spectrum of these 
drugs expanded.  Dr James Fagin and the candidate hypothesised that because of the 
shared lineage of MTCs with neuroendocrine tumours, mTOR may play a significant 
role in MTC progression. The paucity of data of the role of mTOR in MTC, together 
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with the results from clinical trials of neuroendocrine tumours, provided the impetus 
for studying mTOR inhibitors in these tumours.  
Chapter 3 of this thesis showed potent inhibition of mutant RET thyroid cancer cells 
lines with an mTOR inhibitor, INK128.  There was a reduction in cell proliferation 
associated with inhibition of downstream signalling pathways.  Furthermore, INK128 
was able to augment apoptosis following treatment with a RET inhibitor.  Chapter 4 
demonstrated the tolerability and outcome of INK128 in a transgenic mouse model of 
RET driven papillary thyroid cancer.  In the Tg-RET/PTC3 mouse model, there was a 
decrease in cell proliferation seen through reduced Ki67 as detected by IHC. These 
observations are consistent with recent reports in the literature confirming the 
activation of the mTOR pathway in MTCs and with in vitro work showing profound 
inhibition with mTOR inhibitors [91, 152].   
As a therapeutic strategy, mTOR is emerging as a pivotal target. In breast cancer, the 
combination of mTOR inhibitors with hormonal therapy can triple progression-free 
survival [96]. In renal cell carcinoma mTOR inhibition is now well known to improve 
mortality [82]. mTOR is a major intersection, linking signalling from the extracellular 
milieu to constantly changing intercellular processes.  
When preclinical models demonstrate success of mTOR inhibition (as shown in this 
thesis) the ready availability of these drugs, allows for timely translation to clinical 
trials.  For instance, preliminary data from a thyroid cancer clinical trial reported that 
the addition of everolimus (mTOR inhibitor) to sorafenib (a TKI with known RET 
inhibitory activity) in advanced disease improved progression-free survival [178].  
Data in chapters 3 and 4 of this thesis was one stimulus for this clinical trial 
performed at Memorial Sloan Kettering Cancer Centre and was a crucial component 
in the translational study. 
7.3 Destabilisation of the dominant oncogene RET is vital to targeted 
therapy regimens 
In the three RET mutant cell lines, inhibiting or destabilising RET proved an essential 
ingredient in impairing cell viability.  Following treatment with the RET kinase 
inhibitor AST487, cell lines showed profound growth inhibition and an increase in 
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cell death.  When the chaperone protein HSP90 was inhibited with AUY922, the 
subsequent dislocation of RET and its downstream targets also led to impairment of 
function.  Finally, to demonstrate specificity, siRNA mediated knock down of RET 
conferred growth inhibition and an impairment of proliferative and anti-apoptotic 
signalling pathways.   
RET mutant thyroid cancers have become dependent on constitutive activation of RET 
for proliferation and survival. This exemplifies Weinstein’s oncogenic addiction 
theory, which is demonstrated in all three RET mutant thyroid cancer cell lines 
utilised in this thesis [149].  By destabilising the primary oncogene RET, there is 
evidence of “oncogenic shock,” originally described by Sharma et al [207].  In this 
scenario, following inactivation of the oncoprotein, pro-survival signals dissipate 
while pro-apoptotic signals linger and commit the cell to apoptosis. In the TT and 
MZ-CRC-1 cell lines there was an increase in apoptosis following treatment with the 
RET kinase inhibitor AST487.  This was augmented with INK128 (Figure 3.6B).  It is 
unclear why mTOR inhibition increased the proportion of apoptotic cells.  However, 
INK128 does impair signalling through AKT as it inhibits mTORC2 in addition to 
mTORC1. This inhibition of the pro-survival factor, AKT, may contribute to the 
overall mechanism of cell death in the combination of the compounds.  Furthermore, 
if mTOR acts to integrate proliferative responses in RET driven tumours, it could be 
hypothesised that once RET is inhibited, subsequent inhibition of its primary 
downstream effector will augment apoptosis. Future directions in this research could 
involve examining the role of AKT in this hypothesis.  Determination of apoptosis 
following transient knock down of AKT or mTOR targets, in combination with 
inhibition of the oncogenic kinase driver may provide an answer.  
The results of inhibiting RET in these preclinical models described, are reassuring in 
light of the Phase III trials, but there are caveats when translating this to the clinic. In 
all the clinical studies cited in this thesis, there is no quantification of RET inhibition 
after treatment. The actual degree of RET inhibition in vivo is unclear.  Potentially, 
other off target effects may be involved in the clinical outcome.  Conceivably, a post-
treatment biopsy of the tumour with subsequent IHC could be used to determine the 
activity of individual targets but this would not be without significant impact on 
patients’ quality of life, and so may be difficult to implement.  
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There is also a concern with resistance to RET inhibitors.  Specificly RET mutations 
V804M and V804L are resistant to vandetanib [208]. These mutations are found in 
both hereditary and sporadic MTC and involve the substitution of a small valine 
residue with a larger leucine or methionine residue. Structural studies have shown that 
the physical nature of these substitutions prevents vandetanib from adequately 
targeting the enzyme pocket [125].   It is not yet known if AST487 has a similar effect 
or whether destabilising RET with HSP90 inhibitors can overcome this issue. 
Both clinical successes and challenges outlined above ensure that RET inhibition will 
be a focus of thyroid cancer research in the next decade.  This thesis has contributed 
to understanding mechanisms and alternative pathways in RET mutant thyroid cancer.  
Here, by demonstrating the importance of RET inhibition and how RET drives 
mTOR, this data has paved the way for alternative treatments for patients who are 
unable to tolerate, or are resistant to current therapy.  
7.4 Combination therapy is an effective technique of achieving 
maximal inhibition to prevent resistance and enhance patient 
tolerability 
The next aim of this project was to determine the effect of combined therapy, 
specifically, whether the addition of the dual mTOR inhibitor to a RET inhibitor 
augmented growth and apoptosis.  As reported in chapter 3 of this thesis, dual therapy 
was able to target actively the same pathway using submaximal doses of each 
compound.  Data presented in this thesis demonstrated co-operative effects of mTOR 
inhibition in addition to RET inhibition, and pharmacologic synergy was validated by 
siRNA-mediated knock down of RET.  
Classical oncogene addiction theory predicts that tumours are maximally inhibited by 
small molecule inhibitors that overwhelm an oncogenic driver. It follows that a 
successful TKI should either have intrinsically very high affinity for the oncogenic 
protein, and/or be tolerable enough to allow maximal up-titration. Mostly there is 
some combination of both. For the TKIs discussed in this thesis, side effects are 
significant and can be debilitating.  For example, in the phase III vandetanib study, 
55.4% of patients experienced a Grade 3 adverse event [77]. This is a particularly 
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high frequency for new generation drugs. Chapter 1 emphasises the regularity of dose 
reductions and withdrawal from study (Table 1.5).  
The concept that an oncogene can be overpowered by using combinations of different 
compounds at submaximal doses is an important finding of this thesis.  It also 
provided the impetus to study the benefit of HSP90 inhibition in thyroid cancer, since 
HSP90 inhibitors simultaneously inhibit multiple targets. 
7.5 HSP90 inhibition of RET mutant thyroid cancers causes apoptosis 
in MTC cell lines  
Destabilising RET with the HSP90 inhibitor AUY922 inhibited cell proliferation and 
impaired cell viability in all three mutant RET thyroid cancer cell lines.  Treatment 
with AUY922 also led to apoptosis of the RET mutant medullary thyroid cancer cell 
lines, TT and MZ-CRC-1. A likely mechanism for this effect was downregulation of 
the key cell survival mediator AKT (Figure 5.3), which is also a client protein of 
HSP90.  As discussed above, pro-survival factors in cells have shorter half-lives than 
pro-apoptotic signals. AKT is known to inactivate members of the pro-apoptotic 
protein family Bcl-2 including BAD and caspase-9 [209].  Following AUY922 
treatment there was inhibition of pAKT at low nanomolar doses in the MTC cell lines.  
To the candidate’s knowledge, this is the first time that an HSP90 inhibitor has been 
shown to cause apoptosis in MTC cell lines. Others have seen apoptosis with 
AUY922 in different human cancers, most importantly in neuroendocrine tumour cell 
lines [118].  AUY922 has been reported to induce apoptosis in adult and paediatric 
GBM cell lines associated with initiation of multiple apoptotic pathways via caspase 
3, 7 and 8 [210].  Apoptosis following AUY922 treatment has also been observed in 
multiple myeloma [211].  Research into mechanisms triggering cell death has 
provided novel insights.  Stuhmer et al and Gasper et al propose that it is sustained 
inhibition of pERK and pAKT that leads to apoptosis [210, 211].  In this thesis, 
signalling both via MAPK (pERK) and mTOR/PI3K (pAKT) pathways was 
abrogated following AUY922 treatment. Clarifying the role of MAPK in apoptosis 
may also be warranted in the future.  
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Increasing radioiodine uptake in refractory cancers is a current focus of thyroid cancer 
research. Recently, the addition of a MEK inhibitor was shown to improve iodine 
retention and uptake in patients with resistant disease [44].  This correlated to better 
outcomes including more stable disease. Data presented in Chapter 5 showed the 
novel finding that AUY922 increased radioiodine uptake in a PTC cell lines, through 
a non-NIS dependent mechanism. This compound may therefore be worth studying in 
clinical cohorts of both MTC and PTC.  
7.6 Understanding the important players in the tumour 
microenvironment is becoming essential to designing better therapies 
In thyroid cancer research, microenvironment is not well studied in general and there 
is a paucity of data on the role of the microenvironment in mutant RET cancers.  It is 
now well known that the extracellular matrix provides not only a scaffold for tumours 
to implant and metastasise, but is an evolving dynamic structure which directly 
influences tumour behaviour.  Much of this work establishing the role of the stroma 
and tumour associated macrophages has been performed in breast cancer models 
[194]. The work performed by the candidate and Dr Mabel Ryder, presented in 
Chapter 6, was the first time the role of tumour associated macrophages had been 
studied in thyroid cancer initiation and development.  The candidate was able to show 
the effect of the depletion of TAMs in BRAF mutant PTCs.  When TAMs were 
depleted in two different genetic strategies, there was an impairment of PTC initiation 
and a reduction in invasive foci. Additionally, a novel link between TAM depletion 
and CAF recruitment was demonstrated, further signifying the importance of these 
stromal cells in cancer progression.  
Appendix 4, the full manuscript by Ryder et al, shows a recapitulation of the genetic 
strategies of TAM depletion with a novel compound, GW2580.  Through the 
pharmacological inhibition of CSF-1, TAMs were depleted, also causing a similar 
change in phenotype and reduction in malignant cell proliferation.  This potential for 
this translational research lies in the tolerability of these immune modifying drugs in 
clinical trials, which are now in progress. 
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7.7 Future Directions 
The work conducted in this thesis has contributed to the development of alternative 
therapeutic strategies in thyroid cancer management.  It has paved the way for future 
clinical trials with novel compounds and highlighted the importance of combination 
therapy.   
There are several new research directions that have stemmed from this data: 
 
1. The translation of the HSP90 data to xenograft models or clinical trials is the 
next step in drug development.   It may be appropriate to head directly to a 
clinical trial, as in June 2013, there was a dose escalation study of AUY922 in 
patients with solid tumours [188]. Patients were able to tolerate a dose of 
AUY922 that was comparable with the data from xenograft models. Phase II 
studies are in progress.  However, the side effect profile of this compound is 
not fully characterised.  Preliminary findings include diarrhoea, anorexia, 
fatigue and visual symptoms.  An older generation HSP90 inhibitor, 17-AAG 
has complications with clinical translation.  The presence of other effective 
drugs exploiting the same mechanism is promising for patients with refractory 
disease.  
 
2. The role of the microenvironment in RET driven tumours warrants further 
research.  As discussed in chapter 6, RET has a pivotal role in inflammation 
and recruitment of certain immune cells present in the tumour stroma.  
Depleting key proponents of the microenvironment, either TAMs directly or 
CAFs indirectly, in mutant RET tumours would be the first stage to validate 
their role in these tumours.  GW2580 was shown to deplete TAMs in mice, 
and the next stage will be to determine whether this compound extends 
survival in this murine model. 
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3. Combination therapy has become commonplace in targeted therapy regimens.  
At this stage, combination treatments typically focus on separately inhibiting 
multiple downstream targets along parallel signalling axes. Data from this 
thesis provides a rationale for instead combining submaximal doses of 
different compounds that inhibit the same signalling pathway. Future clinical 
trials using RET and mTOR inhibitors can be envisaged.   
7.8 Conclusion 
Thyroid cancer has generated an increasing burden of disease for the individual and 
for society over the past few decades.  The rise in incidence and mortality has 
conferred a greater cost and morbidity on patients suffering this disease and the 
population who supports them. These studies in preclinical thyroid cancer models 
have confirmed a therapeutic effect achieved through an understanding of molecular 
abnormalities in cellular signalling. They have also shown the genetic complexity in 
thyroid cancer that will require the coupling of different therapeutic strategies to 
overwhelm the malignancy. 
This work has contributed to the understanding of the role of mutant RET in driving 
these tumours. Furthermore, the importance of destabilising the oncogene and its 
primary downstream targets has been explored.   
The work in this thesis provides a foundation for the application of these results to 
develop clinical trials.  The pivotal role of the microenvironment has also been 
explored through the function of TAMs.  This thesis has demonstrated a number of 
mechanisms to target RET mutant thyroid cancer in efforts to better treat this 
malignancy. 
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 Appendix 1: Definition of TNM staging system for differentiated thyroid 
cancer (adapted from AJCC/UICC guidelines) 
T0 No evidence of primary tumour. 
T1 The tumour <2cm 
T2 The tumour is >2 to <4cm 
T3 Primary tumour diameter > 4 cm limited to the thyroid or with minimal 
extrathyroidal extension 
T4a Tumour of any size extending beyond the thyroid capsule to invade 
subcutaneous soft tissues, larynx, trachea, 
oesophagus, or recurrent laryngeal nerve 
T4b Tumour invades prevertebral fascia or encases carotid artery or 
mediastinal vessels 
TX Primary tumour size unknown, but without extrathyroidal invasion 
N0 No metastatic nodes 
N1a 
 
Metastases to level VI (pretracheal, paratracheal, and prelaryngeal = 
Delphian lymph nodes) 
N1b Metastasis to unilateral, bilateral, contralateral cervical or superior 
mediastinal nodes 
NX Nodes not assessed at surgery 
M0  No distant metastases 
M1  Distant metastases  
MX Tumour invades prevertebral fascia or encases carotid artery or 
mediastinal vessels 
 
 
  
 Appendix 2: Staging criteria  
 Patients <45 yrs Patients >45 yrs 
Stage I Any T, Any N, M0 T1, N0, M0 
Stage II Any T, Any N, M1 T2, N0, M0 
Stage III  T3, N0, M0 
  T1, N1a, M0 
  T2, N1a, M0 
  T3, N1a, M0 
Stage IVA  T4a, N0, M0 
  T4a, N1a, M0 
  T1, N1b, M0 
  T2, N1b, M0 
  T3, N1b, M0 
  T4a, N1b, M0 
Stage IVB  T4b, Any N, M0 
Stage IVC  Any T, Any N, M1 
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